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ABSTRACT 
 
Saffron extract and its active constituents were evaluated as chemopreventatives and/or 
treatments for prostate cancer. Different models of prostate cancer (in vitro and in vivo) were 
used for studying saffron and its constituents’ mechanisms. In normal prostate cells, saffron 
extract, crocetin, and safranal, in non-toxic concentrations, possessed antioxidant properties 
against the reactive oxygen species induced by H2O2 which further supports saffron constituents 
as chemopreventative agents. Moreover, saffron and its active constituents produced cytotoxicity 
in prostate cancer cells through intrinsic apoptosis pathways. Potential efficacy in minimizing 
prostate cancer metastasis was also examined. Saffron extract, crocetin, and safranal decreased 
the migration and invasion capability of prostate cancer cells in vitro. Among all tested agents, 
safranal caused the lowest cytotoxicity in normal prostate cells.  
A new HPLC analytical method was developed to simultaneously measure saffron 
marker compounds (picrocrocin, crocin, safranal, and crocetin), which can be used to assess the 
quality and to identify adulteration of saffron samples. Our study emphasized the importance of 
standardizing the solvent systems used during extraction to minimize cytotoxicity in normal 
cells. The saffron available commercially differed greatly based on their constituents’ 
concentrations and biological activity, even when the plants came from the same region of 
cultivation, making it essential to evaluate each batch chemically and biologically.  
To overcome the limitations of current mammalian models, a xenograft zebrafish model 
for prostate cancer was developed as a new alternative. A zebrafish transgenic line was created in 
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our laboratory which offered unique characteristics, including physical transparency and 
vasculature system fluorescence. Our study optimized procedures for transplanting cancer cells 
into zebrafish and was validated using docetaxel as a known chemotherapy for prostate cancer.  
In conclusion, the optimized HPLC analytical method is an excellent tool for saffron 
quality evaluation. Saffron extract and its active constituents are considered good candidates as a 
chemopreventative and treatment for prostate cancer. The transgenic zebrafish in vivo model 
minimizes the time needed in preclinical evaluations of new medications and offers the potential 
for personalization of treatment options based on each patient’s case. 
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CHAPTER 1: PROSTATE CANCER 
 
1. Introduction 
The prostate is a gland located inferior to the urinary bladder, anterior to the symphysis 
pubis, and posterior to the rectum. It weighs between 20-25 grams and consists of three different 
zones: the peripheral, central, and transition zone. The peripheral zone represents ≈ 70% of the 
prostate tissue while central zone is 25%, and the transition zone is 5-10%. In the reproductive 
system, the prostate has multi-functions. First, it converts testosterone which is secreted from 
testes and adrenal glands into dihydrotestosterone (DHT), the most potent form of androgen 
hormone. Secondly, it produces 37-44% of seminal fluids which is mandatory for transferring 
and activating sperm. Finally, it closes the prostate duct during urination and urethra, with help 
of sphincter muscles, during ejaculation (Myers et al., 1987, Master and Turek, 2001, Mcneal, 
1988, Ndovi et al., 2007). Prostate cells consist of three different types: basal, secretory luminal, 
and neuroendocrine cells. Each cell type can be distinguished according to specific markers. The 
basal, luminal, and neuroendocrine cells express keratins 5 and keratins 14, keratins 8 and 
keratins 18, and neuron-specific enolase and neuropeptides, respectively (Van Leenders et al., 
2000, Bonkhoff and Remberger, 1996). 
Cancer occurs when cells grow without control and do not respond to normal signaling 
pathways. It can progress to form a tumor and loss of tissue homeostasis. With time, the cancer 
can continue to grow until it gains the ability to invade the adjacent tissues and enter the blood 
stream or lymphatic system to metastasize to distant organs (Hanahan and Weinberg, 2011). In 
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malignant prostate cancer, the luminal cells of prostate tissue provide the origin of 
adenocarcinoma development (Wang et al., 2014c). Prostate cancer develops most often in the 
peripheral zone (68%), followed by the transition zone (24%), and 8% in the central zone 
(Mcneal, 1988).  
Prostate cancer is the most diagnosed malignancy in men and the sixth leading cause of 
cancer deaths in the United States. Despite the improvements with treatment options and earlier 
diagnosis, in 2016, about 26,120 men died from prostate cancer out of the 180,890 cancer cases 
diagnosed in the United States (American Cancer Society, 2016). According to World Health 
Organization (WHO) estimations for 2012, there were 1.095 million new diagnosed cases and 
307,000 person deaths from prostate cancer in the world. In developing countries, in particular, 
the WHO expectation was 353,000 for new diagnosed cases and 165,000 for death cases (Ferlay 
et al., 2012). 
Although the etiology of prostate cancer is still incomplete, some of the greatest 
predisposing factors of prostate cancer are age, family history, race, diet, hormonal disruption, 
and environmental pollutants (Gann, 2002, Hu et al., 2012, Clapp et al., 2008). According to 
2011-2012 data, ≈ 14% of men have a risk to develop prostate cancer during their lifetime. 
Usually the diagnosed prostate cancer cases are associated with older age starting over 45 years, 
and the median age of the diagnosed patients is 66 years old. African Americans have nearly 
1.65-times more newly diagnosed and 2.34-times more deaths compared to Caucasians. 
Generally, the survival rate with prostate cancer is 98.9% at 5 years. The survival rate declines 
dramatically to 28.2% if the patient is diagnosed with metastatic prostate cancer. Therefore, the 
early detection in prostate cancer plays an important role in increased survival time, if found 
early, the majority of tumors are localized which provides more options for patients’ treatments 
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(N.C.I., 2015). While in the USA survival is almost 99% within five years of detection, there 
have been no significant improvements or new discoveries in the prostate cancer treatments in 
the last decade. Since the early 1990s, there has been a drastic increase in newly diagnosed 
patients with prostate cancer due to the development of prostate cancer detection methods. On 
the other hand, this is not an easy option in developing countries. In the United States there is 
almost one death corresponding to each 8 newly diagnosed cases, whereas in the whole world 
this ratio has declined to 1:3.5, and has declined more so in developing countries at 1:2 (Ferlay et 
al., 2012). 
Based on American Cancer Society guidelines for prostate cancer to be diagnosed, there 
are two categories of exams. The first category is early (preliminary) detection tests; the second 
category are confirming exams. In the early detection category, there are two options, PSA 
screening and digital rectal examination (DRE) which should be performed periodically for men 
over 50 years. In case the results are abnormal, the confirming tests should be conducted. The 
confirming tests include transrectal ultrasound and a prostate biopsy to determine the stage of 
prostate cancer and the best treatment options for the patient (Wolf et al., 2010). 
Staging the prostate cancer is a critical step needed to design a treatment regimen for 
each patient and monitor the outcomes of treatment. The prostate cancer staging is based on the 
TNM staging system (Table 1). There are four factors is needed to use the TNM staging system 
which include primary tumor location, size, metastasis to nearby lymph node, and metastasis to 
distant location (Edge and Compton, 2010, Edge et al., 2010). 
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Table 1: Prostate cancer stages 
Group T N M Gleason score PSA level 
Stage I 
1a-c 0 0 ≤ 6 ˂ 10 
2a 0 0 ≤ 6 ˂ 10 
Stage IIa 
1a-c 0 0 7 ˂ 20 
1a-c or 2a 0 0 ≤ 6 10 ≤ PSA ˂ 20 
2a-b 0 0 ≤ 7 ˂ 20 
Stage IIb 
2c 0 0 Any Any 
1a-c or 2a-c 0 0 Any ≥ 20 
1a-c or 2a-c 0 0 ≥ 8 Any  
Stage III 3a-b 0 0 Any Any 
Stage IV 
4 0 0 Any Any 
Any 1 0 Any Any  
Any Any 1 Any Any  
TNM system stands to: Tumor site and size (T), Node (N), and Metastases (M). More 
information about TNM staging system is provided in Appendix 1. 
 
The treatment of prostate cancer is a complicated task and varies depending on the 
diagnosis and the stage of the cancer. Different types of treatments are available to patients with 
prostate cancer. In cases of localized prostate cancer, radical prostatectomy and radiation therapy 
have been used to destroy the cancerous cells (Heidenreich et al., 2011). In almost 30% of 
patients with metastatic prostate cancer, tumor  growth is androgen-dependent (Small and Ryan, 
2006). The treatment options for these patients is either orchiectomy or luteinizing hormone-
releasing hormone (LHRH) agonists, often in combination with androgen receptor (AR) 
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antagonists to block the effect of additional available androgens in circulation (See, 2003). In 
advanced stages of prostate cancer, the patient survival rate has not increased in the last decade 
(Chu et al., 2003). There are no effective therapies after conventional treatment failure 
(Shinohara, 2003). Therefore, there have been attempts to explore new approaches and find new 
treatments. For example, changes in genetics and epigenetics participate in cancer development 
can disable apoptosis pathways and/or affecting the pathways that control the cell cycle arrest. 
Cancers have a selective growth advantage and growth becomes out of control. One of the 
available treatment strategies for cancer focuses on activating apoptosis and cell cycle arrest by 
interfering with the changes caused through abnormal genetics and epigenetics functions (Lowe 
and Lin, 2000, Zhou and Elledge, 2000). 
 
1.1. Oxidative stress and prostate cancer 
Oxidative stress occurs as a result of disrupted balance between oxidants including 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) and their elimination by 
antioxidant mechanisms. The oxidants are normally produced during cellular metabolism 
especially by the mitochondrial respiratory chain in the mitochondria. Sustained oxidative stress 
over a long time can cause significant damage to the structure and functions of the cells and 
result in somatic mutations and neoplastic transformation. Specifically, oxidative stress can 
induce DNA mutations, genome instability, and chronic inflammation that in turn raises the risk 
of several tumors including prostate cancer (Reuter et al., 2010). There are relationships between 
antioxidant enzyme expression and prostate cancer. Superoxide and catalase protein expression 
were found to be lowered in prostate cancer compared to normal prostate cells (Bostwick et al., 
2000). 
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Generally, the obtained effects on cells from highly acute ROS exposure caused 
irreversible cell damage and triggered cell death. In the case of prostate cancer, chronic exposure 
to elevated ROS levels contribute to prostate cancer development by playing important roles as 
secondary messengers and controlling multiple signal pathways in addition to their ability to 
damage the DNA. These roles are essential for the activation of different transcription factors 
such as hypoxia-inducible factor 1-alpha (HIF-1α) and mitogen activated protein kinase (MAPK) 
that control oncogenes. Furthermore, the high ROS level can drive the cancer to a more 
aggressive phenotype (Khandrika et al., 2009). 
 
1.2. Migration and invasion 
The migratory properties of the cells are required in the development and maintenance of 
normal physiological conditions and functions of human tissues such as embryogenesis, immune 
functions, angiogenesis, and wound healing. Furthermore, these mechanisms are involved in the 
pathophysiology of many medical disorders including inflammation and cancer (Cho and 
Klemke, 2000). The most life threating cancers are characterized by their ability for metastasis 
which represents 90% of the deaths related to cancer. Metastasized cells are aggressive and more 
resistant to treatments than the original cancer cells (Mehlen and Puisieux, 2006). The primary 
cancer cells undergo five major steps which are necessary for metastasis to distant areas. These 
steps include separating of metastatic cells from the primary tumor, invading adjacent tissues, 
intravasating into circulation, leaving the circulation by extravasation into a distant area, and 
proliferating to grow at the distant organ while forming a secondary tumor. Each step consists of 
a series of molecular mechanisms (Chambers et al., 2002). It is often fundamental for the cancer 
to metastasize to distant sites in order to find suitable microenvironments, similar to the primary 
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cancer source for successful spreading from the primary location.  Normally, motility is 
necessary for the cancer cells to invade the adjacent tissue, colonize and grow in the area that 
provides it with an ideal microenvironment (Joyce and Pollard, 2009). Before the cancer cells 
invade surrounding tissues and/or enter the blood or lymphatic streams, they will move to 
proliferate using two strategies. These strategies use the organ space in which the tumor 
originated. When the cells cannot expand anymore because they have taken up the available 
space and reached the maximum volume, they will secrete proteolytic enzymes such as matrix 
metalloproteases (MMPs) to degrade the extracellular matrix (ECM) to form de novo space that 
is required for the metastasizing cancer cells to escape their primary tumor area (Mccawley and 
Matrisian, 2000). The cancer cells migrate as individuals (amoeboid and mesenchymal behavior) 
or groups (strands, vascular sprouts, and clusters behavior), which is determined by the cell type 
and tissue environments. In the majority of the invasion cases, the MMP enzymes are required 
for the migrated cells as a group to invade distant places, especially in solid tumors. In rare cases, 
the cells will migrate in a single cell migration pattern which does not require proteolytic 
enzymes but uses mechanical forces, squeezing through tight junction spaces for invasion (e.g. 
leukemia) (Friedl, 2004). 
MMPs are a major class of zinc-endopeptidase belonging to the metzincin superfamily 
which exert protease activity to break down different types of ECM proteins including collagens, 
elastins, matrix glycoproteins, and proteoglycans (Engel et al., 2005, Maskos, 2005). The MMP 
family of enzymes in humans consists of 23 members which are classified into six categories 
according to their substrate specificity. The MMP enzyme categories include the collagenases 
(MMP-1, -8, -13 and -18), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10 and -11), 
matrilysins (MMP-7 and -26), MT-MMPs includes type I transmembrane proteins (MMP-14, -
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15, -16, and -24) and GPI anchored proteins (MMP-17 and -25), and miscellaneous (MMP-12, -
19, -20, -21, -23, -27, and -28) (Nagase et al., 2006). 
Generally, in normal conditions MMP enzyme activities are low. Their transcription is 
regulated by inflammatory cytokines, growth factors, hormones, tumor promoters, and the 
interactions between cells with ECM (Ala-Aho and Kähäri, 2005). Higher levels of MMP 
enzymes particularly MMP-2 and -9 were detected in prostate cancer patients with metastasis 
compared to local carcinoma, BPH, and healthy cases. After the patients received therapy, the 
enzyme levels dropped significantly (Morgia et al., 2005, Zhong et al., 2008). MMP-1 and 
MMP-9 are characterized by a hemopexin domain or three fibronectin type II motifs in their 
structures, respectively. MMP-9 cleaves multiple ECM molecules such as type IV collagen and 
gelatins, whereas, MMP-1 has a broad digestion capability for collagen types I, II and III (Wang 
et al., 2002, Iyer et al., 2006, Bode et al., 1999). Furthermore, the MMP-1 and MMP-9 degrade 
the vascular basal membrane to facilitate the migration of endothelial cells for angiogenesis. 
Angiogenesis is necessary for the cancer to form new vascular systems. The new blood vessels 
will help to nourish the needs of the growing tumor. In addition, high expression of MMP causes 
the release of VEGF and growth factors that help cancer growth (Bergers et al., 2000, Tang et 
al., 2005, Risau, 1997). Therefore, measuring MMP-1 and -9 levels are crucial to monitor 
prostate cancer metastasis. Furthermore, MMP could represent an important druggable target to 
get minimize to their activities and lower the invasion risk of a prostate tumor. 
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1.3. Mechanism of death 
There are two mechanisms for cell death namely: apoptosis and necrosis. They are 
characterized by different biochemical sequences and morphological shapes. In addition, 
apoptosis requires ATP in order to commit suicide; however, in contrast, necrosis is associated 
with ATP depletion (Wyllie, 1981). 
 
1.3.1. Necrosis 
After cells are exposed to a strong stressor or toxic agent that leads to ATP depletion, 
cells may undergo necrosis. As a result, the necrotic cells will swell and burst, in turn, causing 
the cells’ contents including their enzymes, proteins, and nucleic acids to be spilled out onto the 
surrounding cells and tissues. Ultimately an inflammatory response will be triggered which 
causes additional damage to neighboring cells and tissues. One of the major differences between 
apoptosis and necrosis, in terms of saving the neighboring cells and tissues from inflammation, is 
removing the contents of the dead cells by phagocytosis which is not achieved in necrosis. The 
cytoplasmic swelling and cell membrane rupture are considered as microscopic markers of 
necrotic cells (Savill, 1997, Haslett, 1992, Gores et al., 1990). 
 
1.3.2. Apoptosis 
Apoptosis is programmed cell death, which is characterized by nuclear membrane 
degradation, DNA fragmentation, chromatin condensation, cell shrinkage, and membrane 
blebbing to make the membrane segments that bind cell fragments and form separated vesicles 
called apoptosis bodies. These changes are triggered by the proteolytic activities of caspase 
enzymes. Later, cellular fragments undergo phagocytosis to remove them by neighboring cells or 
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macrophages (Kerr et al., 1972, Thornberry and Lazebnik, 1998). The major caspase enzymes 
involved in different pathways of apoptosis induction are caspase-3, 7, 8, 9, and 10 (Kuida et al., 
1998, Varfolomeev et al., 1998, Fernandes-Alnemri et al., 1996). Apoptosis mechanisms have 
crucial roles in normal, as well as in disease conditions. An example of apoptosis’ role under 
normal conditions is what happens during fetal limb development, in which the interdigital space 
between fingers is separated by inducing apoptosis pathways to remove the cells that connect an 
embryo’s fingers together (Mori et al., 1995). Also, when a somatic cell becomes abnormal, for 
example due to a DNA damage, the tumor protein p53 (TP53) gene will be activated to repair the 
damage. If the process of repair is incomplete, TP53 gene will turn on apoptosis mechanisms to 
remove this cell. The removed cell will be replaced by a new daughter cell from the neighboring 
cell. Therefore, there will be a balance between dead and newly formed cells in normal situations 
(Delong, 1998).  
There is a strong association between the genes controlling the apoptosis process, 
dysfunction, and disease. In the case of Alzheimer’s disease, which is a neurodegenerative 
disorder, abnormal induction of caspase enzymes is responsible for neuron cell death due to a 
high level of amyloid-β peptide that upregulates the TP53 gene (Ohyagi et al., 2005). On the 
other hand, when the damaged cells are not removed and the caspase enzymes are down-
regulated, the cells will continue dividing and the daughter cells will inherit the mutated genome. 
Finally, the abnormal cells under these conditions will be able to form a tumor (Moll and 
Schramm, 1998). 
There are two main pathways that activate caspase cascades, particularly the intrinsic 
pathway that involves the mitochondria, and the extrinsic pathway which is initiated by cell 
surface death receptors. Downstream of these pathways is the activation of caspase-3/7 enzymes. 
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These enzymes are considered the endpoint in the caspase cascade pathway. After their 
activation, the degradation of the cell components will be started in a programmed way to form 
apoptotic bodies. The last component to be degraded in the apoptotic cells will be the 
mitochondria which is an essential part of cells and is needed to complete the apoptosis process 
because they provide the necessary ATP (Cohen, 1997, Zou et al., 1999, Saleh et al., 1999, 
Earnshaw et al., 1999, Thornberry and Lazebnik, 1998). 
 
1.3.2.1. Intrinsic pathway 
Normally, cytochrome c is present in the mitochondrial intermembrane space, whereas 
the Apaf-1 and procaspase-9 are present in the cytoplasm. The intrinsic pathway depends on 
mitochondrial permeability which can be induced when exposure activates proapoptotic and/or 
inhibits antiapoptotic genes to produce the corresponding proteins. In the case of the activation 
of antiapoptotic genes such as Bcl-2 and Bcl-xL, cytochrome c will not be released from the 
mitochondria (Vander Heiden et al., 1997, Kluck et al., 1997). On the other hand, when 
proapoptotic genes such as Bax and Bid are expressed, mitochondrial permeability will occur. As 
a result, cytochrome c will be released from the mitochondrial intermembrane space into the 
cytoplasm (Luo et al., 1998). Three essential proteins are necessary to initiate the intrinsic 
apoptosis pathway including cytochrome c, Apaf-1, and procaspase-9. For example, when an 
agent activates proapoptotic genes, it will produce proapoptotic proteins which bind to the outer 
mitochondrial membrane to facilitate cytochrome c leakage from the mitochondrial 
intermembrane space into the cytoplasm. The cytochrome c with Apaf-1 will form an 
apoptosome. The apoptosomes have caspase activation and recruitment domains (CARD) which 
facilitate their binding to the CARD domain of procaspase-9 to activate the caspase-9 initiator 
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enzyme. Caspase-9 in turn, converts procaspase-3 and 7 into the caspase-3 and 7 active forms  
(Hu et al., 1998, Saelens et al., 2004, Li et al., 1997, Scaffidi et al., 1998, Liu et al., 1996). 
Finally, the activation of caspase-3/7 will cause cytoskeletal degradation, DNA fragmentation, 
and apoptotic body production (Martinvalet et al., 2005) . 
 
1.3.2.2. Extrinsic pathway 
The extrinsic apoptosis pathway is activated by the initiator caspase enzymes (caspase-8 
and caspase-10). Usually, these caspases are activated after a specific death receptor on the cell 
surface is activated by their specific ligand such as FasL binds to the Fas receptor, TNF binds to 
the TNFR1, and Apo-2 binds to TRAIL-R1 and TRAIL-R2  which affects intercellular signals 
and activates caspase effector enzymes (Ashkenazi and Dixit, 1998). As a general rule, different 
death receptors upon activation, behave a similar way to activate the executioner caspase. Fas 
receptor pathway can be used as an example to summarize the activation processes of the 
extrinsic pathway. The activation process works according to the following steps: first, FasL 
binds to Fas receptor on the cell surface which activates the death domain in the cytoplasmic 
region of the receptor. Second, the death domain of the Fas receptor will bind to the death 
domain of the FADD protein which forms a complex called DISC. Third, the DISC complex 
contains DED in the FADD proteins that allow for the DED in procaspase-8 to bind to the DISC 
complex through FADD. Fourth, procaspase-8 is hydrolyzed to an active form called caspase-8. 
Finally, caspase-8 will hydrolyze procaspase-3 and 7 into the caspase-3 and 7 active forms. 
Following the activation of the caspase effector enzymes, the cell degradation process will start 
to form apoptotic bodies. In the case of TNFR1, the activated initiator caspase enzyme will be 
caspase-10 (Varfolomeev et al., 1998, Muzio et al., Boldin et al., Sprick et al., 2002). 
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1.4. In vitro cell lines models 
In vitro studies are important to determine the efficacy and potential mechanisms of any 
new cancer drug lead against prostate cancer disease. In this study, saffron and its active 
constituents will be specifically tested in vitro. Choosing the proper in vitro model is considered 
a critical step, accordingly three different cell lines were chosen to represent different scenarios 
of prostate tissue cancer. The cell lines include normal prostate (PNT1A), early stages of prostate 
cancer (22Rv1), and late stages of prostate cancer (PC-3). The results can then suggest the 
selectivity and effectiveness of saffron treatments among different stages of prostate cancer. All 
the previous cell lines were derived from human prostate tissue, each with special characteristics 
to provide an opportunity to test saffron extracts in different conditions. 
 
1.4.1. PNT1A  
PNT1A is a cell derived from the normal human prostate tissue of a 35-year-old post 
mortem Caucasian male. The cells were then immortalized by transfecting them with a plasmid 
containing a defective replication origin of a SV40 genome to establish a normal cell line. They 
express cytokeratin 8 and 18 markers of luminal prostatic cells (Cussenot et al., 1991). The cells 
express wild type androgen receptor, respond to testosterone and DHT and their growth is 
stimulated by EGF (Avances et al., 2001). PNT1A lacks the ability to invade due to normal cell 
behaviors, therefore, these cells were non-tumorigenic in nude mice. The doubling time of this 
cell line is 30 hours (Berthon et al., 1995). 
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1.4.2. 22Rv1 
In 1999, 22Rv1, a new prostate cancer cell line, was introduced into the prostate cancer 
research field as a primary prostate carcinoma. It was derived from xenografted CWR22R cells 
(Sramkoski et al., 1999). Originally CWR22, which was established from the primary prostate 
tumor, was taken from a prostate cancer patient with a Gleason tumor grade 9, stage D and bone 
metastasis (Wainstein et al., 1994). Then, it was propagated in mice with androgen ablation for 
3-10 months to establish the new subline called CWR22R. The major difference between 
CWR22 and CWR22R is androgen dependency. CWR22 cells are androgen-dependent prostate 
cancer cells that will not grow in female or castrated male mice. Whereas, CWR22R cells are 
androgen-independent and can grow in an androgen free environment such as in female or 
castrated male mice (Nagabhushan et al., 1996). The CWR22R cells were cultured in a 
pretreated flask with irradiated STO cells as a feeder layer, after a few passages the new cell line 
was able to grow in a cultured flask without pretreatment. The new cell line, 22Rv1 is androgen 
sensitive and has similar characteristics to primary prostate cancer in the early stages of 
development. For example, AR mRNA and protein are expressed, but PSA is expressed as 
mRNA only. 22Rv1 growth can be stimulated by epidermal growth factor and weakly stimulated 
by DHT, but is not inhibited by TGF-β1. The doubling time of this cell line is 40 hours 
(Sramkoski et al., 1999). 
 
1.4.3. PC-3 
The last cell line is PC-3, a traditionally studied prostate cancer cell line that is the most 
aggressive type, and was derived from a 62-year-old Caucasian patient with metastatic prostate 
cancer cells in his bones (Kaighn et al., 1979). PC3 has similar characteristics to late stage 
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prostate cancer characterized by androgen independency, lack of androgen receptors, inability to 
express PSA at both mRNA and protein levels, and a mutation in the TP53 gene which 
contributes to their survival (Van Bokhoven et al., 2003). Their growth is not affected by 
stimulatory hormones such as insulin and epidermal growth factor or by inhibitory hormones 
such as TGF-β1. The PC-3 cell line is able to grow in androgen free environments such as female 
mice. The doubling time of this cell line is 33 hours (Kaighn et al., 1979). 
 
1.5. Animal models for prostate cancer 
Under controlled conditions, in vitro cancer models offer important details about cancer 
development, the mechanism of action of drugs, and reproducibility (Cekanova and Rathore, 
2014). One of the main reasons for failure of preclinical trails in the drug development processes 
is direct translation of in vitro studies into clinical applications, because the in vitro models lack 
the microenvironments and show inadequate similarity to human cancer conditions (Sharpless 
and Depinho, 2006). Therefore, pairing the in vivo with in vitro experiments greatly improves 
our knowledge about cancer growth and metastatic cascades which are predicted to reveal new 
biomarkers, drug mechanisms, and new innovation of cancer therapies (Hoelder et al., 2012). 
There are various animal models used as in vivo prostate cancer models, but the histology 
and physiology of each species are both different among each other and from humans. The most 
common animal models are canines, rats, and mice. Canines, like humans, have a single prostatic 
gland. The prostate gland has the ability to develop prostatic intraepithelial neoplasia (PIN) and 
adenocarcinoma when they become older, which mimics humans regarding age as a risk factor. 
Dogs’ natural spontaneous development of prostate cancer without any intervention is 
considered an advantage for use in prevention studies. Some rat strains also have the ability to 
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develop prostate cancer spontaneously induced by using a chemical such as androgenic 
hormones and carcinogenics. The size of prostate tissue in rats is larger than in mice. Like mice, 
transgenic rats are available but with limited options compared with mice. All of the previous 
models are costly and not easy to maintain in labs, which has made mice the most commonly 
used animal in prostate cancer research for decades (Navone et al., 1998, Ittmann et al., 2013). 
 
1.5.1. Mice prostate cancer model 
Normally, it is rare for wild type mice to develop spontaneous cases of prostate cancer 
during their lifespan (Suwa et al., 2002). Therefore, there are two major options used to induce 
prostate cancer in the mouse models. These options are either inserting viral oncogenes into the 
prostate tissue or using genetically modified mice that make the animal more susceptible to 
develop prostate cancer through specific pathways. Using the viral oncogene insertion strategy, 
one of the oldest mouse models for prostate cancer is known as the mouse prostate reconstitution 
(MPR) model. The MPR is usually developed with a higher rate of occurrence > 90% using 
inbred C57BL/6 mice to originate poorly differentiated prostate cancer when the ras and myc 
oncogenes are delivered by using a recombinant retrovirus into each of the mesenchymal and 
epithelial compartments of the urogenital sinus. The genetically engineered mouse is another 
option that aims to upregulate or dysregulate specific genes that are responsible for particular 
pathways that are involved in prostate cancer development. For example, the transgenic 
adenocarcinoma of the mouse prostate (TRAMP) model is the earliest successful transgenic 
mouse model created and uses the -426/+28 bp probasin promoter expressing the PB-SV40 T to 
exclusively target the dorsolateral and ventral lobes of prostatic epithelial cells. Male mice are 
raised with progressive prostatic neoplasia, and by 10 weeks the mice will have prostatic 
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hyperplasia, and by 18 weeks they develop a prostate adenocarcinoma with the possibility of 
metastatic spread to distant locations (Gingrich et al., 1996, Thompson et al., 1992). 
Despite the convenience provided by the previous models, there are several significant 
drawbacks. Humans and mice do not share the same histological and physiological 
characteristics of the prostate. Thus, using the mouse as a model to mimic the prostate cancer 
development in humans and evaluate the treatment options is more difficult and an unreliable 
option. There are many examples for the uniqueness of mice prostate tissues’ structures and 
functions. For example, the mouse prostate tissue consists of four lobes which are the anterior, 
ventral, dorsal, and lateral lobes. Whereas the human prostate consists of transitional, central, 
and peripheral zones. Therefore, there is little correlation between the lobes and zones of mouse 
and human prostate tissues, respectively (Huss et al., 2001, Mcneal, 1988). Also, the mouse 
prostate does not secrete PSA in response to abnormal circumstances, unlike humans (Diamandis 
et al., 2004). The pharmacokinetic data obtained from a mouse model is not able to be directly 
used to predict human pharmacokinetic behaviors because of variations between species in both 
weight and lifespan (Demetrius, 2005). In mice, the cancer originates from mesenchymal cells 
whereas in humans it originates from epithelial cells. Human prostate cancer metastasizes to 
bone, which is not typical in mouse prostate cancer (Depinho, 2000). In conclusion, the mouse 
prostate lacks PSA, does not have the same zones as human, and has different origin and 
metastasis patterns. Therefore, the need for xenograft models has been raised as an alternative to 
the classic model of cancer. 
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1.5.2. Human prostate cancer cells xenografted mice 
The introduction of human cancers in xenograft models using mice completely 
transformed cancer research to more advance level by covering many of the disadvantages 
previously described (Sausville and Burger, 2006). Therefore, the xenograft model of prostate 
cancer is now considered the best available choice. Human prostate cancer cells are xenografted 
into immunodeficient mice, because these mice’ bodies will provide the prostate cancer cells 
with environments that mimic the human body, including hormones and nutrition. 
Immunodeficient mice were chosen because of their ability to host external tumors without 
rejection due to a lack of immunity (Gray et al., 2004). 
There are many advantages of using xenograft models such as monitoring different 
aspects of the transplanted tumor including its three dimensional shape, angiogenesis, and 
paracrine with hormonal components, tumor-stroma interactions, and metastasis (Van Der Pluijm 
et al., 2001, Cheung et al., 2005). Just like human prostate cancer, each of the xenografted 
human prostate samples release PSA and the proportion of free PSA is similar to human patient 
values time of tumor harvest (Buhler et al., 1998). In addition, the effectiveness of certain 
treatment options can easily be assessed as the result of transplantation of the patient samples 
simultaneously into multiple mice groups. This helps to customize the therapy plan that is 
suitable for each human patient case (Troiani et al., 2008).  
The most widely used immunocompromised mice used as a host in xenografted models 
are SCID (severe combined immunodeficiency), Foxn1nu (nude mouse), NOD (non-obese 
diabetic), and RAG1 and RAG2 (recombination activating gene) knockout mice strains. Each of 
these strains has special characteristics (Table 2). The available strains have been crossed to 
maximize the advantages and minimize the drawbacks of using them such as SCID x NOD 
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crossed strain (Belizário, 2009). There still remain limitations of using mice as a host in 
xenograft models including that the working area should be pathogen free because the mouse 
lacks immune system, the number of cells needed for the transplantation processes is large, the 
experiment duration to complete the studies is long, and the experiments are costly. 
 
 
Table 2: Mice strains used as hosts in xenograft models (Belizário, 2009) 
Strain Characteristics 
SCID 
These mice have a mutation in the Prkdc (protein kinase, DNA 
activated, catalytic polypeptide) protein required for linking non-
homologous ends of double-stranded DNA. As they grow older, mice 
will naturally produce T and B lymphocytes (immunoglobulin 
leakiness) so they are very sensitive to irradiation. 
Foxn1nu 
These mice have a mutation in the Foxn1 gene that inhibits thymus 
derived T cells. As a result, they are athymic, but they possess 
activated natural killer cells. 
NOD 
NOD mice do not express the crucial histocompatibility complex 
(MHC) haplotype known as H-2g7 and SNP in CTLA-4 gene, that are 
necessary for diabetes-induced autoimmunity. 
RAG1 and RAG2 
These mice have deleted Rag1 or Rag2 resulting in the arrest of B 
and T cell receptor rearrangement and lacks differentiation of T and 
B cells. They have high levels of natural killer cells and are less 
sensitive to radiation. 
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1.5.3. Human prostate cancer cells xenografted zebrafish 
In recent years, zebrafish (Danio rerio) have become an attractive animal model for many 
different scientific research projects (Chakraborty et al., 2009). As shown in Figure 1, 70% of 
the genes of this fish species are similar to the human genome, which make the zebrafish an 
excellent model to assist and aid in the studying of various human diseases which are related to 
genetic disorders. Examples of the diseases include dilated cardiomyopathies, and Duchenne 
muscular dystrophy which is caused by a mutation of the cardiac troponin T gene (tnnt2) and 
dystrophin gene (DMD), respectively (Howe et al., 2013, Santoriello and Zon, 2012). Moreover, 
humans and zebrafish have similar tumor suppressor genes and oncogenes which are involved in 
critical pathways such as proliferation, migration, and apoptosis. As a consequence, the zebrafish 
is considered a valuable vertebrate animal model in cancer research (Feitsma and Cuppen, 2008). 
In addition, this animal also shares basic characteristics and structures of human cardiovascular, 
kidney, and optic systems (Briggs, 2002, Gestri et al., 2012).  
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Figure 1: The similarity between human, zebrafish, and mouse genome. The diagram 
shows the number of shared genes among the species’ genomes (Howe et al., 2013). 
 
 
While genetic similarities are critical for the zebrafish to be used in such scientific 
experiments, there are also immense practical and logistical advantages to using zebrafish. They 
are capable of producing a large number of easily-harvested fertilized eggs in a laboratory 
environment using simple and affordable methods. In addition, using fish is immensely practical 
as their embryos develop externally, so larvae/embryos can readily be placed, individually, in a 
single well of 96-multiwell plate (Mathias et al., 2012, Vander Heiden et al., 1997, Williams, 
2010). It is also important to note that there are two ways to deliver the tested compounds to 
zebrafish, either through injecting a compound into the zebrafish directly, or dissolving a 
compound in water or a delivery solvent such as DMSO and ethanol, after which each well can 
be individually dosed with any miscible or solubilized drug load (Maes et al., 2012, Stewart et 
al., 2011, Ali et al., 2011). Additionally, one of the best sites to transplant cancer cells is in the 
yolk sac of an embryo because it is easy to inject with low mortality rate (less than 20%), is less 
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susceptible to the embryo tissues signaling, and is rich in nutrition and elements that provide the 
proper microenvironments for cancer cells (Geiger et al., 2008). 
The xenotransplantation of cancer cells into zebrafish embryos does not require immune 
suppression because the zebrafish do not develop their immune system completely until 28 dpf. 
Lack of an immune response in zebrafish provides a great opportunity to use them as an animal 
host for transplanted human cancer cells (Trede et al., 2004, Taylor and Zon, 2009). 
Accordingly, it is possible to use zebrafish embryos and larvae in high throughput anticancer 
screens for rapid and easy drug administration when compared to an alternative, such as injecting 
mice. 
In this latter situation however, immunocompromised mice lack specific genes that are 
responsible for immune system maturation, plus those genes also have different roles in many 
pathways. This may interfere with the normal behavior of transplanted cancer cells. For example, 
in the nude mice model, the Foxn1 gene is mutated to prevent immunity maturation (Macor et 
al., 2008). The Foxn1 gene, plays an important role in the regulation and activation of fibroblast 
growth factor (FGFR) family genes. Hence, a mutation in Foxn1 gene causes a downregulation 
of FGFR protein expression as a consequence of its downstream cascades (Turner and Grose, 
2010). However, high expression of FGFR protein is usually associated with the growth of 
different cancer types, including breast and prostate cancer (Eswarakumar et al., 2005, 
Nakamoto et al., 1992, Toi et al., 1994). Therefore, using these mice for xenograft procedures 
especially for prostate and breast cancer should be reconsidered because it does not provide the 
optimum microenvironment condition compared to zebrafish, that may produce a response in the 
transplanted cancer independently of treatment. 
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The xenotransplantation of human cells into the available xenograft animal models, such 
as mice, requires a large number of prostate cancer cells to graft successfully (e.g. 1-5 million 
cells) (Workman et al., 2010). This creates the problem of having to obtain sufficient cells to do 
multi-groups and becomes more challenging if the cells are from a primary patient sample. As a 
result, the zebrafish provide an ideal alternative because the fish can be used for the same type of 
experiment but require the availability of far fewer cancer cells (hundreds to thousands of cells) 
(Nicoli et al., 2007, Taylor and Zon, 2009). When using zebrafish, it is possible to determine the 
maximum tolerated compound dose before the xenograft experiment is conducted (Eimon and 
Rubinstein, 2009). Establishing a suitable dose will help avoid misinterpretation due to the 
effects of drug toxicity. Thus, the value of the zebrafish as a xenograft model is increased as it 
can provide more-detailed results and valuable data where in vivo studies are concerned. In 
addition, the results of these studies can be obtained within a short time frame (2 days – 1 month) 
while other animal models, such as the nude mice xenograft model takes appreciably longer (2 – 
12 months) (Stoletov and Klemke, 2008, Siolas and Hannon, 2013). Table 3 highlights more 
comparisons between mice and zebrafish as a xenograft models.  
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Table 3: The differences between mice- and zebrafish-based xenografted models. 
 
  
Age At least 2 months At least 3 days 
Experiment duration 2-4 months 3-6 days 
Animal cost $ 45-60 $ 1-2 
Maintenance cost $ 1-3 per mouse Cents per tank 
Cancer cell tracking Tumor mass Single cells 
Visualizing cancer cells End Point of the experiment Daily basis 
Histology Each organ must be sectioned 
separately 
A whole fish can be sectioned 
per slice 
 
 
 
1.5.3.1. Tg(fli1a:EGFP) and Casper 
Aside from wild-type zebrafish, there are various transgenic and mutant zebrafish lines. 
These fish lines are used in cancer research fields and one advantage of certain lines is their 
benefit for visualization. Another reason for the popularity and suitability of zebrafish relates to 
their transparency facilitating the straightforward ability to observe cancer development in living 
zebrafish. Transgenic zebrafish present a rare opportunity to observe the cancer development 
process and the effects of drugs on, for example, prostate cancer in real-time under a fluorescent 
microscope (Feitsma and Cuppen, 2008). In this dissertation, two different types of transgenic 
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zebrafish, Tg(fli1a:EGFP) and Casper, were used to develop a new in vivo model for human 
prostate cancer. The endothelial cells of Tg(fli1a:EGFP) transgenic zebrafish are stably green 
fluorescently labeled, thus giving researchers the opportunity to examine zebrafish blood vessels 
under a fluorescent microscope (Lawson and Weinstein, 2002). The Casper zebrafish are 
characterized by their transparency because they do not form pigmentation during growth, which 
allows for tracking their body and organ development with a bright field microscope, and the 
cancer cells under a fluorescent microscope. Casper fish lack melanocytes and iridophores due to 
mutations in the nacre and roy genes. Because these mutant genes are recessive, the fish must be 
homozygous to be a Casper fish (White et al., 2008). One of the biggest advantages is that we 
can image cancer cells in the same fish with mild anesthesia over the course of the experiment 
time. Importantly, this advantage will decrease any variability caused by monitoring different 
animals during a series of experiments (Taylor and Zon, 2009, Amatruda et al., 2002).  
 
1.5.3.2. Crossed Tg(fli1a:EGFP) and Casper 
Crossing the Tg(fli1a:EGFP) with Casper zebrafish lines produces a unique and ideal 
model as an animal host for the xenograft procedure. The uniqueness of this cross-bred fish line 
allows for clear monitoring of the angiogenesis and invasiveness of the transplanted labeled 
prostate cancer cells without interference from zebrafish pigmentation that develops after 48 hpf 
in wild-type and Tg(fli1a:EGFP) zebrafish larvae. This advantage allows the researcher to 
measure the cancer’s fluorescence intensity accurately, which is proportional to the growth of 
cancer cells. Therefore, we can explore the in vivo transplanted cancer cells’ behavior and 
metastasis. Furthermore, by assessing prospective chemotherapeutics compounds ability to 
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decrease tumor volume, the model can be used in new drug screening. So, this line will provide a 
great model with more sensitive data, a shorter time for the in vivo results at a far lower cost. 
Because there is no ideal animal model, the pros and cons of each animal model must be 
weighted and optimized accordingly. For example, in the cases of prostate and breast cancers, 
when comparing the animal-originated cancer (specific animal organ becomes cancerous through 
extrinsic intervention) with the xenograft model (transplanted human cancer cells in animal 
body), the xenograft model is preferred because the animal breast and prostate organs have little 
correlation to human organs. Moreover, when comparing mice and zebrafish for use in a 
xenograft model, the zebrafish is preferred because no genetic modification or chemicals to 
immunocompromise their systems are required in order to conduct any cancer transplantation 
procedure. Without the need for genetic modification or chemicals for immunocompromising, 
plus cost-effectiveness and speed of obtaining study results, the benefits of using the zebrafish 
are often far greater than those offered by mice. 
 
1.6. Natural products for prostate cancer 
Currently, natural products are a promising source for developing new treatment 
modalities. Finding compounds that work as chemo-preventative agents that prevent prostate 
cancer development, at the same time as cytotoxic agents to treat existing cancer cells is 
considered a valuable achievement. Saffron extract and its active constituents possess antioxidant 
properties and additionally have tumoricidal activity. Now, there is a critical need to study the 
actual mechanisms of saffron against the development, progression, and metastasis of prostate 
cancer.   
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1.6.1. Saffron 
Saffron consists of the dried stigmas and tops of the styles of Crocus sativus (Iridaceae). 
Saffron has reddish-brown stigmas, a sweet aromatic odor, and a bitter taste. Saffron content 
analyses identified different chemical compounds which include water, proteins, fats, minerals, 
reduced and free sugars, and pigments. Vitamins such as thiamine and riboflavin were also found 
in saffron, in addition to trace amounts of different volatile oils (Sampathu et al., 1984). As a 
result of the agricultural conditions and geographical origin, the chemical composition of saffron 
can be different (Maggi et al., 2011). Generally, saffron contains over 150 components, and the 
major components are crocin (24 - 34%) and picrocrocin (5 - 21%). In the case of hydrolysis 
processes, crocin produces gentiobiose and crocetin (6 - 11%), while picrocrocin yields glucose 
and safranal. In saffron, crocin is responsible for color, safranal (0.11 – 1.8% is present in saffron 
as a free component and represents up to 72% of their total volatile oil) is responsible for its 
odor, and picrocrocin is responsible for its bitter taste (Figure 2) (Winterhalter and Straubinger, 
2000, Schmidt et al., 2007, Lautenschlager et al., 2014, Alonso et al., 1996, Lage and Cantrell, 
2009). Saffron plants are used in food for added coloring, flavoring, and aroma. In folk medicine, 
saffron has been used to treat different disorders and as an antispasmodic, expectorant, sedative, 
and analgesic natural product (Ríos et al., 1996). Recently, many studies have suggested, that 
saffron extracts can be used in the treatment of depression (Noorbala et al., 2005), anxiety 
(Hosseinzadeh and Noraei, 2009), memory impairment (Zhang et al., 1994), hypertension 
(Imenshahidi et al., 2010), inflammatory diseases (Hosseinzadeh and Younesi, 2002), and 
cancers. Saffron extracts induce apoptosis and cell cycle arrest, but inhibit cellular proliferation 
and tumor progression in various cancer cell lines (Dhar et al., 2009, Aung et al., 2007, 
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Feizzadeh et al., 2008, Abdullaev and Frenkel, 1992, Escribano et al., 1996, Chryssanthi et al., 
2007).  
Saffron is a good candidate to prevent prostate cancer through its antioxidant effects 
because it is rich in carotenoids. Dietary carotenoids show the ability to decrease the occurrence 
of prostate cancer due to their potent antioxidant activity (Willis and Wians, 2003). In clinical 
trials, it was found that daily intake of nutrients rich in carotenoids such as α-carotene, β-
carotene, and lycopene were associated with a decreasing risk of hormone related neoplasms 
such as prostate cancer (Mccann et al., 2005). A different study emphasized the inverse 
relationship between tomatoes (lycopene) intake and prostate cancer development risk 
(Giovannucci et al., 2002). Moreover, a large consumption of lycopene provided more protective 
effects against prostate cancer development in individuals with a family history compared to 
those who do not have family history of prostate cancer (Kirsh et al., 2006). We will study the 
potential chemopreventative effects of saffron, especially as it relates to prostate cancer. 
Recognized active constituents of saffron are crocetin and safranal. 
  
29 
 
Picrocrocin
CrocetinSafranal
Crocin
 
Figure 2: Chemical structures of saffron constituents 
 
 
 
1.6.2. Active constituents 
Numerous studies, highlighted below, on saffron have been performed in order to define 
the important pharmacological active compounds which include crocin (glycosyl ester of 
crocetin), crocetin (dicarboxylic acid), picrocrocin (monoterpene glycoside), and safranal. Those 
compounds make contributions for the physical, as well as the medical properties of saffron.  
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1.6.2.1. Crocin 
Crocin is a natural water-soluble carotenoid found in saffron in different derivatives and 
isomers. The multiple crocin derivatives were given names from crocin-1 to crocin-7 (Figure 3). 
The molecular weight of crocin varies dependent on its specific derivative which ranges from 
434.44 to 1301.25 g/mole. Its structure is composed of dicarboxylic acid, crocetin and D-
gentiobioside moieties. It is characterized by its yellow-reddish color which is responsible for 
saffron’s color. It has multiple unique properties as a glycoside carotenoid, which include 
hydrophilicity, abundant availability in a single source (saffron plant), and surfactant character 
due to its amphiphilicity as a result of the presence of highly unsaturated and conjugated sugars 
(Naess et al., 2006).  
Crocin-1 is the derivative that is most extensively studied because it is available in large 
amounts in saffron and its readily commercially available as a pure compound. A literature 
review showed that the protective effects of crocin against cancer are suggested via two 
pathways. First, crocin contains scavenger properties in which the crocin donates a hydrogen 
bond to a free radical. In a previous study, 500 and 1000 µg/ml of crocin decreased the available 
free radicals by 50 and 65%, respectively (Assimopoulou et al., 2005). Moreover, crocin 
demonstrated its ability to activate the antioxidative defense mechanisms of cells by inducing 
SOD, CAT, GST, and GSH enzymes (Hemshekhar et al., 2012, El-Beshbishy et al., 2012, Zheng 
et al., 2007). Second, crocin inhibited inflammation by decreasing the specific gene expression 
of proinflammatory cytokines and inducible inflammatory enzymes such as interleukin-6 (IL-6), 
interferon γ, cyclooxygenase-2, and nitric oxide synthase. Therefore, using crocin as a dietary 
supplement significantly prevented the conversion of inflammation induced by azoxymethane 
and dextran sodium sulfate into colonic adenocarcinomas in mice (Kawabata et al., 2012). 
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In breast cancer, the estrogen-independent cells (MDA-MB-231) were more sensitive to 
crocin treatment compared to the estrogen-dependent cells (MCF-7). The IC50 concentrations 
were 700 and >1000 µM, respectively. This study showed that crocin is a good candidate to treat 
the advanced stages of breast cancer (Chryssanthi et al., 2007). Exposure of gastric 
adenocarcinoma (AGS) cell lines to crocin also showed anticancer activity. This activity was 
selective to cancer cells whereas no toxic effect was detected in normal cells. The cytotoxic 
effect was induced by an intrinsic apoptosis pathway (Hoshyar et al., 2013). The pancreatic 
cancer cell line (BxPC-3) was exposed to 10 µg/ml for 72 hours and resulted in cell viability 
reduction by activating the apoptosis pathway. This activity was dependent on the dose and time 
of treatment (Bakshi et al., 2010). The SW-480 human colon cancer cell line growth was 
inhibited by 52% when dosed with 1 mM crocin (Aung et al., 2007). Similarly, an IC50 of 3 mM 
was found in cervical cancers (Escribano et al., 1996). 
In an in vitro study, crocin was used at 60 µg/ml and caused a reduction of dalton’s 
lymphoma ascites cell line (DLA) by 50% in a dose- and time-dependent manner. However, in 
vivo xenograft mice revealed the ability of crocin to protect the mice from developing cancer 
when it was consumed before cancer induction. Crocin exposure increased the lifespan by 44% 
compared to the control group and lowered the tumor volume by 95.6% after 31 days of 
treatment in comparison to the untreated group (Bakshi et al., 2009).   
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Figure 3: Structures of different crocin derivatives 
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1.6.2.2. Crocetin 
Crocetin is one of the carotenoids available in saffron with a molecular weight of 328 
g/mole and is chemically known as 8,8’-diapocarotene-8,8’-dioic acid. It is a compound that is 
responsible for the reddish color of saffron along with crocin. Crocetin is available in different 
isomers where the ‘trans’ isomer is more intensely colored than the ‘cis’ isomer. In general, 
crocetin is present in conjugated form with carbohydrates moieties (Tsimidou and Biliaderis, 
1997, Tarantilis and Polissiou, 2004). Storage conditions such as temperature, light, and 
humidity have an effect on the crocetin activity (Tsimidou and Tsatsaroni, 1993).  
Crocetin exhibited scavenger activity and decreased free radicals by 40% and 80% in 
burn-induced intestinal injury model, when the crocetin was added at concentrations of 10 and 
100 µM, respectively. Furthermore, crocetin activates endogenous antioxidant enzymes 
including SOD, CAT, and GPx and reduced lipid peroxidation levels protecting the cardiac cells 
from oxidative stress injuries induced by norepinephrine. In addition to the antioxidant activities, 
crocetin reduced inflammatory reactions by significantly decreasing the levels of 
proinflammatory cytokines such as IL-6 and TNF-α (Zhou et al., 2015, Shen and Qian, 2006). 
Crocetin has the ability to protect the normal cells from carcinogenic substances such as 
benzo(a)pyrene (BaP). When cells were pretreated with crocetin the covalent binding of BaP-
diol-epoxide with DNA was significantly decreased and inhibited the genotoxicity inhibited 
(Chang et al., 1996). 
Crocetin inhibited the proliferation of the estrogen-dependent breast cancer cell line 
(MCF-7) at 25µM, whereas the activity against estrogen-independent breast cancer cells (MDA-
MB-231) was weak and the IC50 was above 1000 µM. These results indicate that crocetin is the 
most potent saffron components demonstrated cytotoxicity against MCF-7, so it was 
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recommended to use this as a chemopreventive agent for breast cancer (Chryssanthi et al., 2007). 
The mechanism of cell death was through the intrinsic apoptosis pathway by inducing the 
expression of Bax protein (Mousavi et al., 2009). In another study, incubating 2 μM of crocetin 
with a promyelocytic leukemia cell line (HL60) for 48 hours resulted in a 50% inhibition of the 
leukemia cell growth. Interestingly, this study demonstrated that using crocetin at high doses had 
a less toxic effect compared to retinoids because it is not a provitamin A precursor (Tarantilis et 
al., 1994). Researchers in a different study found that crocetin displayed antitumor activity 
against different pancreatic cancer cell lines, including Mia-PaCa-2, as well as pancreatic cancer 
in an in vivo model.  The study showed that the crocetin significantly decreased the expression of 
the epidermal growth factor receptor (EGFR) and activated the intrinsic apoptosis pathway 
through inducing Bax and decreasing Bcl-2 proteins (Dhar et al., 2009). 
 
 
1.6.2.3. Picrocrocin 
Picrocrocin is naturally found in saffron and represents one of the major constituents of 
saffron that is responsible for its bitter taste. It is a colorless glycoside with a molecular weight of 
330.37 g/mole and is known as 4-(β-D-glucopyranosyloxy)-2,6,6-trimethyl-1-cyclohexene-1-
carboxaldehyde (Iborra et al., 1992). Among saffron’s major components, picrocrocin does not 
possess antioxidant properties (Ochiai et al., 2007). 
In a previous study, researchers concluded that picrocrocin had the ability to work as a 
competitive inhibitor for heat shock protein 90 alpha (HSP 90α) by forming hydrogen bonds in 
the ATPase catalytic site of HSP 90α (Bhattacharjee et al., 2012). It is known that HSP 90 
expression activates multiple pathways that induce cell survival and inhibit apoptosis, by the 
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activation of STATs, Akt, Bcl-2, and JNK 1/2 (Kim and Kim, 2011). During inactive androgen 
receptor (AR) status, AR is bound to HSP 90 to prevent its degradation (Vanaja et al., 2002). In 
early stages of prostate cancer, tumor growth is usually associated with a high expression of AR 
with HSP 90 (Solit et al., 2002, Abe et al., 2004). It could be hypothesized that prostate cancer 
cell survival would be reduced because the picrocrocin inhibits HSP 90, leading to a decrease in 
AR availability which is required for prostate cancer growth in the early stage of its 
development. 
Despite the fact that picrocrocin lacks antioxidant activity, it demonstrated strong 
antiproliferative effects on different human cancer cell types, which included adenocarcinoma 
and hepatocarcinoma cells (Kyriakoudi et al., 2015). In addition, picrocrocin exhibited antitumor 
activity against cervical cancer cells (HeLa) with an IC50 corresponding 3 mM (Escribano et al., 
1996). Incubating the mouse lung cancer cell line (TC-1) and non-cancerous monkey kidney 
fibroblast-like cell line (COS-7) with different concentrations of picrocrocin resulted in selective 
cytotoxic effects on malignant cells in comparison to normal cells which were dependent on dose 
and time of exposure. The IC50s of picrocrocin for TC-1 cells were 4 and 3 mM at 24 and 48 
hours after treatment, respectively. The cytotoxicity was achieved through an apoptosis 
mechanism (Khavari et al., 2015).  
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1.6.2.4. Safranal 
Safranal is a monocyclical terpenic aldehyde which is chemically known as 2, 6, 6-
trimethyl-1, 3-cyclohexadiene-1-carboxaldehyde. It is a small molecule with a molecular weight 
of 150.21 g/mole that can be obtained naturally as a free compound or bound form (picrocrocin) 
in saffron, or synthetically with a high purity and yield (Könst et al., 1974, Giaccio, 2004). 
Chemically, safranal possesses free radical scavenger properties and 500 µg/ml 
scavenged 34% of free radicals in DPPH assay through donating the hydrogen atom to the free 
radical (Assimopoulou et al., 2005). In an in vivo study, safranal demonstrated antioxidant 
activity. Briefly, safranal was administrated to rats prior to inducing oxidative stress by the 
ischemia-reperfusion injury method which causes damage to the hippocampus.  Safranal 
protected the hippocampal tissue by increasing the antioxidant capacity of the hippocampus 
(Hosseinzadeh and Sadeghnia, 2005). In another study, safranal restored antioxidant enzymes 
including SOD and GST which were decreased in rat brains as a result of aging (Samarghandian 
et al., 2015). Similarly, safranal protected stomachs from developing ulcers caused by using non-
steroidal anti-inflammatory drugs. The protective activity was related to the ability of safranal to 
decrease gastric ulcer lesions and lipid peroxidation as well as elevate the gastric tissue 
glutathione levels in a dose-dependent manner (Plants and Karaj, 2009). 
Providing the mice with different concentrations of safranal prior to DNA damage 
induction by methyl methanesulfonate (MMS) exposure caused a reduction between ≈ 25 – 31% 
of DNA damage in different organs including the liver, kidney, spleen, and lung. This study 
revealed a dose-dependent protective activity of safranal against genotoxic substances 
(Hosseinzadeh and Sadeghnia, 2007). A different study showed the ability of safranal to reduce 
the hematological toxicity that was caused by organophosphate insecticides such as diazinon, a 
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cholinesterase inhibitor. Diazinon reduced hemoglobin, hematocrit, and red blood cells and these 
adverse outcomes were reversed and restored to normal levels by safranal. The safranal did not 
show any activity on cholinesterase (Hariri et al., 2011). 
In a previous study, safranal demonstrated its ability to block histamine (H1) receptors. 
Briefly, isolated tracheal chains of guinea pigs were exposed to 1.4 μM of indomethacin that 
resulted in histamine release. The histamine induced contractions of the tracheal chains. This 
activity was significantly inhibited by safranal in a concentration-dependent manner by blocking 
H1 receptors (Boskabady et al., 2011). It is known that histamine plays an important role in 
cancer biology by stimulating tumor growth, progression, and metastasis (Blaya et al., 2010). 
One of the predominant sites of H1 receptor expression is prostate tissue (Wang et al., 2014a). 
Using an H1 receptor antagonist such as terfenadine against prostate cancer cell lines inhibited 
cell proliferation and activated an apoptosis intrinsic pathway (Wang et al., 2014b). These 
observations indicate the ability of safranal to be used as an anticancer therapeutic targeting 
histamine receptors. 
Safranal also showed activity in treating type 2 diabetes mellitus by producing 
antidiabetic effects after an oral administration of 20 mg/kg on a daily basis in mice. The safranal 
worked using two different mechanisms to lower the blood glucose level. It significantly induced 
the translocation of glucose transporter type 4 from muscle and fat cells’ intracellular vesicles to 
the plasma membrane that increased glucose uptake. Moreover, safranal is a protein tyrosine 
phosphatase 1B (PTP1B) inhibitor which decreased insulin resistance by inhibiting the tyrosine 
dephosphorylation of insulin receptors (Maeda et al., 2014). A high expression of PTP1B which 
is under the control of androgen receptor activity was associated with a high risk of prostate 
cancer. PTP1B was required for the growth of androgen-dependent prostate cancer. It was also 
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required for cell migration and the invasion of androgen-independent prostate cancers. 
Therefore, a PTP1B inhibitor is considered a new target for prostate cancer drug development 
(Lessard et al., 2012). 
Safranal showed a cytotoxic effect against the neuroblastoma cell line (N2A) with an IC50 
of 11.1 μg/ml after 48 hours of incubation by inducing apoptotic cell death (Samarghandian et 
al., 2014). It showed a stronger antiproliferative activity by treating cervical cancer cells (HeLa) 
at lower concentrations (IC50 of 120 μg/ml after 24 hours) compared to saffron extract, crocin, 
and picrocrocin with an (Escribano et al., 1996). In breast cancer, safranal induced cell toxicity 
in both estrogen dependent and independent cancer cells at 75 μg/ml (48 hours) a similar 
concentrations (Chryssanthi et al., 2007). 
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS 
Based on existing literature, we hypothesize that saffron and its active components could 
both prevent prostate cancer development and treat existing cancer cells. Our project aims to 
systematically verify saffron’s mechanisms of action for the first time using different models of 
prostate cancer. Both in vitro and in vivo studies will provide better and more specific 
interventions to prevent and/or treat prostate cancer. Therefore, this project will determine 
whether or not these natural products can be used as a natural supplement for antioxidant and 
anti-cancerous benefits. Regardless of saffron’s efficacy, a new in vivo model using zebrafish for 
prostate cancer drug discovery will be developed. Research in this dissertation addresses five 
main aims. 
Aim 1. Compare cytotoxicity of saffron and its active constituents in normal and prostate 
cancer cells in vitro. 
Hypothesis: Saffron extract and/or its active components will prevent prostate cancer cell 
proliferation by activating cell apoptosis. 
Approach: Use the XTT cytotoxicity assay to determine in vitro IC50s following exposure and 
the Caspase-Glo kit to quantitate apoptosis. 
Aim 2: Investigate the antioxidant potential of saffron’s active constituents in normal 
prostate cells. 
Hypothesis: Saffron’s active components will reduce free radicals by acting as a scavenger 
and/or by activating antioxidant enzymes. Therefore, these natural components will work as 
chemo-preventative agents against prostate cancer development. 
  
40 
 
Approach: After the in vitro cell lines are exposed to saffron constituents, ROS products will be 
measured by using H2DCFDA. 
Aim 3: Investigate the ability of saffron and its active constituents to inhibit migration 
and/or invasion via decreased matrix metalloproteinase enzymes (MMP) resulting in the 
inhibition of prostate cancer metastasis. 
Hypothesis: Saffron and its active constituents inhibit prostate cancer metastasis by decreasing 
the migration and invasion as a result of decreased MMP 1/9 production. 
Approach: In vitro migration and invasion will be assessed with a wound healing assay and 
modified Boyden (invasion) chambers, respectively. RT-PCR will be used to measure the gene 
expression of MMP1/9. 
Aim 4: Establish and validate the zebrafish xenograft model as a new alternative to 
mammalian xenograft models for prostate cancer. 
Hypothesis: The xenografted zebrafish model for prostate cancer cells is an accurate, faster, 
easier, and cheaper in vivo model to host human prostate cancer cells. 
Approach: Use known drug, docetaxel, as a positive control (used for chemotherapy to treat 
prostate cancer) to validate the model. 
Aim 5: Determine the in vivo effects of saffron’s active components on human prostate 
cancer cells in a successful xenografted zebrafish model. 
Hypothesis: Human prostate cancer cells xenografted in zebrafish will undergo cytotoxicity 
when exposed to safranal. 
Approach: Following exposure, the fluorescence intensity of transplanted fluorescein-labeled 
prostate cells will be used to determine cytotoxicity. Tracking transplanted human prostate cells 
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in different types of zebrafish will be performed to detect the proliferation and invasion behavior 
of cancerous cells. 
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CHAPTER 3: MATERIAL AND METHODS 
3.1.Materials 
22Rv1 and PC-3 cell lines were purchased from ATCC and PNT1A cell line from Sigma. 
Matrigel matrix growth factor reduced without phenol red (356231) was from BD Biosciences. 
Fetal Bovine Serum (FBS) – Advantage (S11050) was from Atlanta Biologicals. Sterile cell 
culture inserts 8 µm pore size for 24 well plates (662638) were from Greiner Bio-One. LB Broth, 
Miller (BP1426), Formic acid (10775711), and Kanamycin monosulfate (BP906) were from 
Fisher Scientific. Xfect single shots transfection reagent (631366), NucleoSpin® RNA Plus 
(740984), NucleoBond® Xtra Maxi (740414), G418 (631307), and pCMV DsRed-Express2 
vector (632539) were from Clontech laboratories. Crocetin (193543) and Hydrogen peroxide 
(194057) from were MP Biomedicals. H2DCFDA (D399) and DH5α E. coli competent cells 
were from Invitrogen. Accumax® (AM105) was from Innovative Cell Technologies. Picrocrocin 
(CS-T-60315) was from Clearsynth. Caspase-Glo® 3/7 Assay (G8091) was from Promega. 
RaqMan® reverse transcription reagents (N8080234) and Sybr® green PCR master mix 
(4309155) were from Applied Biosystems. Sodium Bicarbonate (7412) was from Mallinckrodt. 
QIAEX® II gel extraction kit (20051) was from Qiagen. OmniPur® Agarose (2081) was from 
EMD. Docetaxel (D-1000) was from LC laboratories. Ethanol 200 proof (2701) was from Decon 
laboratories. Methanol HPLC grade (A452), water HPLC grade (W5), and Acetonitrile HPLC 
grade (A21) were from Fisher chemicals. RPMI-1640 medium (R8755), F-12 Ham Kaighn′s 
Modified medium (N3520), DMEM medium (D2902), DPBS (D5652), D-Glucose (G5400), 
DMSO (D4540), Ethyl 3-aminobenzoate methanesulfonate salt (A5040), Crocin-1 (17304), 
  
43 
 
Safranal (W338907), Giemsa Stain (32884), HEPES (H4034), Sodium pyruvate (P2256), 
Ethidium bromide solution (E1510), Bovine Serum Albumin (A7906), Diethyl pyrocarbonate 
(159220), Trypsin Solution 10X (59427C), Antibiotic Antimycotic Solution (100×) (A5955), 
Trypsin inhibitor (T6414), Phenol red sodium salt (P4758), formaldehyde solution (F1635), XTT 
sodium salt (X4626), and PMS (P9625) were all purchased from Sigma. 
 
 
3.2. Methods 
 
3.2.1. Saffron identification, extraction, and fractionation 
3.2.1.1. Saffron extraction 
Saffron stigmas were extracted using 95% ethanol unless stated otherwise at ratio of 1 
gram: 100 ml for 24 hours in dark at room temperature using a shaker at speed of 150 rpm. After 
24 hours, the extract was filtered using a polyethersulfone (PES) membrane filter with a 0.22 µM 
pore size. The ethanol was evaporated using a rotary evaporator (Buchi rotavapor, model # R-
114) equipped with water chiller system at a medium rotation speed and 40oC for water bath 
temperature. The whole extract obtained from this procedure was saved at 4oC in the dark for 
future work. 
 
3.2.1.2. Commercial samples of saffron 
A total of 11 different commercial samples were obtained from multiple growing regions 
including Iran, Spain, and Afghanistan and were extracted using a 95% ethanol solvent (Table 
4). All extracts were tested for their biological activities. All saffron stigmas were acquired 
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commercially and had botanical identified Crocus sativus stigmas and were coded by National 
Center for Natural Products Research (NCNPR). We conducted HPLC analysis on all samples 
and the marker compounds, such as safranal, picrocrocin, crocin, and crocetin were present in 
every extract, although the concentrations of constituents differed significantly among each 
other. The presence of crocin, picrocrocin, safranal, and crocetin indicated that the samples were 
correctly labeled with their genus and species of the plant material (see Appendix for HPLC 
graphs). 
 
 
Table 4: The summary of the growing regions of commercial saffron samples with their 
given codes 
Code Country 
18248 Iran 
18249 Afghanistan 
18250 Spain 
18251 Spain 
18252 Spain 
18253 Spain 
18254 Spain 
18255 Spain 
18256 Iran 
18257 Spain 
18258 Iran (Reference) 
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3.2.1.3. Fractionation of saffron extract using the centrifugal thin layer chromatography 
(Chromatotron) 
A Chromatotron is a preparative Thin Layer Chromatography (TLC) instrument that 
produces a centrifugal force through spinning, which makes the mobile phase solvent move from 
the center area to the side of the device (Figure 4) (Ilias et al., 2014). This movement will make 
the compounds separate between the mobile and the stationary phases. At the end, the mobile 
phase eluates the compounds depending on their polarities. There are multiple factors controlling 
the performance of the Chromatotron regarding separation including types of stationary and 
mobile phases used, rotation speed, and mobile phase flow rate. This method of fractionation 
provides many advantages which include the ability to separate large amounts, quick, and less 
damage to sensitive compounds. 
 
 
 
Figure 4: Chromatotron instrument used in fractionation of the saffron extract 
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The saffron #18256 extract was fractionated using Chromatotron. The stationary phase 
used in Chromatotron was amino-bonded silica normal phase. A gradient mobile phase consisted 
of dichloromethane (DCM) and methanol was used. Whole extract (113 mg) was dissolved in a 
mixture of DCM and methanol in a ratio of 8:2, respectively. The stationary phase was saturated 
and equilibrated with DCM before adding the sample. The gradient mobile phase started with 
100% DCM and ended with 100% methanol by increasing the methanol solvent concentration in 
5% increments. The final step was adding the methanol containing 1% of acetic acid. Each 
increment volume was 10 ml of the solvent mixture. The highest separation and resolution of 
fractionation was achieved when the flow rate of the mobile phase was 5 ml/minute and the 
rotation speed was 1000 rpm. The eluents were collected based on the volume and the 
compound’s bands detected by using the UV detector at 254 and 365 nm wavelengths. The 
fractions were collected in 63 test tubes held in a tube rack. After collection, the obtained 
fractions were analyzed using reverse phase TLC (as described in 3.2.1.4) with standard 
references (crocin, crocetin, and safranal) to combine similar compounds that yielded 13 
fractions after combination (Figure 5). The fractions were dried using a speed vacuum 
concentrator (Speedvac SC210A, Thermo) to keep them stable and avoid sample cross-
contamination with regular methods. The total fraction weight was 101.2 mg which was equal to 
90% of the starting weight. All samples were then kept in the dark at 4oC for further work. The 
purity of each fraction was measured using HPLC. 
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62-63        57-61        53-56       49-52        46-48       41-45       36-40           35          27-34        21-26    18-20         3-17          1-2        Crocetin     Crocin     Safranal    Extract
 
Figure 5: RP-TLC of Chromatotron fractions of the saffron extract compared to standard 
references (crocetin, crocin, safranal, whole extract). Sixty-three fractions were combined 
into 13 prior to RP-TLC. 
 
 
3.2.1.4. Analysis of fractions using RP-TLC 
Thin-layer chromatography was performed on a reverse phase silica gel plate containing 
UV indicator (F254s). After spotting each fraction on the plate, the TLC plate was transferred 
into a developing chamber. Then, 20 ml of mobile phase consisting of 90% acetonitrile and 10% 
water was placed into the chamber. When the mobile phase migrated and covered 90% of the 
TLC plate, the plate was dried, viewed under UV light, and photographed. 
 
  
48 
 
3.2.2. HPLC and UHPLC-MS analysis 
3.2.2.1. Chromatographic parameters 
Quantitative HPLC analysis was conducted using an Agilent 1100 HPLC system 
equipped with a degasser (G1379A), quaternary pump (G13311A), auto sampler (G1313A), 
column oven (G1316A), and UV-Diode detector (G1315B) controlled by Chemstation software. 
The separation of analytes was carried out on RP-C18 column (3×250 mm; particle size 4 µm; 
Phenomenex, Synergi Hydro-RP) with column oven temperature set at 25°C and using the 
gradient system of eluent water (A) and methanol (B) for the separation of target compounds. 
The gradient condition was as follows: 0-2 min (20% B), 2-47 min (100% B), 47-52 min (100% 
B), 52-52.25 min (20% B), 52.25-60 min (20% B). The flow rate of the solvent was 0.3 ml/min 
and the injection volume was 5 µl. All the analysis was carried out at wavelengths of 257, 325, 
and 440 nm with a run time 60 minutes. 
 
3.2.2.2. Mobile phase system 
HPLC grade acetonitrile and water solvents were used. Formic acid was added as a 
modifier to achieve a final concentration of 0.1% in each solvent. Using the ultrasonic bath, the 
resulting mixture solution was sonicated for 5 minutes. 
 
3.2.2.3. Preparation of stock solution of standard compounds 
A stock of standard solutions of four major high-purity compounds present in saffron was 
prepared in appropriate solvents to ensure complete solubility (picrocrocin and crocin in water, 
safranal in methanol, and crocetin in DMSO (1%) then in water) with a concentration of 4 mg/ml 
of crocin, 0.4 mg/ml of safranal, 0.3 mg/ml of crocetin, and 2.5 mg/ml for picrocrocin. Serial 
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dilutions were then prepared from the stock solutions to create a calibration curve. These were 
stored in darkness at 4°C until analysis was conducted. 
 
3.2.2.4. Preparation of sample solution 
A sample solution of 10 mg/ml of fresh saffron extract was prepared for HPLC analysis. 
Briefly, the saffron extract sample was prepared by dissolving 10 mg of fine ground powder of 
fresh saffron stigma in 1 ml of the specified solvent (HPLC grade solvent) and left overnight. It 
was then centrifuged at a speed 4000 rpm for 5 minutes at a room temperature of at 25oC. An 
aliquot of the top layer was filtered through a 0.45 µm PTFE filter, then transferred into vials for 
HPLC analysis. The extract sample was kept in darkness at 4°C until analysis was carried out. 
 
3.2.2.5. Validation parameters of the developed method 
3.2.2.5.1. Linearity 
The linearity-developed HPLC analytical method was validated using four marker 
compounds. Two of these were found to be in abundant quantity in saffron which were 
picrocrocin and crocin, whereas the remaining two were available in small quantities in the plant. 
Standard solutions ranging from 33.33-2500 µg/ml of picrocrocin, 250-4000 µg/ml of crocin, 10-
300 µg/ml crocetin, and 1.25-400 µg/ml of safranal were prepared. Five µl of each prepared 
standard solution was injected and analyzed using the developed HPLC method. Each 
concentration of each compound’s standard solution was injected in triplicate. Using the analysis 
data from the HPLC analysis method of each compound, it was possible to produce calibration 
curves of marker compounds through the linear regression analysis. Calibration curves were 
created by plotting the peak area on the y-axis versus concentration of each pure compound in 
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the x-axis. The linear regression equation (y = mx+b) was calculated by the least-square 
regression method to determine the linearity. Using the developed analytical HPLC method, the 
calibration curves of all standard compounds showed good linearity regression, as presented in 
Figures 6-9. 
 
 
 
 
Figure 6: The calibration curve of picrocrocin ranging from 33.33-2500 µg/ml (three 
injections for each concentration). 
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Figure 7: The calibration curve of crocin ranging from 250-4000 µg/ml (three injections for 
each concentration). 
 
 
 
 
Figure 8: The calibration curve of safranal ranging from 1.25-400 µg/ml (three injections 
for each concentration). 
 
  
52 
 
 
Figure 9: The calibration curve of crocetin ranging from 10-300 µg/ml (three injections for 
each concentration). 
 
 
3.2.2.5.2. Specificity 
A blank control (consisting of methanol and water, which is similar to the used gradient 
system), standard solutions, and saffron extract samples were injected separately in a fixed 
volume to analyze them for the specificity validation of the developed analytical HPLC method.  
 
3.2.2.5.3. Accuracy 
For accuracy determination, the recovery studies of the developed HPLC method were 
used. A specific amount of each of the four major compounds was accurately prepared and 
analyzed. The percentage of the recovered amount was calculated using the following formula: 
recovered amount (%) = (amount spiked - amount present)/amount spiked ×100. 
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3.2.2.5.4. Precision 
The precision of the developed analytical method was examined using the intraday 
precision (repeatability) as well as the interday precision (intermediate precision) analysis which 
was conducted on six replicates for saffron extract samples on the same day for intraday 
precision and after one week for interday precision. The results were expressed as %RSD 
= (SD/mean) ×100%. 
 
3.2.2.5.5. Sensitivity 
Under the conditions of the developed HPLC method, the limit of detection is the lowest 
compound’s concentration that can be detected distinguished from the baseline noise, whereas 
the limit of quantification is the lowest compound’s concentration that can be precisely and 
accurately quantified. The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated according to the following equation formula 3.3 σ/S and LOQ = 10 σ/s, respectively. S 
and σ stand for the slope of the calibration curve and the standard deviation of response, 
respectively. 
 
3.2.3. Cell culture and maintenance 
All cell lines were grown in RPMI-1640 phenol red free growth medium supplemented 
by 2.5 g of D-Glucose (4.5 g/l as a final concentration of D-Glucose), 110 mg of sodium 
pyruvate, 1% of antibiotic-antimycotic solution (10,000 units’ penicillin, 10 mg streptomycin, 
and 25 µg amphotericin), 2.383 g of HEPES, 1.5 g sodium bicarbonate, and 10% fetal bovine 
serum (FBS) in a humidified incubator with 5% CO2 in the air at 37
oC. Cells were grown in 75 
cm2 tissue culture flasks and passaged when they became 80% confluent by treating them with 
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0.25% trypsin reagent, after cells detached an equal amount of trypsin inhibitor was added to 
stop trypsin activity. Then, the cells were transferred into conical tubes and centrifuged at 1000 
rpm for 5 minutes using a Sorvall® RT7 centrifuge. Finally, the supernatant was discarded, 
replaced with fresh growth medium, subdivided into 1:5 ratios, and dispensed into a new culture 
flask. 
 
3.2.4. Cytotoxicity assay 
A cytotoxicity assay was done to determine the in vitro viability IC50 of saffron extract 
and its active constituents in each cell line. The second generation tetrazolium salt, XTT reagent 
(sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium 
salt) measures mitochondrial activity which reflects live cell percentage (Scudiero et al., 1988). 
To seed cells (100 µL) of growth media with 10,000 cells was added in each well of 96 well 
plate. After 24 hours, 50 µL of growth media was added containing the desired concentration of 
test compounds or vehicle solvent control. After 24, 48, and 72 hours the cells were incubated 
with 75 µL of XTT reagent (that contained 1 mg/ml of XTT and 7.66 µg/ml of PMS activator). 
After 4 hours of incubation, the absorbance at 488 nm was taken using a HTS 7000 microplate 
reader (PerkinElmer® connected to an HP computer and HT 2.0 software). This method was 
modified for saffron extract, crocin, and crocetin cytotoxicity measurements.  There were two 
reasons for these modifications. First, these substances are colored and they absorb at 420 - 460 
nm which interferes with the XTT reagent absorption. Second, the usual OD background for 
these substances can reach 2.2 and the OD for converted XTT tetrazolium salt by cells can reach 
2, so the total OD will be over 3, and the maximum OD range measured by this model of 
microplate reader is 3. Therefore, the following steps have been followed after the specific 
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incubation time of the cells with treatments; the microplate was centrifuged at a speed of 1000 
rpm for 5 minutes, then the growth media containing the treatment was aspirated and 150 µL of 
DPBS was used to wash wells and remove the treatment residuals, centrifugation and aspiration 
steps were repeated. Then, 150 µL of growth media containing 50 µL of XTT reagent (that 
contains 1 mg/ml of XTT and 7.66 µg/ml of PMS activator) were added. After 4 hours, the 
microplate was read using the microplate reader. Each treatment concentration group and their 
background had at least 3 replicates. For data analysis, the mean of the blank replicates was 
subtracted from each replicate of treatment concentration group, then was normalized to a 
control group that represented 100% cell survival according to the equation shown below. The 
normalized treatment concentration groups were analyzed using a Graphpad Prism 5 to 
determine IC50 and statistics. 
% 𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙 (𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = (
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑔𝑟𝑜𝑢𝑝 − 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘 𝑔𝑟𝑜𝑢𝑝
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝 − 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘 𝑔𝑟𝑜𝑢𝑝
) × 100 
 
3.2.5. Apoptosis assay 
To measure the apoptotic effects of saffron and its active components, caspase-3/7 
enzymes were measured using a Caspase-Glo kit for in vitro studies. This assay is based on the 
fact that the effector caspase-3/7 enzymes are members of the cysteine aspartic acid-specific 
protease group. In the presence of the poly ADP-ribose polymerase (PARP) protein, the effector 
caspase-3/7 will remove the caspase cleaved domain (cleavage site) to deactivate PARP which 
decreases ATP production and initiates programmed cell death. This assay consists of two 
components which are the luminogenic caspase-3/7 substrate and cell lysis buffer. The substrate 
has tetrapeptide sequence Asp-Glu-Val-Asp (DEVD) which is recognized by caspase enzymes to 
free the bond recombinant luciferase. This thermally stable luciferase releases a stable 
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luminescent signal that directly correlates with the caspase-3/7 levels available inside the cells 
which is quantitated after cell lysis. 
Prior to conducting the assay (24 hours before), a fresh mixture of the Caspase-Glo® 3/7 
Reagents were prepared by mixing and thoroughly dissolving the lyophilized substrate 
component in the provided buffer, and this was stored at 4oC until use. Cells (10,000) were 
seeded in each well of the 96 well white plates. After 24 hours, two different concentrations of 
each compound were added in addition to a vehicle only control. After 6 additional hours of 
incubation with the treatment, the microplate was centrifuged and the growth media containing 
the treatments was replaced with warm Dulbecco's phosphate buffered saline (DPBS) for wash. 
Then 100 µL of DPBS was added, followed by the addition of 100 µL of Caspase-Glo 3/7 
reagent in each well to make the total volume 200 µL and achieve a 1:1 ratio of the reagent to the 
sample volume. The plates were then covered with their lids and the reagents were mixed using 
the plate shaker at speed of 150 rpm for 1 minute. The plate was removed from the shaker and 
covered with aluminum foil to protect it from light and was then incubated at room temperature 
for 30 minutes to allow for development of the signals. The readings were taken using the 
Synergy microplate reader (BioTek®) at the luminescent wavelength of 528/20 nm. 
𝐶𝑎𝑠𝑝𝑎𝑠𝑒 3/7 𝑙𝑒𝑣𝑒𝑙 𝑓𝑜𝑙𝑑 (𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = (
𝑙𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑔𝑟𝑜𝑢𝑝 − 𝑙𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝 − 𝑙𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘
) 
 
 
3.2.6. Oxidative stress 
A 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) probe was used to determine 
the radical scavenging capacity of saffron and its active constituents by measuring the reactive 
oxygen species (ROS) levels after H2O2 exposure. This probe is non-fluorescent until the reagent 
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is oxidized by ROS present inside the cells. Briefly, when the cells absorb the H2DCFDA, the 
intracellular esterases cleave the diacetate group which is a lipophilic blocking group. After 
esterification a charged form of the dye is created which prevents H2DCF from leaving the cells 
and retains them inside. When the cells generate free radicals upon H2O2 exposure, the free 
radicals will oxidize the H2DCF which is non-fluorescent into DCF which is fluorescent. 
Therefore, the fluorescence intensity level directly correlates to the cellular oxidative stress level 
(Lebel et al., 1992). 
PNT1A, normal prostate cells were seeded at density of 2.5 × 104 cells in 400 µL in each 
well of a 24-well plate. After 24 hours of incubation, the cells were treated with two different 
nontoxic concentrations of saffron extract, safranal, and crocetin for 4 hours. The plate was then 
centrifuged at a speed of 1,000 rpm for 5 minutes and the medium containing the treatment was 
removed carefully and washed with warm DPBS. Then, a final working concentration of 10 μM 
H2DCFDA prepared in DPBS was added in the dark and incubated at 37
oC to allow for the cells 
to load the probe. After 30 minutes, the loading buffer was removed and the cells were washed 
twice with warm DPBS to ensure all of the extracellular probe was removed, which prevents 
result errors produced from the interaction of extracellular H2DCFDA and the added H2O2. After 
the cells were washed, 50 μM of H2O2 in 400 µL DPBS was added to each well and was further 
incubated for 30 minutes to produce free radicals and induce cellular oxidative stress. The 
fluorescent intensity was measured using a HTS 7000 microplate reader (PerkinElmer® 
connected to an HP computer and HT 2.0 software). The measurements were taken from the well 
bottom and the parameters were set up at 492 nm for excitation, 535 nm for emission, and 129 
for gain. 
% 𝑂𝑥𝑖𝑑𝑎𝑡𝑖𝑣𝑒 𝑙𝑒𝑣𝑒𝑙 (𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = (
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑔𝑟𝑜𝑢𝑝 − 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝 − 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘
) × 100 
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3.2.7. Migration assay (wound healing assay) 
A wound healing assay is considered a traditional method to measure the ability of cells 
to migrate (move) from a condensed area to a less condensed area. Therefore, we used it to 
detect the ability of saffron and its active components to inhibit migration behavior of prostate 
cancer cells. Briefly, one million cells were seeded in each well of a 6 well plate. After 24 hours, 
in each well a scratch line was made using a 10 µL micropipette tip. Then, the growth media was 
aspirated and washed with DPBS. The growth media containing the treatment was added. Each 
treatment group had 3 replicates. After 24 hours, the cells were assessed for their ability to 
migrate toward the scratched area that was previously cell-free. Pictures were taken using an 
inverted microscope with 4X objective (Nikon TS 200). ImageJ 1.49 software (NIH) to measure 
the area covered by the cells. Normalized data to the control group that represented 100% of 
migrated cells according to the equation mentioned below. The normalized data was analyzed 
using a Graphpad Prism 5 to determine IC50 for migration. 
% 𝐶𝑙𝑜𝑠𝑒𝑑 𝑔𝑎𝑝 (𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
= (
𝑢𝑛𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑎𝑟𝑒𝑎 𝑏𝑦 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑎𝑡 0 ℎ𝑜𝑢𝑟𝑠 − 𝑢𝑛𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑎𝑟𝑒𝑎 𝑏𝑦 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑎𝑡 24 ℎ𝑜𝑢𝑟𝑠
𝑢𝑛𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑎𝑟𝑒𝑎 𝑏𝑦 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑎𝑡 0 ℎ𝑜𝑢𝑟𝑠 − 𝑢𝑛𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑎𝑟𝑒𝑎 𝑏𝑦 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑎𝑡 24 ℎ𝑜𝑢𝑟𝑠
) × 100 
 
3.2.8. Migration and invasion assay using Boyden (transwell) chamber 
The Boyden chamber assay is a valuable tool used to determine the ability of treatments 
to inhibit or reduce the migration and/or invasion behaviors of cells. The advantage of this 
method over a wound healing assay is it is more relevant as an in vitro tool to in vivo conditions 
(Kramer et al., 2013). The Boyden chamber involves a three dimensional condition compared to 
two dimensions in a wound healing assay. It also mimics in vivo conditions where cancer cells 
are attracted to a reach area which leads to upregulation of the genes responsible for secretion of 
matrix metalloprotease enzymes needed to degrade basement membranes to facilitate metastases 
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to distant locations. Therefore, we used Matrigel growth factor reduced (GFR) to coat the 
transwell chamber membrane in order to mimic the basement for the invasion assay. Whereas, in 
a migration assay, the transwell is used without a Matrigel coating (Figure 10). To aliquot 
matrigel for assay, the matrigel was transferred from -20oC to 4oC for overnight. On the second 
day, all materials were chilled at 4oC for 6 hours such as the micropipette tips, the 24 well plate, 
and the transwell before contact with Matrigel. In the fume hood, the Matrigel was diluted to 1 
mg/ml using cold DMEM without FBS, then 35 µL of diluted matrigel was transferred to each 
transwells and spread evenly without introducing bubbles. After that, the 24 well plates 
containing coated transwells were incubated overnight at 37oC to gel. On the third day, when the 
cells in the culture flask were 80% confluent, the regular growth media was replaced with FBS 
free growth media contains 0.1% bovine serum albumin (BSA) to starve the cells. After four 
hours, the FBS free growth media was removed and the cells detached using Accumax® for 45 
minutes to form a single cell suspension and avoid cluster cells which interfere with the assay’s 
accuracy. Cells were then transferred from the flask into the incubator for 10 minutes to 
deactivate the reagent. The cells were transferred from the culture flask into a conical tube and 
centrifuged at 1,000 rpm for 5 min at room temperature. The supernatant was removed, the cells 
were suspended in FBS free growth media, and the cell number was counted using a 
hemocytometer. The cell concentration was adjusted to be 1.5x106/ml and the desired treatment 
concentration was added. The treated cell suspension (200 µL) was added to each transwell, then 
the transwell was transferred into the lower chamber of a 24 well plate containing 800 µL of 
growth media with 10% FBS which was used as a chemoattractant for cell migration and 
invasion. Cells were then incubated for 36 hours. After the incubation period, the media was 
carefully removed from the insert and washed twice with DPBS. The cells were fixed with 4% 
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formaldehyde diluted with DPBS for 10 minutes, the formaldehyde was then removed and 
washed twice with DPBS. Methanol (100%) was used to permeabilize the cells for 20 min, 
methanol was then removed and washed twice with DPBS. The cells were stained for 20 min 
using a modified Giemsa stain, afterwards the stain was removed and the cells washed three 
times with DPBS. The non-migrating and invading cells which stayed in the upper side of the 
insert membrane were removed by scraping them using a cotton swab. Finally, the migrating and 
invading cells were counted using an inverted Nikon microscope (TS-100) with 40X objective 
and the picture was taken with the AmScope camera (MD130).  
 
 
Medium without FBS
Medium with FBS
Matrigel coat
Cell
Migration Assay
Invasion Assay
0 hr 36 hr
 
Figure 10: The differences between migration and invasion assays using Boyden chambers 
(transwells) 
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3.2.9. Preparation and optimization of pCMV-DsRed Express2 plasmid for transfection: 
Originally, the DsRed Express vector was generated from Discosoma species red 
fluorescent protein (DsRed) by substituting nine amino acids to accelerate the protein 
maturation, increase the solubility, and decrease the green emission. It lacks the tendency to 
aggregate compared to the wild type DsRed (Bevis and Glick, 2002). Later, DsRed Express 2 
vectors were engineered to use in sensitive cells and in vivo applications. The engineering of 
DsRed Express 2 from its original version of DsRed Express improved the maturation rate, 
solubility, and cell viability with high photostability. The cytotoxicity and phototoxicity effects 
were negligible when the bacterial and mammalian cells were transfected with the DsRed 
Express 2 vector. The toxicity was reduced as a result of minimizing protein aggregation which 
is responsible for toxicity, although the DsRed Express 2 protein is expressed in the same level 
as the older version but with a higher level of fluorescence (Strack et al., 2008).  
The pCMV-DsRed Express2 plasmid is used for whole cell labeling purposes, so it 
becomes easy to monitor the cells after transplanting in animals for in vivo study. As shown in 
Figure 11, the plasmid contains the active human cytomegalovirus immediate early promoter 
(PCMV IE) to drive the DsRed Express2 gene expression, which make the transfected cells 
constitutively express the red fluorescent protein. The red fluorescence of DsRed Express2 in 
transfected live cells is easily detected and quantified using a fluorescent microscope and flow 
cytometry. This plasmid is characterized by the presence of two antibiotic resistant genes which 
include the G418 resistant gene for a stable transfection in mammalian cells and the kanamycin 
resistant gene for E. coli propagation (Clontech-Laboratories, 2008). 
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Figure 11: pCMV-DsRed Express 2 map  (accessed 2/1/2016,  
www.clontech.com/US/Products/Fluorescent_Proteins_and_Reporters/Fluorescent_Protein
s_by_Name/ibcGetAttachment.jsp?cItemId=51774&fileId=6346463&sitex=10020:22372:U
S) 
 
 
3.2.9.1. Amplification of DsRED protein plasmid 
In the bottom of a culture tube, 5 μl (1 μg/μl) of DsRed Express 2 stock was gently mixed 
with 100 μl of a DH5α strain of Escherichia coli (E. coli) cells and chilled on ice for 30 minutes. 
To insert the plasmid into the DH5α, the heat shock technique was used by incubating the 
mixture at 37oC for 1 minute, followed by chilling on ice for 2 minutes. SOC medium (1 ml) was 
added into the tube and incubated at 37ºC at a speed of 220 rpm for one hour in a shaking 
incubator. After incubation, the E. coli was pelleted using a centrifuge at a speed of 3,000X g for 
5 minutes and 1 ml of the supernatant was removed. The remaining 100 μl of transformed E.coli 
was spread on prewarmed selective LB agar plate containing 50 µg/ml of kanamycin antibiotic 
to select the cells containing the plasmid. The plate was then incubated upside down at 37ºC for 
16 hours and the plate was stored at 4ºC until extraction and purification. The plasmid was 
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extracted from the transformed E. coli and purified according to the company protocol using a 
NucleoBond® Xtra Maxi kit. The obtained plasmids were run in 1% agarose gel containing 
ethidium bromide to get rid of residual RNA contamination for further purification purposes 
(Figure 12). The plasmid bands were cut out and extracted using a QIAEX II Gel Extraction Kit 
following the manufacturer’s instructions. 
 
 
DsRed Express2 plasmid
E. coli RNA contamination
 
Figure 12: Residual RNA from E. coli were removed by extracting the plasmids only 
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3.2.9.2. Measurement of G418 cytotoxicity using clonogenic assay 
A clonogenic assay was used to determine the survival cells rate in which it measures the 
ability of a single cell in the population to form a colony. A fraction of the cells when seeded can 
generate colonies (Franken et al., 2006). Our study used a clonogenic assay to determine the 
minimum concentration of geneticin (G418) required to induce the selection pressure on 
transfected cells. The advantages of using a clonogenic assay over regular cytotoxicity assays, 
such as XTT and MTT, are the incubation time and cultural maintenance are more relevant to the 
selection process, because the selection process usually takes place for one month with a high 
concentration and that can be decreased later to a lower concentration as a maintenance 
procedure to indefinitely keep the selection pressure on transfected cells.  
Prostate cancer cell lines (22Rv1 and PC3) were grown on 6-well culture plates for 
10 days in which 500 cells of each type were seeded in each well in triplicate. After 24 hours, 
two concentrations of the G418 antibiotic were added to the cells in addition to the control 
group. Every three days, the growth media was replaced with fresh growth media containing the 
exact concentration of the antibiotic. On day 10, the formed colonies were stained using ethidium 
bromide (Guda et al., 2007). Briefly, the growth media was removed and a freshly prepared 
solution of 0.05% of 10 mg/ml ethidium bromide in 50% ethanol was added to cover the 
colonies in each well. After 15 seconds, the ethidium bromide solution was aspirated and the 
colonies were immediately visualized and pictured using a VersaDoc 3000 imaging system 
(BioRad®) interfaced with PDQuest software under the control of the connected computer (HP®). 
The colonies were counted using ImageJ software and analyzed using GraphPad software. 
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3.2.10. Cell line stable transfection with DsRED protein 
Prostate cancer cells (22Rv1 and PC3) were seeded with 3x105 into each well of 6 well 
plates. After 24 hours, 5 µg of purified DsRed Express 2 plasmid was suspended in 100 µL of 
autoclaved water. The diluted plasmid was mixed with xfect single shots and vortexed for 10 
seconds. After 10 min at room temperature, the suspension was added to 1 ml of the complete 
regular growth medium. Then, the old growth media was removed from the well and replaced 
with the new prepared growth media containing the plasmid. After 72 hours, each well 
containing the cells was subcultured as usual and seeded in a 75 cm2 culture flask containing the 
selection concentration of G418 antibiotic (1000 µg/ml) for stable transfection. The growth 
media that contained the selective concentration of G418 was changed twice weekly. Enough 
cells expressing the DeRed Express 2 protein were obtained after one month of cell growth and 
maintenance. The protein expression was confirmed using a fluorescent microscope. The G418 
were decreased to the maintenance concentration (250 µg/ml) for regular cell maintenance 
during the study period. 
 
3.2.11. Doubling time 
To determine the cells doubling time after 48 hours of incubation in the specified 
conditions (37oC vs. 35oC and transfected vs. non-transfected). Two 96-well plates were 
prepared by seeding the cells in six replicates of each plate. After 24 hours of seeding the cells, 
the XTT along with its activator PMS agents were added in the first plate as previously described 
in the cytotoxicity method. Three hours later, the absorbance of the first plate was measured. 
Then, the second plate was measured after 48 hours from first plate absorbance measurement (72 
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hours after seeding). The population doubling time was calculated according to the following 
formula (Atcc, 2014): 
Doubling Time = 𝑇 ×
𝑙𝑛2
ln (
𝐴
𝐵)
 
T: is the incubation time in hours. 
A: is the cell absorbance at the beginning of the incubation time. 
B: is the cell absorbance at the end of the incubation time. 
 
3.2.12. Zebrafish culture 
Tg(fli1a:EGFP)y1 zebrafish was  a generous gift from Dr. Robert Tanguay (Oregon State 
University) and roya9; mitfaw2 zebrafish “Casper” was purchased from ZIRC, catalog ID: 
ZL1714 (Eugene, OR). Zebrafish have been raised according to IACUC protocol #14-020 and 
kept in restricted access clean facilities. The light cycle in the zebrafish facilities was 14 hours of 
light and 10 hours of dark (9 pm - 7 am) to mimic natural breeding conditions. The zebrafish 
water parameters were 26-30oC for water temperature, 7.4-7.6 for pH, and 60 ppm for 
conductivity which adjusted by Instant Ocean salt. Adult fish were fed twice daily with tropical 
flake fish food and live brine shrimp which is enough to be consumed in five minutes to avoid 
overfeeding problems. Larvae at age 5 dpf were fed twice daily with 20-80 micron size ArteMac-
0 powered (Bio-Marine), at 11-13 dpf with ArteMac-0 powered in the morning and live brine 
shrimp in the evening, at 14-30 dpf, live brine shrimp twice daily. When the larvae become older 
than 30 dpf, they were fed as adults. Prior to 9/10/2015, zebrafish were fed as described above. 
After 9/10/2015, the culture colonies were transitioned to Gemma food (75 micro for 5-30 dpf, 
150 micro 30-70 dpf, and 300 micro for > 70 dpf).  For egg collection, 1:1 male to female ratio 
of matured zebrafish were spawned twice weekly in a spawning trap tank. Two hours after the 
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onset of the light cycle, the fertilized eggs were collected from the breeding zebrafish. Then, the 
fertilized eggs were washed, dead removed, and transferred into a petri dish that contained 
embryo zebrafish water with 0.5 ppm methylene blue and kept in a zebrafish incubator (28oC 
temperature and 14:10 hour light cycle). Dead zebrafish embryos were removed from the petri 
dish and the water was changed on a daily basis. When the larvae reached the age of 5 dpf, they 
were transferred to a regular tank in the zebrafish system. 
 
3.2.13. Crossbreeding zebrafish 
The Casper zebrafish genome should possess homozygous mutated roya9 and mitfaw2 
genes to be transparent and lack pigmentation on their body. These mutated genes are recessive 
alleles. On the other hand, Tg(fli1a:EGFP) transgenic zebrafish express the enhanced green 
fluorescent protein permanently in their endothelial cells under the control of the fli1a promoter 
during their whole life. Therefore, Tg(fli1a:EGFP) transgenic with Casper lines were crossed to 
produce a transparent Tg(fli1a:EGFP) zebrafish that would make it easier to monitor their 
labeled vasculature system under the fluorescent microscope without pigmentation interfering 
with imaging. The Casper and Tg(fli1a:EGFP) transgenic lines were maintained, bred separately, 
and then crossed together in order to generate the hybrid line and stock them for experiments 
according to the approval # 14-020 obtained from the Institutional Animal Care and Use 
Committee (IACUC) of the University of Mississippi at University, MS. 
The crossing was conducted in multiple steps and took almost one year to complete, for 
more clarification see Figure 13. Adult Tg(fli1a:EGFP) male and Casper female zebrafish were 
crossed at a ratio of 1 male to 1 female in the breeding tanks. The fertilized eggs were collected 
from the lower chamber of the breeding tanks which is separated by a plastic mesh. These 
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embryos represented the first generation (F1) of the crossed lines. All F1 generation embryos 
have heterozygous dominant wildtype and recessive mutated versions of roya9 and mitfaw2 genes 
as a result of equal distributions of the parent’s alleles. Therefore, the appearance of F1 zebrafish 
are similar to Tg(fli1a:EGFP) transgenic line as a result of the dominant allele. Furthermore, all 
embryos gained Tg(fli1a:EGFP) which makes their vasculature fluorescent. After 48 hpf, all 
embryos were examined under a fluorescent microscope to keep the strongest and exclude the 
weakest expressing EGFP, the selected embryos were then raised to adulthood. After 4 months, 
the F1 generation reached sexual maturation and were incrossed to produce the second 
generation (F2). Besides the ability of all F2 generation to express EGFP, they are variable in 
their appearances due to differences in inheritance patterns. The probability of getting a Casper 
with two homozygous mutated genes is 1/16 (Tables 5-6). The obtained Casper Tg(fli1a:EGFP) 
transgenic were raised to adulthood and bred to obtain the third generation (F3). All experiments 
related to the zebrafish were conducted using the embryos of the founded colonies from F3. The 
hybrid line of crossing the Tg(fli1a:EGFP) with Casper did not reveal any defects in animal 
development. 
 
Table 5: Crossing of F-1 zebrafish, AaBb x AaBb whereas (A) and (B) letters represent 
roya9 and mitfaw2, respectively. The uppercase and lowercase letter represent the dominant 
wildtype allele and recessive mutated allele, respectively.  
 AB Ab aB ab 
AB AABB AABb AaBB AaBb 
Ab AABb AAbb AaBb Aabb 
aB AaBB AaBb aaBB aaBb 
ab AaBb Aabb aaBb aabb 
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F0
F1
F2
F3 Tg(fli1a:EGFP) x Casper
 Casper Tg(fli1a:EGFP)
 
Figure 13: Description of zebrafish crossing steps 
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3.2.14. Zebrafish optimization for transplantation 
3.2.14.1. Determination of the maximum tolerated temperature by zebrafish 
The optimum temperature for human cultured cells is 37oC whereas it is 28oC for 
zebrafish larvae. Multiple temperature points were used to find the maximum tolerated 
temperature without affecting zebrafish survival rates. Three temperature points: 28oC, 32oC, 
35oC, and 37oC were selected for evaluation. Afterwards, each fertilized egg was transferred into 
each well of a 96-well uncoated plate and incubated at the specified temperature point for up to 
six days with daily monitoring and changing their water. 
 
3.2.14.2. Optimizing the microscopic fluorescent filters setting 
It is known that the enhanced green fluorescent protein (EGFP) emission wavelength is 
broad. Because it has an autofluorescence background which can cause an interference with the 
red wavelength emission, the fluorescent filter combination should be carefully selected for the 
DsRed Express 2 protein to obtain the specific spectrum with high efficiency rather than the 
EGFP autofluorescence effects (Figure 14). Overestimating the cancer cell’s signal intensity is 
possible as a result of using the crossed zebrafish which express EGFP with transfected cancer 
cells expressing DsRed Express 2 protein. Therefore, it is necessary to find the proper filter set 
combination to overcome this problem especially when a quantitative fluorescence intensity is 
required. Narrowing the excitation and emission filter bands by using the proper dichromic 
extended reflector (dcxr) with the correct cut-off between the excitation and emission 
wavelengths minimizes the interference between wavelengths and will help to exclusively 
monitor the DsRed Express 2 while removing the EGFP emission in DsRed Express 2 protein 
wavelength emission range (Table 7). It is very important to swiftly obtain pictures of both 
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proteins after the fluorescent light path is opened to avoid photobleaching effects which may 
produce inaccurate results of their intensity. Therefore, the bright field was used when each 
individual zebrafish larvae was transferred from its plate and prepared for imaging. 
 
 
 
Fluorescence 
Intensity
Wavelength (nm)  
Figure 14: The excitation and emission wavelength spectrums of EGFP and DsRed Express 
2 proteins. (University of Arizona, www.spectra.arizona.edu). 
 
 
Table 7: The suitable filter combination to detect EGFP and DsRed proteins 
Filter Ex (nm) DCXR (nm) Em (nm) 
EGPF 483/35 500 523/20 
DsRed Express 2 555/11 587 589/10 
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3.2.15. Xenografted of human transfected prostate cell into crossed zebrafish and treatment 
3.2.15.1. Preparation of cells for transplantation 
On the injection day, the growth media that contains G418 antibiotic was removed and 
replaced with DPBS as a wash. After washing the cells, the DPBS was removed and replaced 
with an Accumax® solution to detach the cells from the culture flask. After 45 minutes of 
incubation at room temperature to form a single cell suspension, the suspension was transferred 
to a centrifugation tube and then it was centrifuged for 5 minutes at 1000 rpm and 4oC and then 
the cells’ debris and solution was aspirated. The cells pellet was suspended in cold FBS-free 
DMEM which contained 1.5% of matrigel and 0.04% phenol red, then it was placed on ice until 
injection time. The cell concentration was 20x106 cells/ml. 
 
3.2.15.2. Preparation of zebrafish for transplantation 
Zebrafish embryos (1dpf) were dechorionated by placing them in a petri dish containing 
0.5 mg/ml of protease and swirling them occasionally for 4 minutes, then removing the 
protease and washing the embryos twice with water. After that they were transferred into a new 
petri dish containing fresh culture water. 
 
3.2.15.3. Xenograft procedure 
The zebrafish larvae were anaesthetized with 0.02% tricaine methanesulfonate: 0.04% 
sodium bicarbonate until they became inactive. Under a dissecting microscope (Carl Zeiss), the 
injections were conducted. The transfected prostate cancer cells were loaded into a pulled glass 
micropipette which was attached to an air-driven microinjector (Narishige IM 300). The needle 
was inserted into the yolk sac of each zebrafish larvae and cancer cells were delivered in a single 
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injection. The injection volume ranged from 15 nl to 20 nl of cell suspension. The number of the 
injected cells was optimized to between 300-400 cells in each injection used using a 25 ms pulse 
time and 14 psi pressure. After injection, the zebrafish larvae were transferred immediately into 
embryo water for recovery and placed in an incubator at (35oC). 
 
3.2.15.4. Visualizing the zebrafish 
The endothelial cells of the Tg(fli1a:EGFP) zebrafish express a green fluorescent protein 
and the cancer cells express red florescent proteins. After 24 hours of transplantation (2dpf), non-
successful cancer transplantation into zebrafish larvae and dead larvae were removed. The 
successful xenografted zebrafish larvae were anesthetized and examined under a fluorescent 
microscope (Nikon Eclipse E600) for a visible prostate cancer cell mass in the yolk to exclude 
non-successful transplanted zebrafish. Then the images were captured using a CCD camera 
(Nikon) using NIS elements software (Nikon). Each active xenografted zebrafish was transferred 
into a single well of a 48-well plate and labelled.  
 
3.2.15.5. Treating the xenografted model 
The experiment was conducted using these zebrafish which were examined daily through 
to 4 dpf. Each well had 200 µl of water that contained a specified treatment concentration 
(maximum DMSO concentration was 0.05%). After 24 hours of treatment, the prostate cancer 
fluorescent intensity zebrafish were measured again using a fluorescent microscope.  At 4 dpf 
and after visualizing the zebrafish larvae, they were euthanized using a tricaine methanesulfonate 
overdose (2%) to terminate the experiment. The red fluorescence images were analyzed using 
ImageJ software and quantified as described in the following equations: 
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(1) 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 =  𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 
(2) % 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑡𝑜 24 ℎ𝑝𝑖) =  
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑎𝑡 2 𝑜𝑟 3 𝑑𝑝𝑖
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑎𝑡 1 𝑑𝑝𝑖
 × 100 
 
 
3.2.16. Gene expression using Real Time PCR 
Cells (2x105) were seeded in a 6-well plate and after 24 hours, the specified treatment 
was added in triplicate for each concentration. After 72 hours of incubating with the treatment, 
the cells were washed with DPBS twice and the cells were detached from the plate by using the 
cell scraper. They were then transferred into micro-tubes and centrifuged at 1000 rpm for 5 
minutes. The DPBS was replaced by the lysis buffer provided by the kit for homogenization. 
Afterward, the total RNA was isolated using the NucleoSpin® RNA Plus (Clontech). The RNA 
quantity was determined by the NanoDrop 2000 spectrophotometer (Thermo Scentific). Using 
small PCR tubes, 250 ng of total RNA was mixed with the reaction buffer (Random Hexamers, 
RNase Inhibitor, and Multiscribe RT) to form a final concentration of 10 ng/µl of RNA. The 
mixture incubated in the thermocycler at: 25°C for 10 minutes, 37°C for 60 minutes, and 95°C 
for 5 minutes to inactivate the reverse transcriptase. Then it was stored at -80oC until analysis. A 
mixture of 2 µl of cDNA, 6.5 µl of water, 1 µl of each primer pair (5 μM) and 12.5 µl of SYBR 
Green PCR master mix were added in triplicate to measure the gene expression using an Applied 
Biosystems 7500. Table 8 demonstrates the primer sequences which were used in the 
measurements of six genes. The expression of all genes was normalized using the reference gene 
(18S). The relative gene expression was calculated according to the Pfaffl formula; the obtained 
results were then analyzed for any significant differences in their expression using GraphPad 
(ANOVA, n=3) (Pfaffl, 2001). 
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The relative expression ratio = (Etarget)
∆CPtarget(control–sample) / (Eref)
∆CPref(control–sample) 
E: the PCR efficiency for the gene’s primers  
∆CP: the difference of crossing point 
Table 8: Genes’ primer sequences 
Pathway Gene Forward primer Reverse primer 
Reference 18S 5'-TGGTTAATTCCGATAACGAACGA-3' 5’-CGCCACTTGTCCCTCTAAGAA-3' 
Apoptosis 
CASP3 5'-TGGAATTGATGCGTGATGTTTC-3' 5'-CATGGCTCAGAAGCACACAAAC-3' 
CASP7 5'-TGCTAATCCTCGATACAAGATCCC-3' 5'-CCACGAGTAATAGCCTGGAACC-3' 
CASP9 5'-GACCCTGGACGACATCTTTGAG-3' 5'-CAGCATTAGCGACCCTAAGCAG-3' 
Migration 
and Invasion 
MMP1 5'-GGGAGATCATCGGGACAACTC-3' 5'-ATTGTTGGTCCACCTTTCATCTTC-3' 
MMP9 5'-CTTCCAGTACCGAGAGAAAGCC-3' 5'-CCACCTGGTTCAACTCACTCC-3' 
 
 
3.2.17. Statistical analysis 
All results were presented as mean ± S.E. and analyzed using GraphPad Prism 5.04 
software (La Jolla, CA). Statistical differences between treatment groups were determined by 
one-way analysis of variance (ANOVA) followed by Newman-Keuls post hoc test or student t-
test. Statistical significance between treatment and corresponding control groups was accepted at 
p ≤ 0.05. 
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CHAPTER 4: DEVELOPMENT OF EXTRACTION AND ANALYSIS METHODS FOR 
SAFFRON AND ASSESSMENT OF COMMERCIALLY AVAILABLE SAFFRON 
 
4.1. Results 
4.1.1. The effect of different solvent systems used for saffron extraction on its cytotoxic 
activity 
The cytotoxic effects of different concentrations of methanolic and ethanolic saffron 
extract #18258 on normal human and prostate cancer cell lines were evaluated with the XTT 
assay, as described in Chapter 3. All cell lines were exposed to multiple concentrations (0.125–2 
mg/mL) of saffron extracts for 72 hours. All the extracts inhibited cell proliferation in all cell 
lines in a concentration-dependent manner. There was a direct relationship between the 
concentration of ethanol used in saffron extraction and the cytotoxic effects. On the other hand, 
when methanol solvent was used, the relationship also applied to 22Rv1, but PNT1A and PC3 
cytotoxicity did not directly correlate when methanol concentration was lower than 70%. The 
study showed that the 95% ethanol extraction was least cytotoxic on normal cells and more 
cytotoxic to PC3 compared to 95% methanol. Generally, ethanolic extracts comparably 
demonstrated stronger growth inhibition on all prostate cancer cell lines than the methanolic 
extracts. This suggests that the anticancer compounds were primarily concentrated in the ethanol 
and the compounds responsible for normal prostate cell toxicity were mostly concentrated in the 
methanol. 
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4.1.1.1. The cytotoxicity of different ethanolic concentrations of saffron extracts 
Different concentrations of ethanol solvent were used to extract the saffron. The 
cytotoxic response differed significantly as the solvent / water ratio was changed. The weakest 
cytotoxic effects against the prostate cancer cell lines was obtained using 50% ethanolic saffron 
extract, but the cytotoxic effect increased when a higher percentage ethanolic saffron extract was 
used. Incubation of 50% ethanolic extract with the cells produced a significant decrease in cell 
viability of PNT1A cells starting at 0.125 mg/ml with an IC50 equal to 0.73 ± 0.16 mg/ml, while 
at the same time cell viability of 22Rv1 decreased at 0.5 mg/ml with an IC50 equivalent to 2.27 ± 
0.72. The survival of PC3 decreased at 1 mg/ml with an IC50 corresponding to 3.23 ± 0.83 mg/ml 
(Figure 15). When 60% ethanolic extract was used, it led to decreases in the required extract 
concentration to produce cytotoxic activity on all cells. A significant reduction in cell viability of 
PNT1A cells started at 0.125 mg/ml with an IC50 of 0.66 ± 0.15 mg/ml, while cell viability of 
22Rv1 and PC3 declined at 0.5 mg/ml with an IC50 matching 2.09 ± 0.5 and 2.77 ± 0.65 mg/ml, 
respectively (Figure 16). Using 70% ethanolic saffron extract significantly increased the 
cytotoxicity of PNT1A cells which was induced at 0.25 mg/ml with an IC50 equal to 0.63 ± 0.13 
mg/ml. Cytotoxicity in 22Rv1 was detectable at 0.25 mg/ml with an IC50 corresponding to 1.71 ± 
0.33, while in PC3 cytotoxicity started at 1 mg/ml with an IC50 equivalent to 2.35 ± 0.63 mg/ml 
(Figure 17). A significant decrease in cell viability of PNT1A, 22Rv1, and PC3 cells was found 
with 0.125, 0.25, and 0.5 mg/ml respectively when 80% ethanolic saffron extract was used. The 
IC50s were 0.49 ± 0.10, 1.55 ± 0.26, and 2.2 ± 0.88 mg/ml for PNT1A, 22Rv1, and PC3, 
respectively (Figure 18). The maximum inhibitory effects were found with 95% ethanolic saffron 
extract. A significant growth inhibition of PNT1A cells began at 0.125 mg/ml with an IC50 of 
0.38 ± 0.07 mg/ml, whereas cell viability of 22Rv1 was reduced at 0.5 mg/ml with an IC50 
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matching 1.32 ± 0.19. PC3 viability started to decrease at 0.25 mg/ml with an IC50 equal to 1.77 
± 0.23 mg/ml (Figure 19). Therefore, the strongest cytotoxic effects were achieved using 95% 
ethanolic saffron extract. As a general rule, the cytotoxic effects toward normal cells were higher 
than early and advanced stages of prostate cancer cells, respectively, with all ethanol solvent 
concentrations used. 
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Figure 15: The cytotoxicity of prostate cell lines after 72 hours using 95% ethanolic saffron 
extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 16: The cytotoxicity of prostate cell lines after 72 hours using 80% ethanolic saffron 
extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 17: The cytotoxicity of prostate cell lines after 72 hours using 70% ethanolic saffron 
extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 18: The cytotoxicity of prostate cell lines after 72 hours using 60% ethanolic saffron 
extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 19: The cytotoxicity of prostate cell lines after 72 hours using 50% ethanolic saffron 
extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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4.1.1.2. The cytotoxicity of different methanolic concentrations of saffron extracts 
With all methanolic solvent concentrations used to extract the saffron, a significant 
inhibitory effect of saffron extracts on the early stages of prostate cancer cells (22Rv1) started at 
0.5 mg/ml. The cytotoxic activities produced by all concentrations of methanolic solvent system, 
except 95%, against the advanced stages of prostate cancer (PC3) were triggered at 1 mg/ml of 
saffron extract, whereas for 95% the methanol extract at 0.5 mg/ml induced cytotoxicity. The 
IC50s of 50% methanolic extracts were 2.17 ± 0.64 and 2.98 ± 0.67 mg/ml for 22Rv1 and PC3, 
respectively (Figure 20). Incubation of 60% methanolic saffron extract with the cancerous cells 
produced a significant decrease in cell viability of 22Rv1 and PC3 with IC50s equal to 2.27 ± 0.6 
and 2.95 ± 0.74 mg/ml, respectively (Figure 21). Methanolic saffron extract (70%) significantly 
increased the cytotoxicity of the cells with an IC50s corresponding to 1.91 ± 0.38 for 22Rv1 and 
2.99 ± 0.66 mg/ml for PC3 (Figure 22). Regarding the activity of methanolic saffron extracts on 
normal prostate cells (PNT1A), our study found that all methanolic extracts began to exert their 
cytotoxic effects at concentrations as low as 0.125 mg/ml. When 50-70% methanolic extracts 
were used, they produced similar activity and their IC50 was 0.4 ± 0.07. The responses of PNT1A 
and PC3 cells were unchanged when the concentration of methanol used in saffron extraction 
was increased from 50% to 70%. In contrast, 22Rv1 cell line growth was declined when the 
concentration of methanol used in extraction process was increased. In addition, when 80% 
methanolic saffron extract was used, the IC50s were 0.36 ± 0.06, 1.53 ± 0.32, and 2.44 ± 0.6 
mg/ml for PNT1A, 22Rv1, and PC3, respectively (Figure 23). Finally, the maximum inhibitory 
effects on cellular proliferation of all cell types was gained with 95% methanolic extract. The 
IC50 on PNT1A, 22Rv1, and PC3 was 0.32 ± 0.05, 1.26 ± 0.25, and 1.98 ± 0.39 mg/ml, 
respectively (Figure 24). 
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Figure 20: The cytotoxicity of prostate cell lines after 72 hours using 95% methanolic 
saffron extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 21: The cytotoxicity effects of prostate cell lines 72 hours using 80% methanolic 
saffron extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 22: The cytotoxicity of prostate cell lines after 72 hours using 70% methanolic 
saffron extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
 
 
mg/ml
%
 C
e
ll
 s
u
rv
iv
a
l
(R
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
C
tr
l
0.
12
5
0.
25 0.
5 1 2
0
20
40
60
80
100
120
PNT1A
22RV1
PC3
*
*
*
**
*
**
*
*
 
Figure 23: The cytotoxicity of prostate cell lines after 72 hours using 60% methanolic 
saffron extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
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Figure 24: The cytotoxicity of prostate cell lines after 72 hours using 50% methanolic 
saffron extract # 18258. Bars with * symbol are statistically significant from control group 
(ANOVA; N = 4) 
 
 
4.1.2. The cytotoxicity effects of different commercial saffron samples on prostate cells 
Our study measured the differences in the cytotoxicity and selectivity of 10 commercially 
available saffron (Crocus sativus) samples, grown abroad and all available in the USA, on 
prostate cancer cells. All samples were identically prepared using 95% ethanol solvent with the 
exact steps of the extraction process and the cytotoxicity evaluated in normal (PNT1A) and 
prostate cancer (22Rv1 and PC3) cell lines after 72 hours of exposure using an XTT assay as 
described in Chapter 3. Our study revealed that all concentrations of the obtained saffron extracts 
differed significantly in their cytotoxic effects on the normal as well as the prostate cancer cell 
lines (Figures 25-34). Also, two out of the ten tested samples (#18250 (Spain) and #18252 
(Spain)) produced significant cell cytotoxicity against prostate cancer cells at a concentration 
lower than 2 mg/ml. 
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Of particular interest, the PNT1A cells exposed to saffron extracts #18250 showed a 
slight decrease in viability compared to other commercial samples that were tested in this study. 
The IC50 after incubation was 1.69 ± 0.5, 1.78 ± 0.27, and 1.97 ± 0.34 mg/ml for PNT1A, 22Rv1, 
and PC3, respectively. However, using 2 mg/ml of saffron extract #18252 resulted in an only 
26% increase in cytotoxicity in PNT1A cells indicating that this saffron sample had the lowest 
toxicity against normal cells compared to other extract samples. The IC50s using the extract 
#18252 on PNT1A, 22Rv1, and PC3 corresponded to 1.15 ± 0.19, 1.67 ± 0.49, and 1.97 ± 0.35 
mg/ml, respectively. 
In contrast, saffron extract #18253 (Spain) demonstrated weak activity against cancerous 
cells (22Rv1 and PC3) where the IC50s were 3.08 ± 0.56 and 5.01 ± 1.25 mg/ml for 22Rv1 and 
PC3, respectively. In addition, saffron extract #18257 (Spain) had similar cytotoxicity in 22Rv1 
and PC3 cells with an IC50s equal to 8.19 ± 2.36 and 10.22 ± 2.38 mg/ml, respectively, but only 
0.76 ± 0.12 mg/ml was needed in PNT1A cells to produce a similar effect. Therefore, our study 
showed this commercial sample extract (# 18257) was highly cytotoxic in normal cells and only 
had weak activity against cancer cells. Moreover, saffron extracts #18248 and 18249, from Iran 
and Afghanistan respectively, exhibited no significant effect against the PC3 cell line, and the 
predicted IC50s of 8.22 ± 2.56 mg/ml and ≥ 34.47 mg/ml were projected to be above the dose 
range tested.  
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Figure 25: The cytotoxicity of prostate cell lines of saffron commercial sample # 18248 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.37 ± 0.33, 2.56 ± 0.46, and 8.22 ± 
2.56 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 26: The cytotoxicity of prostate cell lines of saffron commercial sample #15249 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.78 ± 0.39, 2.85 ± 0.67, and ≥ 34.47 
mg/ml for PNT1A, 22Rv1, and PC3, respectively.  Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 27: The cytotoxicity of prostate cell lines of saffron commercial sample #15250 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.69 ± 0.5, 1.78 ± 0.27, and 1.97 ± 
0.34 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 28: The cytotoxicity of prostate cell lines of saffron commercial sample #15251 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.64 ± 0.42, 3.05 ± 0.65, and 3.91 ± 
1.19 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 29: The cytotoxicity of prostate cell lines of saffron commercial sample #18252 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.15 ± 0.19, 1.67 ± 0.49, and 1.97 ± 
0.35 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 30: The cytotoxicity of prostate cell lines of saffron commercial sample #15253 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.42 ± 0.28, 3.08 ± 0.56, and 5.01 ± 
1.25 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 31: The cytotoxicity of prostate cell lines of saffron commercial sample #15254 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.09 ± 0.18, 2.39 ± 0.55, and 3.85 ± 
1.02 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 32: The cytotoxicity of prostate cell lines of saffron commercial sample #15255 after 
72 hours using 95% ethanolic solvent. The IC50s were 1.06 ± 0.17, 1.88 ± 0.34, and 3.76 ± 
0.99 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 33: The cytotoxicity of prostate cell lines of saffron commercial sample #18256 after 
72 hours using 95% ethanolic solvent. The IC50s were 0.79 ± 0.12, 4.2 ± 0.45, and 4.77 ± 0.9 
mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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Figure 34: The cytotoxicity of prostate cell lines of saffron commercial sample #18257 after 
72 hours using 95% ethanolic solvent. The IC50s were 0.76 ± 0.12, 8.19 ± 2.36, and 10.2 ± 
2.38 mg/ml for PNT1A, 22Rv1, and PC3, respectively. Bars with * symbol are statistically 
significant from control group (ANOVA; N = 4) 
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4.1.3. HPLC analysis 
4.1.3.1. HPLC analytical method development and optimization 
Development of a new analytical HPLC method that has the capability to measure, 
simultaneously, multiple compounds in complex extracts is considered a challenging task that 
relies on obtaining high resolution peaks for each compound’s quantification. The selection of 
appropriate HPLC parameters such as column, temperature, flow rate, mobile phase, gradient 
system, and wavelength are crucial optimization steps. That parameters’ selection of the 
developed method was targeted to produce a high resolution chromatogram with low baseline 
noise when it is used to separate the major saffron compounds including the four marker 
compounds (picrocrocin, crocin, safranal, and crocetin). 
During the development process different solvents were tried, including methanol, 
acetonitrile, and water. A mobile phase composed of gradient methanol and water was found to 
be the most effective system to separate the saffron extract constituents. Moreover, adding the 
formic and acetic acids to the mobile phase was evaluated. Adding 0.1% formic acid enhanced 
peak’s shape by increasing its sharpness and decreasing tailing. Multiple run times with flow 
rates were examined and 60 minutes with 0.3 ml/minute was found to be the best combination to 
produce a good separation of different compounds. After the solvents with their additives were 
chosen, the gradient system selection was made based on the obtained results of various tests of 
the starting organic percentage such as 10, 20, and 30% of methanol at the beginning of the run. 
The best composition of the mobile phase at the beginning of the run was 20% methanol:80% 
water. The gradient system comprises water (A) and methanol (B) as: 0-2 min, 20% B; 2-47 min, 
100% B; 47-52 min, 100% B; 52-52.25 min 20% B; 52.25-60 min, 20% B (Figure 35). 
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Maximum wavelength absorbance for each of marker compounds was optimized and 
found to be 257 nm for picrocrocin, 315 nm for safranal, and 428 nm as well as 458 nm for 
carotenoids (crocin and crocetin) as presented in Figure 36. Although the maximum absorbance 
wavelengths of safranal and carotenoids were determined, shifting from these wavelength was 
employed for several reasons. For safranal there were noticeable interfering compounds that had 
higher absorbance at 315 nm which affected the peak baseline and thus the detection sensitivity. 
Therefore, the safranal absorbance was shifted to 325 nm to minimize the interference peaks. 
The 440 nm rather than double peaks (428 and 458 nm) was used for detecting the absorbance of 
carotenoids (crocin and crocetin) because the single 440 nm wavelength was between the two 
maximum wavelengths.  
 
 
 
Figure 35: Gradient system used in the developed HPLC method. 
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Figure 36: Spectrophotometer scan from 190-700 nm for saffron extract. 
 
 
4.1.3.2. Validation parameters of the developed analytical HPLC method 
4.1.3.2.1. Linearity 
The linearity of the developed analytical HPLC method was validated using multiple 
concentrations of each of the pure compounds ranging between 1.25-400 µg/ml of safranal, 10-
300 µg/ml crocetin, 33.3-2500 µg/ml of picrocrocin, and 250-4000 µg/ml of crocin. The 
concentration range of each pure compound was chosen based on the expected concentration to 
be found in saffron extract in addition to the maximum linearity that could be achieved. Serial 
dilution of the pure stock solution was prepared for the purpose. The analysis of standard 
solutions was carried out in triplicate for each concentration. As shown in Table 9, the obtained 
standard calibration curves depicted linearity in the tested range for each compound with good 
correlation coefficients for all marker compounds, ranging between 0.9992 and 0.9996. 
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Table 9: The linearity and regression equations of saffron’s marker compounds. 
Marker compound Calibration curve * R2 Linear range (µg/ml) 
Picrocrocin y = 11.745x – 75.563 0.9992 33.33-2500 
Crocin y = 8.5293x + 380.17 0.9992 250-4000 
Safranal y = 48.006x – 35.122 0.9993 1.25-400 
Crocetin y = 6.003x + 20.291 0.9996 10-300 
* The calibration curves were generated by plotting the peak areas on the y-axis versus the 
concentration of each pure compound on the x-axis. 
 
 
 
4.1.3.2.2. Specificity 
The elution of the four marker compounds with well resolved and symmetric peaks were 
found to be at 21.48 ± 0.84 min for picrocrocin, 31.33 ± 0.58 min for crocin, 41.87 ± 0.42 min 
for safranal, and 49.55 ± 0.39 min for crocetin. In Figure 37, the saffron extract chromatograms 
at different wavelengths show all markers compounds with a good separation of their peaks. 
Monitoring each peak retention time and peak shape for each marker compounds, including start, 
apex, and end of spectral peak revealed that each chromatogram was well resolved with highly 
symmetrical peak shape. Therefore, the developed HPLC analytical method showed acceptable 
specificity toward the saffron constituents with high sensitivity and without interference peaks. 
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Figure 37: HPLC analysis of saffron #18258 extract using 95% ethanol at wavelengths (A) 
257 nm, (B) 325 nm, and (C) 440 nm. 
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4.1.3.2.3. Accuracy 
The accuracy evaluation of the developed analytical HPLC method was done using 
known amounts of each pure compounds to spike a pre-measured extract. Then, the ability to 
recover the added amount was assessed, as shown in Table 10. The recovery of the added 
amount ranged from 97.9% to 101% for picrocrocin, 98.8 to 99.9% for crocin, 99.1 to 101% for 
safranal, and 98.5 to 102.7% for crocetin and relative standard deviations ranged from 0.45 to 
6.09%. The recovery results demonstrated the high accuracy of the developed method. 
 
 
Table 10: Recovery percentage of saffron marker compounds. 
Spiked sample Concentration 
(µg/ml) 
Amount recovered ± 
SD 
% Average recovery % RSD 
Picrocrocin 2200 2195 ± 32.7 99.8 1.49 
1100 1111 ± 18.6 101.1 1.68 
300 293 ± 8.21 97.9 2.8 
Crocin 3600 3596 ± 16.3 99.9 0.45 
2400 2395 ± 23.8 99.8 0.99 
1200 1185 ± 16.1 98.8 1.36 
Safranal 300 300 ± 4.2 100 1.4 
200 202 ± 3.46 101 1.71 
20 19.8 ± 0.86 99.1 4.34 
Crocetin 240 241 ± 4.19 100.5 1.74 
120 118 ± 3.01 98.5 2.55 
30 30.8 ± 1.88 102.7 6.09 
 
  
98 
 
4.1.3.2.4. Precision 
The % relative standard deviation (RSD) for both inter- and intra-day precision was 
below 3.15%, which indicated a good precision of the analytical method (Table 11). The 
repeatability of the analytical method was examined by RSD values of peak areas which was < 
1.93%. 
 
 
Table 11: Intra- and inter-day precision of saffron marker compounds. 
Sample (µg/ml) 
Intra-day precision Inter-day precision 
Amount recovered + SD % RSD Amount recovered + SD % RSD 
Picrocrocin (1300) 1303 ± 19.4 1.49 1270 ± 34.6 2.72 
Crocin (2200) 2195 ± 23.8 1.08 2172 ± 68.5 3.15 
Safranal (250) 251 ± 4.84 1.93 248 ± 5.2 2.1 
Crocetin (180) 180 ± 3.25 1.81 177 ± 3.83 2.17 
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4.1.3.2.5. Sensitivity 
The quantification parameters including limit of detection (LOD) and limit of 
quantification (LOQ) were calculated and are shown in Table 12, which indicated the high 
sensitivity of the developed method.   
 
 
Table 12: LOD and LOQ of saffron’s marker compounds 
Marker compound LOD (µg/ml) LOQ (µg/ml) 
Picrocrocin 44.2 134 
Crocin 71.7 217 
Safranal 1.98 5.99 
Crocetin 4.84 14.7 
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4.1.4. Identification of saffron chemical composition using HPLC-MS 
One of the developed HPLC method’s advantages is the capability to link it with mass 
spectrometry for detection. Mass spectrophotometry provides information regarding the 
compounds presented in the saffron extract which facilitates the detection of adulterated samples. 
The electrospray ionization (ESI) mode was used as the ionization method in mass spectrometry 
and revealed the compounds evident in saffron as shown in Appendix #3. Most of saffron 
constituents were identified by matching the fragmentation patterns obtained from HPLC-MS to 
the known molecular weight of saffron compounds (Table 13). For example, picrocrocin at 3.93 
min was detected using negative ESI mode and spectrum of [M-H+HCOOH]- ions (m/z 375.2) as 
shown in Figure 38. 
 
 
Table 13: Identified compounds present in the saffron extract using UHPLC-MS. 
RT (min) λmax (nm) Formula 
Mode of 
detection 
m/z 
Structural 
elucidation 
3.93 260 C16H26O7 negative ESI 375.2 [M-H+HCOOH]- Picrocrocin 
5.32 440 C44H64O24 negative ESI 975.2 [M-H]- Crocin-1 
5.84 440 C38H54O19 negative ESI 859.2 [M-H+HCOOH]- Crocin-2 
7.80 440 C32H44O14 negative ESI 697.2 [M-H+HCOOH]- Crocin-3 
11.44 325 C10H14O positive ESI 151.2 [M+H]+ Safranal 
11.80 440 C20H24O4 positive ESI 329.2 [M+H]+ Crocetin 
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Figure 38: Fragmentation patterns of picrocrocin detected using negative ESI mode of 
UHPLC-MS 
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4.1.5. HPLC quantification of saffron constituents produced using different solvent systems 
Our study investigated the amount of saffron constituents present in saffron extract after 
using different solvent systems. It was found that each solvent system had a different affinity to 
extract specific compounds which became obvious when the concentration of the aqueous 
portion was increased. Table 14 shows the ability of different organic solvents as well as their 
concentration to extract each marker compound in saffron. The concentrations of picrocrocin and 
crocin increased when the aqueous portion in the used solvents (ethanol and methanol) was 
increased. This observation was expected because the picrocrocin and crocin are hydrophilic 
compounds which are more soluble in water than organic solvents. However, regardless of 
extraction solvent there were no significant changes in the concentrations of safranal and 
crocetin likely due to their low presence in saffron extracts. Specifically, safranal and crocetin 
made up only approximately 0.4 and 0.8% of the dry weight of the #18258 extract. In contrast 
picrocrocin and crocin were maximally 20 and 40% dry weight of the same extract (Table 14). 
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Table 14: The constituent concentrations in saffron extract #18258 produced by using 
different solvent systems. 
Solvent 
Concentration (µg/ml) % Dry weight 
Picrocrocin Crocin Safranal Crocetin Picrocrocin Crocin Safranal Crocetin 
EtOH 
95% 1022 ± 36.4 3063 ± 85.4 32.9 ± 0.41 43.2 ± 0.49 10.2 ± 0.36 30.6 ± 0.85 0.33 ± 0.01 0.43 ± 0.01 
80% 1667 ± 27.4 3204 ± 61.3 35.6 ± 2.05 71.3 ± 3.17 16.7 ± 0.27 32 ± 0.61 0.36 ± 0.02 0.71 ± 0.03 
70% 1643 ± 31.3 3311 ± 63.3 38.4 ± 1.65 79.1 ± 2.66 16.4 ± 0.31 33.1 ± 0.63 0.38 ± 0.02 0.79 ± 0.03 
60% 1838 ± 30.8 3591 ± 24.8 36.1 ± 1.11 70.4 ± 1.74 18.4 ± 0.31 35.9 ± 0.25 0.36 ± 0.01 0.7 ± 0.02 
50% 1922 ± 31.8 3721 ± 44.2 35 ± 2.05 59.3 ± 3.71 19.2 ± 0.32 37.2 ± 0.44 0.35 ± 0.02 0.59 ± 0.04 
MeOH 
95% 1367 ± 66.2 3193 ± 75.6 39.3 ± 0.6 91.9 ± 1.1 13.7 ± 0.66 31.9 ± 0.76 0.39 ± 0.01 0.92 ± 0.01 
80% 1793 ± 62.1 3504 ± 44 42.7 ± 2.5 78.8 ± 3.77 17.9 ± 0.62 35 ± 0.44 0.43 ± 0.03 0.79 ± 0.04 
70% 1794 ± 33.4 3766 ± 25.1 40.8 ± 1.32 71.9 ± 1.88 17.9 ± 0.33 37.7 ± 0.25 0.41 ± 0.01 0.72 ± 0.02 
60% 1875 ± 17.8 3801 ± 55.8 37.5 ± 1.31 53 ± 4.09 18.8 ± 0.18 38 ± 0.56 0.38 ± 0.01 0.53 ± 0.04 
50% 2029 ± 45.6 3999 ± 64.6 34.9 ± 1.65 46.8 ± 10.2 20.3 ± 0.46 40 ± 0.65 0.35 ± 0.02 0.47 ± 0.1 
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4.1.6. Relationship between the solvent used in saffron extraction and their cytotoxicity 
effects 
This study investigated the potential relationship between the solvent system used in 
saffron extraction and the observed cytotoxicity in prostate cell lines. The biological evaluation 
revealed that using different solvent systems resulted in variations in cytotoxicity effects 
(previous Figures 15-24). Moreover, HPLC analysis demonstrated the constituents’ 
concentrations varied in saffron extracts due to the use of different solvent systems for saffron 
extraction. Therefore, it was possible to use regression analysis to investigate the potential 
relationship between the solvent composition versus the mean of cytotoxicity response in each 
cell line produced by saffron extract #18258. As demonstrated in Table 15 and Figure 39, a 
higher organic solvent percentage was negatively correlated to the observed cytotoxicity in all 
prostate cell types. Therefore, when the aqueous portion in the extraction solvent increased, the 
cytotoxicity was decreased. With increasing hydrophilicity, the concentrations of picrocrocin and 
crocin were increased. Therefore, picrocrocin and crocin are not expected to strongly contribute 
to saffron extract cytotoxicity because there was a decline in cytotoxicity in both cancer cell line 
when picrocrocin and crocin concentrations increased (HPLC analysis). 
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Table 15: R2 and p value for the regression organic solvent composition used in saffron 
extraction versus cytotoxicity in each of prostate cell line 
Cell line Methanol Ethanol 
PNT1A 0.8322 (p < 0.0308) 0.9683 (p < 0.0024) 
22Rv1 0.9076 (p < 0.0123) 0.9683 (p < 0.0024) 
PC3 0.8285 (p < 0.0319) 0.9695 (p < 0.0023) 
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Figure 39: The correlation between the solvent used in saffron extraction and cytotoxicity 
effects 
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4.1.7. HPLC quantification of the constituents of commercial saffron samples 
This study determined the chemical composition of commercial saffron samples obtained 
from the USA market (described in Chapter 3). The saffron extracts were subjected to analysis 
using the analytical HPLC method. As shown in Table 16, the saffron samples demonstrated 
variations in their constituents, even in the samples that claimed to have been cultivated in the 
same country. High concentrations of picrocrocin was detected in saffron extracts #18248, 
18253, and 18254, respectively. Moreover, crocin was at higher concentrations in saffron extract 
#18255, 18251, 18253, and 18248.  
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Table 16: The constituent concentrations in commercial saffron samples. 
Sample 
code 
Concentration (µg/ml) % Dry weight 
Picrocrocin Crocin Safranal Crocetin Picrocrocin Crocin Safranal Crocetin 
18248 1819 ± 36.6 2542 ± 51.7 20.6 ± 1.18 54.5 ± 0.35 18.2 ± 0.37 25.4 ± 0.52 0.21 ± 0.01 0.55 ± 0.01 
18249 1205 ± 41.8 906 ± 9.44 28.5 ± 0.58 50.3 ± 0.72 12.1 ± 0.42 9.06 ± 0.09 0.29 ± 0.01 0.5 ± 0.01 
18250 495 ± 9.81 1309 ± 79.8 7.93 ± 1.25 25.7 ± 1.48 4.95 ± 0.1 13.1 ± 0.8 0.08 ± 0.01 0.26 ± 0.02 
18251 1039 ± 40.7 2842 ± 43.8 34.4 ± 0.26 68.9 ± 0.48 10.4 ± 0.41 28.4 ± 0.44 0.34 ± 0.01 0.69 ± 0.01 
18252 1039 ± 22.3 1681 ± 28.8 29 ± 0.72 45.4 ± 1.86 10.4 ± 0.22 16.8 ± 0.29 0.29 ± 0.01 0.45 ± 0.02 
18253 1358 ± 24.5 2695 ± 58.5 33.1 ± 0.31 53 ± 0.58 13.6 ± 0.25 27 ± 0.59 0.33 ± 0.01 0.53 ± 0.01 
18254 1170 ± 2.86 1824 ± 49.5 30.3 ± 1.02 42.8 ± 0.47 11.7 ± 0.29 18.2 ± 0.5 0.3 ± 0.01 0.43 ± 0.01 
18255 739 ± 38.5 3037 ± 30.6 10.9 ± 0.24 39.9 ± 1.07 7.39 ± 0.39 30.4 ± 0.31 0.11 ± 0.01 0.4 ± 0.01 
18256 831 ± 29.8 1665 ± 35 18.1 ± 0.63 35.4 ± 2.71 8.31 ± 0.3 16.7 ± 0.35 0.18 ± 0.01 0.35 ± 0.03 
18257 388 ± 8.56 1359 ± 25.8 6.53 ± 2.17 33.3 ± 2.4 3.88 ± 0.09 13.6 ± 0.26 0.07 ± 0.02 0.33 ± 0.02 
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4.1.8. Exportation and importation data for saffron 
Our analysis of available raw data from the Nations Commodity Trade Statistics 
Database provided a good example of misleading marketing strategies by changing the country 
of origin of saffron. The production of saffron in Iran slightly changed from 205 tons in 2004 to 
210 tons in 2011 (Hosseini, 2012), whereas its exportation declined from 178 tons in 2004 to 96 
tons in 2011. On the other hand, some countries have with no known history of saffron 
agriculture (e.g. UAE) and other countries (France and Italy) import more saffron than export it 
then potentially re-export it as home-grown. This relationship becomes more obvious by 
comparing 2004 and 2011 data when those countries like Spain, France, and Italy decrease 
exportation alongside the Iranian saffron exportation declines as shown in Table 17 (United-
Nations, 2015). 
 
 
Table 17: Exported and imported saffron by country 
        Parameters 
Country  
2004 2011 
Import (tons) Export (tons) Import (tons) Export (tons) 
Iran 0 178 0 96 
Spain 64.1 123 72.2 68.2 
France 40 24.1 30.4 9.5 
Italy 15.3 7.4 18.4 16.1 
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4.2. Discussion 
In recent years, saffron extract used as a natural product supplement has gained 
popularity and numerous different brands of this saffron supplements became available on the 
market. Unlike pharmaceutical drug marketing in the USA, there is no regulatory oversight for 
natural supplements regarding their effectiveness, quality, or safety. There are many methods 
used for adulteration purposes in natural products. This is true especially with saffron stigmas 
because it is the most expensive spice in the world. The adulteration methods include: 1) addition 
cheap bulking agents to increase the weight, such as dyed-red wood filaments and pomegranate 
fibers, 2) adding of synthetic components to increase the quality of saffron such as safranal, 3) 
mixing low quality with high quality of saffron to increase revenue (Gohari et al., 2013). The 
relabeling of the origin country is intended to increase the price of saffron or to overcome 
logistics problems such as economic sanctions, as implicated in Table 17 (Hosseini, 2012, Gresta 
et al., 2009).  Therefore, finding and developing an accurate systemic evaluation method to 
authenticate saffron has become a mandatory step toward insuring the maximum benefits with 
minimum health risks that could arise from using unassessed and adulterated natural product 
supplements like saffron. Any developed evaluation methods should consider both chemical and 
biological aspects, because saffron has hundreds of constituents which it is impossible to detect 
all of using standard basic laboratory methods. By combining biological and chemical analysis, a 
more accurate and simplified saffron evaluation is possible. 
This study has developed RP-HPLC analytical method which is a simple, repeatable, and 
reproducible procedure. This analytical method is specifically designed to analyze the saffron 
stigma as well as the supplemented products by measuring their ‘fingerprint’ including 
picrocrocin, crocin, safranal, and crocetin. The developed method was validated according to 
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International Conference for Harmonization (ICH) guideline. The new method could possibly be 
used in quality control analysis of saffron and its supplemental derivatives, because it provides 
accurate analysis results with a simple and reproducible approach. It has the ability to 
simultaneously quantify the most important saffron constituents in a single process. Using the 
gradient chromatography system enhances the ability to separate the complex combination of 
compounds that are the constituents of saffron, at very low concentrations. It can separate the 
most hydrophilic compounds such as picrocrocin in addition to the most hydrophobic 
compounds like crocetin. 
As demonstrated in this dissertation, the chromatographic peaks presented in saffron 
extract were identified using the retention times of known standards as well as HPLC-MS. The 
mobile phase of the developed method is compatible for use with mass spectrometry because it 
contains 0.1% formic acid which facilitates the protonation of the available compounds in 
saffron extract. The HPLC-MS is useful and provides an easier way to identify the presence of 
unusual peaks that may indicate a potential adulteration in commercially available saffron and 
supplemental products. 
The anti-cancer properties of saffron extracts were determined and summarized in Table 
18. The IC50 of the ethanolic-extracted saffron for normal, early, and advanced stages of cancer 
ranged from 0.38 to 0.73 mg/ml, 1.32 to 2.27 mg/ml, and 1.77 to 3.23 mg/ml, respectively. On 
other hand, the IC50 of the methanolic-extracted saffron for normal, early, and advanced stages of 
cancer ranged from 0.32 to 0.4 mg/ml, 1.26 to 2.27 mg/ml, and 1.98 to 2.99 mg/ml, respectively. 
It is clear that there are differences between the cytotoxicity effects achieved by using different 
solvent types which could be observed when we compared, side by side, each solvent 
concentration. Those differences could exist due to various reasons, such as the chemical 
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interaction between the solvents and the plant components (Wang and Weller, 2006) which may 
decompose plant constituents (Tønnesen et al., 2002) or convert them to toxic compounds; the 
ability of the solvents to extract, exclusively, some components that produced pharmacological 
effects, the solvent polarity that extracts more or less amounts of hydrophilic or lipophilic 
compounds (Maltese et al., 2009), and the required temperature for solvent evaporation to dry 
the extracts (Munin and Edwards-Lévy, 2011).  
 
 
Table 18: Summary of the cytotoxicity effects of solvent systems on the cell lines. All 
concentration units are mg/ml. 
Solvent Concentration PNT1A 22Rv1 PC3 
EtOH 
95% 0.38 ± 0.07 1.32 ± 0.19 1.77 ± 0.23 
80% 0.49 ± 0.10 1.55 ± 0.26 2.2 ± 0.88* 
70% 0.63 ± 0.13 1.71 ± 0.33 2.35 ± 0.63* 
60% 0.66 ± 0.15 2.09 ± 0.5* 2.77 ± 0.65* 
50% 0.73 ± 0.16 2.27 ± 0.72* 3.23 ± 0.83* 
MeOH 
95% 0.32 ± 0.05 1.26 ± 0.25 1.98 ± 0.39 
80% 0.36 ± 0.06 1.53 ± 0.32 2.44 ± 0.6* 
70% 0.4 ± 0.07 1.91 ± 0.38 2.99 ± 0.66* 
60% 0.4 ± 0.07 2.27 ± 0.6* 2.95 ± 0.74* 
50% 0.4 ± 0.07 2.17 ± 0.64* 2.98 ± 0.67* 
* Expected IC50 using GraphPad Prism 5 (IC50 higher than 2 mg/ml, the maximal tested 
concentration) 
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The extraction of saffron constituents using a methanolic solvent regardless of its 
concentrations produced more cytotoxic effects on normal cells compared to cancerous cells. 
This can clearly be seen with the higher concentration of the methanol solvent. In addition, there 
is an obvious relationship of the toxic effects between normal and advanced-stage prostate 
cancer cells. When the concentration of the organic solvent decreased from 95% to 80% and 
from 80% to 70%, the cytotoxicity in both cell types decreased, though when the methanol 
concentration decreased under 70%, there was almost no change in both cell responses. This 
demonstrates the capability of high methanol concentration to extract unique components or 
convert constituents to toxic compounds which exert their cytotoxic effects against those cells; 
the capability for the extraction or the conversion is decreased with low methanol concentration. 
In ethanolic-extracted saffron, there was a noticeable difference regarding the extract 
activity between different concentration groups. Among all groups, the lowest amount required 
to produce cytotoxicity effects for both prostate cancer stages was obtained by using 95% 
ethanolic saffron extract and closely followed by 80%. Without an exception, the cytotoxicity 
response of all cell types to the whole saffron extract declined when using lower concentrations 
of the ethanolic solvent. It is possible the high concentration of ethanol is able to extract 
compounds that are responsible for activation of the cytotoxicity mechanisms which are present 
in all cell types. In both solvents, saffron extracts were strongly dependent on the solvents’ 
organic composition. 
Previous studies found that using different solvents had a significant difference on the 
phenolic and flavonoid content of saffron extracts. The methanolic saffron extract has stronger 
antioxidants and scavenger activity compared to ethanolic saffron extract. These differences are 
interpreted by the ability of methanol to extract two times the amount of total flavonoids than 
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ethanol solvent (Karimi et al., 2010). Moreover, multiple studies have shown a variation in the in 
vitro activities of saffron extract. The response of cervical cancer (HeLa) and hepatocellular 
carcinoma (HepG2) cell lines to saffron extract as anti-cancer therapy represent the best 
examples of the controversial activity results (Table 19). Three studies conducted experiments 
using a HeLa cell line. Two of them used the same solvent but with different solvent 
concentrations, the IC50 after 24 hours of exposure was 2 and 2.3 mg/ml for the 96% and 75% 
ethanolic solvent, respectively (Escribano et al., 1996, Tavakkol-Afshari et al., 2008). A 
different study used 80% methanolic solvent and the IC50 was 653 µg/ml, whereas the IC50 of the 
96% ethanolic solvent was 700 µg/ml after 72 hours of exposure (Rahimi Fard et al., 2011, 
Tavakkol-Afshari et al., 2008). Moreover, two studies were conducted using different solvents 
for saffron extraction. After 72 hours of saffron extract incubation with the HepG2 cell line, the 
IC50 for the aqueous extract was 400 µg/ml whereas it was 650 µg/ml for 96% ethanolic extract 
(Parizadeh et al., 2011, Tavakkol-Afshari et al., 2008). Indeed, the variation of the IC50 obtained 
from the earlier studies is in agreement with our finding regarding the variation of the observed 
activity due to the differences in the extraction solvent system. This study addresses the 
importance of the solvent selection regarding to its pharmacological effectiveness in saffron. Our 
study used the advantage of the variation in saffron constituents as well as biological activity 
which resulted in using different solvent systems for saffron extraction to investigate the most 
likely compounds that are responsible on saffron extract activity. From the correlation study, it is 
clearly picrocrocin and crocin which are the most likely compounds that are not responsible for 
exerted saffron’s cytotoxicity toward prostate cancer. 
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Table 19: The variation in IC50 values reported in literature using different solvents for 
extraction 
Cell line HeLa HepG2 
Incubation time 24 hours 72 hours 72 hours 
Solvents used for 
saffron extraction 
75% 
ethanol 
96% 
ethanol 
80% 
methanol 
96% 
ethanol 
Water 
96% 
ethanol 
IC50 2.3 mg/ml 2 mg/ml 653 µg/ml 700 µg/ml 400 µg/ml 650 µg/ml 
(Escribano et al., 1996, Parizadeh et al., 2011, Rahimi Fard et al., 2011, Tavakkol-Afshari et al., 
2008) 
 
 
A total of 11 different commercial samples were obtained from multiple regions 
including Iran, Spain, and Afghanistan and were acquired commercially and botanical 
identified as Crocus sativus stigmas. Saffron samples were extracted using 95% ethanol solvent 
and tested for biological activities (Table 20). We conducted HPLC analysis for all samples and 
the marker compounds such as safranal, picrocrocin, crocin, and crocetin were present in all of 
them although their concentrations differed significantly among each sample (see appendix for 
HPLC chromatograms). Although we cannot confirm the geographical origins of the commercial 
saffron samples, there were differences in their compositions which were revealed by the HPLC 
profiling results. These results confirm the finding of another study that concluded that the 
changes in the environments of saffron agriculture will cause variations in the saffron component 
concentration. However, even when there are variations, there are no specific compounds which 
could be used as a fingerprint to authenticate the saffron’s origins (Maggi et al., 2011).  
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Table 20: Summary of the cytotoxicity effects of commercial samples of saffron on the cell 
lines. All concentration units are mg/ml.  
Sample code PNT1A 22Rv1 PC3 
18258 (Reference) 0.38 ± 0.07 1.32 ± 0.19 1.77 ± 0.23 
18248 1.37 ± 0.33 2.56 ± 0.46* 8.22 ± 2.56* 
18249 1.78 ± 0.39 2.85 ± 0.67* ≥ 34.47* 
18250 1.69 ± 0.5 1.78 ± 0.27 1.97 ± 0.34 
18251 1.64 ± 0.42 3.05 ± 0.65* 3.91 ± 1.19* 
18252 1.15 ± 0.19 1.67 ± 0.49 1.97 ± 0.35 
18253 1.42 ± 0.28 3.08 ± 0.56* 5.01 ± 1.25* 
18254 1.09 ± 0.18 2.39 ± 0.55* 3.85 ± 1.02* 
18255 1.06 ± 0.17 1.88 ± 0.34 3.76 ± 0.99* 
18256 0.79 ± 0.12 4.20 ± 0.45* 4.77 ± 0.90* 
18257 0.76 ± 0.12 8.19 ± 2.36* 10.22 ± 2.38* 
* Expected IC50 using GraphPad Prism 5 (IC50 higher than 2 mg/ml) 
 
 
The majority of saffron extracts exhibited cytotoxic effects against all three human cell 
lines, include normal and cancerous cells, in a dose-dependent manner. The viability assay 
carried out using different concentrations of saffron extracts ranged from 0.125 – 2 mg/ml. In 
general, all evaluated saffron extracts displayed stronger cytotoxic effects against normal as 
opposed to early prostate cancer cells and the lowest effects were noticed in advanced stages of 
cancer (Table 20). Among all 11 tested saffron extracts, three of them #18250, 18252, and 18258 
showed antiproliferative effects against the cancer cell lines but cytotoxicity was in each case 
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still higher in normal prostate cells. The IC50 for cancer cells was less than 2 mg/ml and from 
0.38 to 1.69 mg/ml for normal cells. The weakest commercial saffron which exerted cytotoxic 
effects on normal prostate cells was sample #18249 whereas sample #18258 had the strongest 
cytotoxicity. These variations in the biological responses matched with the findings of other 
studies. The sources and the geographical origins of saffron have a strong impact on the stigma 
physical characteristics as well as the chemical composition (Zarinkamar et al., 2011). 
Also, our results emphasized an important fact, which is the safety of saffron extracts on 
normal cells. Saffron extracts are available on the market in the form of capsulated supplements 
which are used for weight loss, as antioxidants, for mood improvements, and so on. The FDA 
neither requires safety studies prior to these supplements’ marketing nor need mention the origin 
of the saffron. Our study suggests more caution should be followed by evaluating each saffron 
batch on human normal cells before marketing them as health supplements. 
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4.3. Conclusion 
According to our knowledge this is the first study on the comparison of the chemical 
constituents’ quantification and bio-evaluation of saffron after extraction using different solvent 
systems, as well as the analysis of available commercial samples in US market. The validation 
results of the developed analytical HPLC method demonstrated simplicity, accuracy, selectivity, 
sensitivity, and repeatability. This RP-HPLC used important marker compounds that differentiate 
saffron characteristics which can be effective for rapid analysis of saffron stigma purity as well 
as herbal formulation and analysis of supplemental products that contain saffron. The method 
can be used as an alternative to the ISO method to evaluate the quality of saffron. The purity of 
the saffron stigmas which were used in this study was verified to be high by analyzing saffron 
extracts using HPLC. The solvent systems used in saffron extraction clearly affected their anti-
cancer capability. The results obtained for the anti-cancer activity of extracts differed depending 
on the type, concentration of solvent, and saffron source. Regardless of the saffron’s origin, the 
most efficient solvents for saffron extraction were 95% and 80% ethanol, respectively. Both 
whole extracts exerted similar activities regarding the ratio of normal to cancer cytotoxicity 
effects, although the 95% ethanol is preferred due to its stronger activity on advanced- and early-
stage cancer, respectively. Our study concluded that methanol used for saffron extraction was 
toxic to normal cells with low anti-cancer activity, so it is not recommended to use this as a 
solvent. The study outcomes revealed that the solvent systems with various polarity have major 
effects and play important roles in determining the anti-cancer activity of saffron extracts. The 
concentrations of saffron constituents in the commercial samples varied, which affected the 
biological responses. Therefore, this study highlights multiple points, such as the importance of 
evaluating the saffron for its activity and safety on normal cells. In addition, when a study 
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investigates the activity of natural products, it is best to consider using multiple samples from 
different geographic locations. Because there is no simple method available to detect the 
chemical composition of natural products which could reach hundreds of compounds, it is best to 
combine biological with chemical evaluations. 
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CHAPTER 5: SAFFRON EXTRACT AND ITS CONSTITUENTS AS PREVENTATIVE 
AND/OR TREATMENT AGENTS FOR PROSTATE CANCER 
 
5.1. Results 
5.1.1. Isolation and measurement of picrocrocin compound purity 
Using the chromatotron method to isolate pure compounds from saffron extract provides 
excellent results including: it can quickly recover a large amount of starting material by weight 
(90%) and it isolates compounds with high purity. Sixty-three fractions were obtained from the 
saffron #18258 extract. These fractions were initially analyzed using reverse phase thin layer 
chromatography (RP-TLC), that facilitated the combination fractions with similar band patterns. 
After combination a total of 13 fractions were obtained. Three of fractions contained picrocrocin, 
and one of these fraction (27-34) represented 13.36 % of the recovered weight. The purity of this 
fraction (27-34) was measured by HPLC and determined its purity percentage by using the 
calibration curve of pure picrocrocin as described in Chapter 3 (Figure 40). Fraction 27-34 was 
the purest picrocrocin fraction obtained with 93.49% of purity.   
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Figure 40: Chromatogram of combined fractions 27-34 to measure picrocrocin purity. 
 
 
5.1.2. Antioxidant activity of saffron extract and its active constituents 
The capacity of saffron extract and its active components to activate anti-oxidative 
mechanisms in normal cells against oxidants was assessed using an H2DCFDA probe. The 
normal prostate cells (PNT1A) were pre-incubated with two different nontoxic concentrations of 
saffron extract (100 and 200 µg/ml), safranal (6 and 12 µg/ml), and crocetin (15 and 30 µg/ml) 
for 4 hours as shown in Figure 41. After removing the treatment, oxidative stress was induced 
when 50 µM of H2O2 was added. In untreated groups, the oxidative stress was 60% higher in 
exposed normal cells with H2O2 (positive control) compared to unexposed cells (negative 
control). The oxidative stress significantly dropped when the cells were pre-incubated with both 
concentrations of safranal. The level of oxidative stress decreased by ≈ 50% compared to 
positive control group, but it was still higher by almost 30% compared to negative control group. 
When the cells were pre-incubated with 200 µg/ml of saffron extract or 30 µg/ml of crocetin, 
similar results for both were obtained. The oxidative stress level significant declined to ≈ 46% 
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compared to positive control group, but was not returned to normal level (≈ 27% higher 
compared to negative control group). In conclusion, the results demonstrated that saffron extract 
(200 µg/ml), safranal (6 and 12 µg/ml), and crocetin (30 µg/ml) had antioxidant effects. 
 
 
 
Concentration (g/ml)
%
 R
O
S
 L
e
v
e
l
(R
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
Ctrl H2O2 6 12 15 30 100 200
0
50
100
150
200
Saffron extract
Crocetin
Safranal
*
*
50 M H2O2 + + + + + + +-
#
#
#
#
*# *# *#
 
Figure 41: Antioxidant activity of saffron extract and its active constituents against 
oxidative stress induced by H2O2 in PNT1A cells. Bars with # symbol are statistically 
significant from the control group whereas * symbol are statistically significant from the 
group exposed with H2O2 only (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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5.1.3. Cytotoxicity of saffron extract and its constituents on different prostate cells 
5.1.3.1. Cytotoxicity of saffron extract #18258 
We evaluated the viability of normal and prostate cancer cells treated with increasing 
concentrations of saffron extract which was obtained by using 95% ethanol for extraction (0, 
0.125, 0.25, 0.5, 1, 2 mg/ml) for 24, 48 or 72 hours using the XTT assay, as explained in Chapter 
3, to find whether the saffron extract is effective in treating prostate cancer. A significant 
inhibition in malignant prostate cell growth was achieved using saffron extract in dose- and time-
dependent manners, the effects of saffron extract were more clear after 48 and 72 hours of 
incubation, as shown in Figures 42-44. Only 42.41% of 22Rv1 and 43.68% of PC3 cells survived 
after 72 hours of 2 mg/ml extract exposure. In addition, after 72 hours of exposure, the IC50 for 
both cancer cells was reached. The IC50 concentrations were calculated at 24, 48, 72 hours post 
incubation, and were 7.38 ± 2.16, 2.77 ± 0.67, and 1.32 ± 0.19 mg/ml for 22Rv1, and 10.42 ± 
4.21, 5.85 ± 1.59, and 1.77 ± 0.23 mg/ml for PC3, respectively (p < 0.05).  We also studied the 
effects of saffron extract on normal prostate cells (PNT1A). Saffron extract induced the 
cytotoxicity in normal cells starting at 0.5 mg/ml after 24 and 48 hours of incubation. The 
cytotoxicity was induced with increasing the incubation time, which made the minimum 
concentration necessary for cytotoxicity lower (0.125 mg/ml). Incubating the PNT1A cells with 
2 mg/ml for 72 hours lead to only 27.68% survival of cells compared 100% in the control. The 
IC50 concentrations for PNT1A were determined at 24, 48, 72 hours after incubation, which were 
4.46 ± 1.09, 1.53 ± 0.29, and 0.38 ± 0.07 mg/ml, respectively (p < 0.05). 
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Figure 42: Cytotoxicity of saffron extract against PNT1A, 22Rv1, and PC3 cells after 24 
hours of exposure. Bars with * symbol are statistically significant from control group 
(ANOVA; n = 4 replicates/treatment group, p<0.05). 
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Figure 43: Cytotoxicity of saffron extract against PNT1A, 22Rv1, and PC3 cells after 48 
hours of exposure. Bars with * symbol are statistically significant from control group 
(ANOVA; n = 4 replicates/treatment group, p<0.05). 
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Figure 44: Cytotoxicity of saffron extract against PNT1A, 22Rv1, and PC3 cells after 72 
hours of exposure. Bars with * symbol are statistically significant from control group 
(ANOVA; n = 4 replicates/treatment group, p<0.05). 
 
 
5.1.3.2. Cytotoxicity of picrocrocin 
A cytotoxicity assay was conducted using XTT reagent as described previously in 
Chapter 3, to investigate the picrocrocin effects at different concentrations ranging from 0.125-2 
mg/ml in normal and tumor prostate cell lines as shown in Figure 45. It was expected that 
picrocrocin would show cytotoxicity in prostate cancer similar to other cancer types and because 
its chemical structure contains the safranal moiety. The results indicated that picrocrocin 
exhibited weak cytotoxic effects in all cell lines after 72 hours of incubation. The toxic effect 
was significant at a concentration of 2 mg/ml. The obtained IC50s were 4.03 ± 1.44, 4.48 ± 1.51, 
and 4.52 ± 1.55 mg/ml in PNT1A, 22Rv1, and PC3 cell lines, respectively. The activity of this 
constituent lacked the cell type selectivity because it induced cytotoxicity in normal cells more 
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than cancer cells. Also, compared to other saffron components such as safranal and crocetin it 
showed lower cytotoxicity in prostate cancer cells. 
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Figure 45: Cytotoxicity of picrocrocin against PNT1A, 22Rv1, and PC3 cells after 72 hours 
of exposure. Bars with * symbol are statistically significant from control group (ANOVA; n 
= 3 replicates/treatment group, p<0.05). 
 
 
5.1.3.3. Cytotoxicity of crocin 
The anti-proliferative effects of pure crocin on normal (PNT1A) and prostate cancer 
(22Rv1 and PC3) cell lines are illustrated in Figure 46. The saffron extract showed cytotoxicity 
effect, so we investigated the crocin cytotoxicity alone because it is present in saffron in 
relatively high concentrations. In addition, its structure the contains crocetin moiety, so when 
crocin is hydrolyzed crocetin will be produced. Crocin had a concentration-dependent effect. 
After 72 hours of incubating all cell types with crocin, the IC50s were 1.18 ± 0.3, 1.43 ± 0.32, and 
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1.9 ± 0.48 mg/ml for the PNT1A, 22Rv1, and PC3 cell lines, respectively. At 2 mg/ml, the 
percentage of PNT1A surviving cells was 32%. However, the prostate cancer cells 22Rv1 and 
PC3 did not show as much cytotoxicity as in the PNT1A cells where 39 and 45% of cells 
survived, respectively. Crocin had a greater toxic effect on normal cells than cancerous prostate 
cells. Although a significant decrease in the cell viability of all cell types was observed at high 
concentrations, other saffron components (crocetin and safranal) showed stronger activity. 
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Figure 46: Cytotoxicity of crocin against PNT1A, 22Rv1, and PC3 cells after 72 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
 
 
 
  
127 
 
5.1.3.4. Cytotoxicity of safranal 
Safranal was investigated for its cytotoxicity at different concentrations ranging from 
6.25-100 μg/ml in both normal and cancerous prostate cell lines. In the literature, different types 
of cancer respond to safranal treatment. Therefore, safranal cytotoxicity was studied to determine 
if safranal had activity against prostate cancer cells.  Safranal induced a cytotoxic response in 
time- and concentration-dependent manners for all cell lines. The effect of different 
concentrations and exposure times is shown in Figures 47-49. After 24 hours of safranal 
incubation, the cytotoxicity was initiated at concentrations of 12.5 and 25 μg/ml for 22Rv1 and 
PC3 cells, respectively. A significant inhibitory effect in 22Rv1 at 48 hours started at a safranal 
concentration of 6.25 μg/ml. There was a slightly stronger activity of safranal against PC3 at 48 
hours post incubation, but the minimum concentration required to produce cytotoxicity was not 
changed compared to 24 hours of incubation. The maximum reduction in cellular proliferation 
for both cancer cell lines was achieved after 72 hours post incubation at a concentration of 6.25 
μg/ml and higher. Using 50 and 100 μg/ml for 72 hours caused a reduction in survival rate of 
22Rv1 by 83.25 ± 1.48 and 86.64 ± 3.66%, respectively whereas it was 68.24 ± 7.81 and 84.05 ± 
4.35% for PC3 cell line, respectively. The IC50 of safranal concentrations were determined at 24, 
48, 72 hours post incubation, which were 22.31 ± 6.97, 14.92 ± 3.28, and 10.91 ± 1.71 μg/ml for 
22Rv1 whereas they were 44.4 ± 14.26, 30.22 ± 7.12, and 19.44 ± 4.09 μg/ml for PC3, 
respectively (p < 0.05). The safranal was also used against a normal prostate cell line (PNT1A). 
Incubating the PNT1A cell with 50 and 100 μg/ml of safranal for 72 hours decreased the survival 
of cells by 85.39 ± 4.19 and 88.11 ± 3.52%, respectively. The IC50 concentrations for PNT1A 
were determined at 24, 48, 72 hours after incubation, which were 41.16 ± 12.4, 21.87 ± 3.53, and 
13.9 ± 3.04 μg/ml, respectively (p < 0.05). These results indicated that unlike early prostate 
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cancer cells (22Rv1), all used safranal concentrations were less cytotoxic towards the PNT1A 
cell line after 24 - 72 hours of incubation. In contrast to advanced stage of prostate cancer cells 
(PC3), the safranal had stronger cytotoxic effects on PNT1A compared to PC3.  
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Figure 47: Cytotoxicity of safranal against PNT1A, 22Rv1, and PC3 cells after 24 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
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Figure 48: Cytotoxicity of safranal against PNT1A, 22Rv1, and PC3 cells after 48 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
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Figure 49: Cytotoxicity of safranal against PNT1A, 22Rv1, and PC3 cells after 72 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
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5.1.3.5. Cytotoxicity of crocetin 
Multiple studies found that the crocetin was the strongest saffron constituent to produce 
anti-cancer activity in different cancer types. Therefore, we investigated crocetin cytotoxicity 
against prostate cancer. The crocetin cytotoxicity at different time points was determined using 
concentrations ranging from 25 - 200 µg/ml for 24, 48, and 72 hours as depicted in Figures 50-
52. After 24 hours of crocetin exposure, the cytotoxicity was significantly increased in all 
prostate cell lines at a concentration of 100 µg/ml. After 24 hours of treatment, the IC50s were 
93.52 ± 30.72, 172.2 ± 49.31, and 165 ± 39.33 µg/ml for the PNT1A, 22Rv1, and PC3 cell lines, 
respectively. When PC3, 22Rv1, and PNT1A cells were incubated with 200 µg/ml of crocetin, 
survival was 47.29%, 48.82%, and 37.56%, respectively. Furthermore, after 48 hours of 
treatment, increased cytotoxicity was observed. The IC50s were 69.75 ± 19.91, 86.3 ± 23.75, and 
90.31 ± 26.12 µg/ml for the PNT1A, 22Rv1, and PC3 cell lines, respectively. At an exposure of 
200 µg/ml, PNT1A, 22Rv1, and PC3 cell viability was significantly reduced to 29.87, 33.26, and 
36.73%, respectively. Finally, when the cells were incubated with the treatment for 72 hours, the 
low concentration of crocetin (25 µg/ml) exerted a toxic effect in all cell types. Moreover, the 
IC50 dropped to 47.51 ± 11.14, 62.85 ± 15.60, and 59.33 ± 13.18 µg/ml for the PNT1A, 22Rv1, 
and PC3 cell lines. Incubating the cells with 200 µg/ml of crocetin for 72 hours resulted in a 
reduction of cell viability of PNT1A to 21.8%, 22Rv1 to 29.16%, and PC3 to 29.08%. 
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Figure 50: Cytotoxicity of crocetin against PNT1A, 22Rv1, and PC3 cells after 24 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
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Figure 51: Cytotoxicity of crocetin against PNT1A, 22Rv1, and PC3 cells after 48 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
  
132 
 
g/ml
%
 C
e
ll
 s
u
rv
iv
a
l
(R
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
C
tr
l
25 50 10
0
20
0
0
20
40
60
80
100
120
PNT1A
22Rv1
PC3
**
*
*
*
*
*
* *
** *
 
Figure 52: Cytotoxicity of crocetin against PNT1A, 22Rv1, and PC3 cells after 72 hours of 
exposure. Bars with * symbol are statistically significant from control group (ANOVA; n = 
3 replicates/treatment group, p<0.05). 
 
 
5.1.4. Determination the mechanism of cell death caused by saffron extract and its active 
constituents 
This study investigated whether saffron and its active constituents caused cell death in 
PNT1A, 22Rv1, and PC3 cells through the apoptosis pathway. For that purpose, the apoptotic 
enzymes caspase 3 and 7 (CASP3 and 7) were measured after 6 hours of treatment as described 
in Chapter 3. Generally, the apoptotic cells were increased in a concentration-dependent manner 
in all of the different treatment groups. In the normal prostate cells (PNT1A), saffron extract at 
different concentrations (0.75 and 1.5 mg/ml) significantly induced the CASP3/7 enzyme levels 
by 3.19- and 4.57-fold, respectively. When the cells were treated with 100 and 200 µg/ml of 
crocetin, the enzymes levels were significantly induced by 3.01-and 4.22-fold, respectively. 
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Also, at concentrations of 25 and 50 µg/ml of safranal, the CASP3/7 significantly increased by 
2.65- and 3.45-fold (Figure 53). 
On the other hand, different responses were observed in prostate cancer cells. As 
observed in Figure 54, when the 22Rv1 cell line was exposed to 0.75 and 1.5 mg/ml of saffron 
extract there was no significant change obtained in CASP 3/7 level. A significant induction by 
3.9-fold in CASP 3/7 was achieved when the cells were treated with 200 µg/ml of crocetin. In 
addition, 25 and 50 µg/ml of safranal resulted in a significant enhancement in CASP 3/7 
enzymes levels by 4.77- and 6.68-fold, respectively in 22Rv1 cell line. 
Moreover, the CASP 3/7 enzyme levels in the PC3 cells were not significantly different 
from the control group when treated with saffron extract at concentrations of 0.75 and 1.5 mg/ml 
as depicted in Figure 55. There was marked induction in CASP 3/7 enzymes by 3.73- and 4.76-
fold at 100 and 200 µg/ml of crocetin exposure, respectively. Furthermore, a significant 
induction by 3.7- and 5.91-fold in CASP 3/7 was measured in cells exposed to safranal at 
concentrations of 25 and 50 µg/ml of safranal, respectively. Thus the primary cell death 
mechanism by saffron and its active components was by inducing apoptosis, which was activated 
through an upstream caspase cascade (intrinsic or extrinsic). 
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Figure 53: The effect of saffron and its active constituents on caspase 3/7 enzyme levels in 
PNT1A cells after 6 hours of exposure. Bars with * symbol are statistically significant from 
control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 54: The effect of saffron and its active constituents on caspase 3/7 enzyme levels in 
22Rv1 cells after 6 hours of exposure. Bars with * symbol are statistically significant from 
control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 55: The effect of saffron and its active constituents on caspase 3/7 enzyme levels in 
PC3 cells after 6 hours of exposure. Bars with * symbol are statistically significant from 
control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
 
 
 
5.1.5. Identification of apoptosis pathway genes using RT-PCR 
Our research used a normal prostate cell line (PNT1A) to mechanistically investigate the 
apoptosis induction produced by saffron extract and its active components either through 
intrinsic or extrinsic pathways. Three genes CASP3, 7, and 9 were measured using real time PCR 
as shown in Figures 56-58. RT-PCR results revealed that at 72 hours safranal dose-dependently 
increased the expression of CASP3, 7, and 9 mRNA. Specifically, the CASP3 expression was 
induced by 1.8- and 2.7-fold upon treatment with safranal at concentrations of 25 and 50 µg/ml, 
respectively. The expression of the CASP7 gene was increased by 2.6- and 3.4-fold when treated 
with 25 and 50 µg/ml of safranal, respectively. An induction of 3.1- and 4.7-fold in CASP9 
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mRNA was achieved with exposure to 25 and 50 µg/ml of safranal, respectively. When the cells 
were treated with 100 µg/ml of crocetin, high gene expression of CASP3, 7, and 9 was obtained 
with respective 3.1-, 4.8-, and 5-fold inductions. High concentrations of crocetin as well as the 
saffron extract did not significantly induce caspase gene expression. 
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Figure 56: The effect of saffron and its active constituents on caspase 3 mRNA expression 
level in PNT1A cells after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 57: The effect of saffron and its active constituents on caspase 7 mRNA expression 
level in PNT1A cells after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 58: The effect of saffron and its active constituents on caspase 9 mRNA expression 
level in PNT1A cells after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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5.1.6. Wound healing assay 
Saffron extract, safranal, and crocetin showed cytotoxicity against prostate cancer, so we 
studied the ability of saffron extract and these active components to prevent prostate cancer 
metastasis development by inhibiting the prostate cancer migration and invasion characteristics 
without affecting normal cell functions. We assessed the migration of normal and prostate cancer 
cells to fill the gap that was created in a wound healing assay after treating them with saffron 
extract and its active constituents. An important consideration of this assay is that the 
concentrations tested do not cause cytotoxicity so that migratory suppression is assessed. Our 
results indicate that 200 µg/ml of saffron inhibited the migration of both prostate cancer types 
(22Rv1 and PC3) and high concentrations of crocetin induced the migration rate of both prostate 
cancer cells. Low concentrations of saffron extract induced migration in normal cells only. The 
high concentration of safranal had opposite effects in normal and prostate cancer cells. It 
enhanced the migration rate in normal cells whereas it decreased the rate in cancer cells. 
 
5.1.6.1. Wound healing assay in normal cell line (PNT1A) 
Two non-cytotoxic concentrations of saffron, safranal, and crocetin were used to 
determine their effects on migration activities in normal prostate cells (PNT1A). The wound 
healing assay was used with the following concentrations: 6 and 12 µg/ml of safranal, 15 and 30 
µg/ml of crocetin, and 0.1 and 0.2 mg/ml of saffron extract as shown in Figures 59-60. After 24 
hours of incubation, the control group of PNT1A cells slightly closed the gap of the scratched 
area, whereas the cells treated with 12 µg/ml of safranal and 0.1 mg/ml of saffron extract were 
found to migrate significantly faster. The remaining treatment groups had similar results to 
control group and did not affect the migratory behavior of normal cells. In contrast, the wound 
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closure rate was almost two times more than the control group with 12 µg/ml of safranal and 0.1 
mg/ml of saffron extract. Generally, this result showed there is no interfering between the 
migratory behavior of normal cells when the saffron extract and its active constituents used in 
non-toxic dose.  
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Figure 59: The effect of saffron and its active constituents after 24 hours of exposure on the 
ability of migrating PNT1A cells to close the scratched wound. Bars with * symbol are 
statistically significant from control group. Area was measured using ImageJ software, 
(ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Group Concentration (µg/ml) 0 hour 24 hours 
Control - 
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Figure 60: Representative images of PNT1A cells in wound healing assay at 0 and 24 hours 
after treatment exposures. Pictures were taken with 4X microscopic magnification. Area of 
gap was measured using ImageJ software. 
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5.1.6.2. Wound healing assay in androgen sensitive prostate cancer cell line (22Rv1) 
The effect of saffron extracts (0.1 and 0.2 mg/ml), safranal (6 and 12 µg/ml), and crocetin 
(15 and 30 µg/ml) on the migratory function of 22Rv1 was evaluated using a wound healing 
assay as presented in Figure 61. Our results demonstrated that 12 µg/ml of safranal significantly 
suppressed the migration of cells into the wounded area by 39% in comparison to the untreated 
control group. A stronger suppression was obtained when saffron extract was used at a 
concentration of 0.2 mg/ml and resulted in 71% decline in migration rate in 22Rv1. On the other 
hand, 30 µg/ml of crocetin significantly stimulated the 22Rv1 cells migration which 
consequently closed the gap of the scratched area at a faster rate (Figure 62). 
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Figure 61: The effect of saffron and its active constituents after 24 hours of exposure on the 
ability of migrating 22Rv1 cells to close the scratched wound. Bars with star symbol are 
statistically significant from control group. Area was measured using ImageJ software, 
(ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 62: Representative images of 22Rv1 cells in wound healing assay at 0 and 24 hours 
after treatment exposures. Pictures were taken with 4X microscopic magnification. Area of 
gap was measured using ImageJ software. 
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5.1.6.3. Wound healing assay in androgen independent prostate cancer cell line (PC3) 
The effect of 6 and 12 µg/ml of safranal, 15 and 30 µg/ml of crocetin, and 0.1 and 0.2 
mg/ml of saffron extract on PC3 cell migration was measured by the wound healing assay as 
shown in Figures 63-64. PC3 cells that were exposed to high concentrations of saffron extract 
(0.2 mg/ml) and safranal (12 µg/ml) showed a reduction in the migration of the cells to fill the 
gap area as compared to the control cells. In contrast, the high concentration of crocetin (30 
µg/ml) promoted the cell migration by 60% compared to the control group. Lower 
concentrations of the compounds did not produce any significant changes in the PC3 cell 
migration behaviors. 
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Figure 63: The effect of saffron and its active constituents after 24 hours of exposure on the 
ability of migrating PC3 cells to close the scratched wound. Bars with * symbol are 
statistically significant from control group. Area was measured using ImageJ software, 
(ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 64: Representative images of PC3 cells in wound healing assay at 0 and 24 hours 
after treatment exposures. Pictures were taken with 4X microscopic magnification. Area of 
gap was measured using ImageJ software. 
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5.1.7. The effects of saffron extract and its active constituents on prostate cell migration 
using a transwell (Boyden chamber) assay 
A transwell assay was conducted to further confirm the observations obtained from the 
wound healing assay. The effects of two concentrations of saffron extract, crocetin, and safranal 
on cell migration were examined on all prostate cell lines. In summary, the results showed that a 
high concentration of safranal (12 µg/ml) inhibited migration on both types of prostate cancer 
cells (22Rv1 and PC3). A high concentration of crocetin (30 µg/ml) induced the migration 
activity of PC3 only. A low concentration of saffron extract (100 µg/ml) promoted the migration 
of the normal prostate cells (PNT1A), whereas it suppressed the migration of 22Rv1. In addition, 
200 µg/ml of saffron extract inhibited only the migration of 22Rv1 cells.   
 
5.1.7.1. The effects of saffron extract and its active constituents on normal prostate cell 
migration using a transwell assay 
As shown in Figures 65-66, after 36 hours of incubating the normal prostate cells 
(PNT1A) with 100 µg/ml of saffron extract, a significant induction in cell migration took place, 
whereas the other investigated compounds did not exert any effects on the cell migration. When 
100 µg/ml of saffron extract was used, the migrated cells increased by ≈ 36%. There was no 
change in the migratory cells achieved when a higher concentration of saffron extract (200 
µg/ml) was used, so the activity obtained from saffron extract did not follow a concentration 
dependent manner. In addition, 12 µg/ml of safranal promoted the migration by ≈ 19%, but that 
induction was not significantly different from the control group. 
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Figure 65: The effect of saffron and its active constituents on migrated PNT1A cells toward 
chemoattractant using 3D Boyden chambers after 36 hours of exposure. Bars with * 
symbol are statistically different from control group. The cells number were counted using 
ImageJ software (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 66: Representative images of PNT1A cells in migration assay using Boyden 
chambers at 36 hours after treatment exposures. The pictures were taken using 40X 
microscopic magnification. The cells number were counted using ImageJ software. 
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5.1.7.2. The effects of saffron extract and its active constituents on the 22Rv1 prostate 
cancer cell migration using a transwell assay 
The effects of two nontoxic concentrations of saffron extract, safranal, and crocetin on 
the migration of 22Rv1 cells was monitored by a transwell assay, as shown in Figures 67-68. The 
result revealed that both concentrations of saffron extract (0.1 and 0.2 mg/ml), as well as 12 
µg/ml of safranal significantly inhibited the migration of 22Rv1 cells activated by an FBS 
stimuli (p < 0.05) after 36 hours of incubation. All these treatments had similar efficacy in which 
≈ 30% of reduction in the migration of 22Rv1 cells was achieved. On the other hand, the crocetin 
did not show any effect on the migration behavior of 22Rv1 cells when compared to the control 
group. 
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Figure 67: The effect of saffron and its active constituents on migrated 22Rv1 cells toward 
chemoattractant using 3D Boyden chambers after 36 hours of exposure. Bars with * 
symbol are statistically different from control group. The cells number were counted using 
ImageJ software (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 68: Representative images of 22Rv1 cells in migration assay using Boyden chambers 
at 36 hours after treatment exposures. The pictures were taken using 40X microscopic 
magnification. The cells number were counted using ImageJ software. 
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5.1.7.3. The effects of saffron extract and its active constituents on the PC3 prostate cancer 
cell migration using a transwell assay 
The effect of saffron extract, crocetin, and safranal on the migratory potential of prostate 
cancer cells (PC3) was determined by using a transwell cell migration assay as demonstrated in 
Figures 69-70. After incubating 12 µg/ml of safranal with the PC3 cells, the migrated cells were 
significantly decreased compared to the control group by 31%. In contrast, 30 µg/ml of crocetin 
exerted a stimulatory effect on the migration behavior of the PC3. That concentration of crocetin 
resulted in a 23% induction of the migratory cells. There was no inhibition in cell migration 
observed when the saffron extract was used at either concentration for this assay. 
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Figure 69: The effect of saffron and its active constituents on migrated PC3 cells toward 
chemoattractant using 3D Boyden chambers after 36 hours of exposure. Bars with * 
symbol are statistically different from control group. The cells number were counted using 
ImageJ software (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 70: Representative images of PC3 cells in migration assay using Boyden chambers 
at 36 hours after treatment exposures. The pictures were taken using 40X microscopic 
magnification. The cells number were counted using ImageJ software. 
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5.1.8. The anti-invasiveness effects of saffron and its active constituents on prostate cell 
lines 
An invasion assay using Boyden (Transwell) inserts which were coated with Matrigel 
was run to assess whether saffron and its active constituents could prevent prostate cancer cell 
invasion. The secretion of MMP enzymes are required from the cells to degrade the matrigel to 
allow movement through the membrane toward the lower chamber. Three cell lines were used in 
this experiment: normal prostate cells (PNT1A) and prostate cancer cells (22Rv1 and PC3). The 
assay was conducted using two sub-toxic concentrations of saffron extract, crocetin, and 
safranal. In summary, the high concentration of safranal inhibited the invasion of both cancer cell 
types and activated invasion in normal cells. The lower concentration of crocetin promoted the 
invasion of PNT1A where an opposite effect was observed in 22Rv1. The saffron extract at low 
concentrations enhanced the invasion of PNT1A and decreased it in 22Rv1, whereas at the 
higher concentration it inhibited the invasion of both types of cancer cells. 
 
5.1.8.1. The effects of saffron and its active constituents on normal prostate cells invasion 
behavior 
In this study, we investigated the effects of different concentrations of saffron extract, 
crocetin, and safranal on the invasive ability of a normal prostate cell line (PNT1A) as shown in 
Figures 71-72. The cells treated with 12 μg/ml of safranal significantly activated the cell invasion 
compared to the control group. The invasion of PNT1A cells was also increased upon exposure 
to 15 μg/ml of crocetin, but no change was obtained at higher concentrations. In addition, 0.1 
mg/ml of saffron extract significantly stimulated the invasion behavior of PNT1A cells whereas 
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no significant differences were gained when a higher concentration of saffron extract was used. 
The induction in cell invasion of the PNT1A cells were between 117 and 124%. 
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Figure 71: The effect of saffron and its active constituents after 36 hours of exposure on 
PNT1A cells invasion. Bars with * symbol are statistically significant from control group. 
The cells number were counted using ImageJ software (ANOVA; n = 3 
replicates/treatment group, p<0.05). 
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Figure 72: Representative images of PNT1A cells in invasion assay using Boyden chambers 
at 36 hours after treatment exposures. The pictures were taken using 40X microscopic 
magnification. The cells number were counted using ImageJ software. 
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5.1.8.2. The effects of saffron and its active constituents on 22Rv1 prostate cancer cells 
invasion behavior 
The invasion activity of prostate cancer cells (22Rv1) was measured when incubated with 
different concentrations of saffron extract, crocetin, and safranal as shown in Figures 73-74. 
22Rv1 cells, treated with 12 µg/ml of safranal, had inhibited ability to invade. The % of cells that 
invaded toward the chemoattractant was only 72% compared to the control group. Upon 
exposure to 15 µg/ml of crocetin, a significant inhibition of invasion was obtained and the % of 
invaded cells decreased by 22% from control (100%), whereas no significant effects were found 
when 30 µg/ml of crocetin was used. A stronger inhibitory effect on cell invasion (invaded cells 
decreased by 33-41%) was achieved when both concentrations of saffron extract were used (0.1 
and 0.2 mg/ml). 
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Figure 73: The effect of saffron and its active constituents after 36 hours of exposure on 
22Rv1 cell invasion. Bars with * symbol are statistically significant from control group. The 
cells number were counted using ImageJ software (ANOVA; n = 3 replicates/treatment 
group, p<0.05). 
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Figure 74: Representative images of 22Rv1 cells in invasion assay using Boyden chambers 
at 36 hours after treatment exposures. The pictures were taken using 40X microscopic 
magnification. The cells number were counted using ImageJ software. 
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5.1.8.3. The effects of saffron and its active constituents on PC3 prostate cancer cells 
invasion behavior 
The invasion behavior was analyzed after exposing the prostate cancer cell line (PC3) to 
saffron extract (0.1 and 0.2 mg/ml), crocetin (15 and 30 μg/ml), and safranal (6 and 12 μg/ml) as 
shown in Figures 75-76. A reduction in the cell invasion was observed when the cells were 
exposed to 0.2 mg/ml of saffron extract, the invaded cells decreased to 72% compared to the 
control group (100%). A stronger inhibitory effect on the invasion ability was observed in PC3 
cells with 12 μg/ml of safranal. The invaded cells were decreased to 60%. On the other hand, 
neither concentration of crocetin affected the invasion activity of prostate cancer. 
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Figure 75: The effect of saffron and its active constituents after 36 hours of exposure on 
PC3 cell invasion. Bars with * symbol are statistically significant from control group. The 
cells number were counted using ImageJ software (ANOVA; n = 3 replicates/treatment 
group, p<0.05). 
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Figure 76: Representative images of PC3 cells in invasion assay using Boyden chambers at 
36 hours after treatment exposures. The pictures were taken using 40X microscopic 
magnification. The cells number were counted using ImageJ software. 
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5.1.9. Effects of saffron extract and its active components on matrix metalloproteases 
mRNA expression using RT-PCR 
At certain concentrations and cell lines, saffron and its constituents showed inhibitory 
effects on cancer cells migration and invasion. Therefore, we investigated which MMP genes 
responded to the various treatments. Two MMP enzymes were chosen to represent two different 
families of MMP enzymes. Matrix Metalloprotease-1 (MMP1) and Matrix Metalloprotease-9 
(MMP9) were picked, and they mainly degrade collagens and gelatins, respectively. Two 
concentrations of saffron extract, crocetin, and safranal were used to measure MMP1 and MMP9 
gene expression. The gene expression was measured by RT-PCR after 72 hours of treatment. 
 
5.1.9.1. MMP1 gene expression 
MMP1 mRNA gene expression was dependent on cell types (Figures 77-79). Safranal, at 
25 and 50 µg/ml, did not cause any significant changes in MMP1 gene expression in any tumor 
cell lines (22Rv1 and PC3), whereas in PNT1A cells MMP1 expression was significantly 
induced by 6.6- and 14-fold, respectively. Crocetin (100 µg/ml) induced the expression of 
MMP1 in PNT1A and 22Rv1 by 7- and 2.7-fold, respectively, whereas there was no change in 
PC3. At the higher concentration of crocetin (200 µg/ml), a 1.9- and 5.1-fold increase was 
achieved in PC3 and 22Rv1. At 0.75 mg/ml of saffron, there was a significant increase by of 
1.72- and 14.3-fold in PC3 and PNT1A cells, respectively.  
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Figure 77: The effect of saffron and its active constituents on MMP1 mRNA expression 
level in PNT1A cell after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 78: The effect of saffron and its active constituents on MMP1 mRNA expression 
level in 22Rv1 cell after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 79: The effect of saffron and its active constituents on MMP1 mRNA expression 
level in PC3 cell after 72 hours of exposure. Bars with * symbol are statistically significant 
from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
 
 
5.1.9.2. MMP9 gene expression 
The MMP9 expression was measured after treating the cells with saffron and its active 
constituents (Figures 80-82). Our study showed there were no changes in MMP9 mRNA 
expression in any cell lines when treated with 25 µg/ml of safranal, but when the cells were 
exposed to 50 µg/ml, a 5-fold induction in normal cells, 40%-inhibition in 22Rv1cells and no 
change in PC3 cells was observed. Incubating the cells with crocetin at 100 µg/ml caused an 
increase in MMP9 gene expression in PNT1A and PC3 cells by 8- and 1.9-fold, respectively, an 
opposite effect was observed in 22Rv1 when MMP9 gene expression was inhibited by 45% 
compared to the control group. At 200 µg/ml of crocetin, different responses were obtained from 
the cancer cell lines. In PC3 cells the MMP9 expression was induced by 1.73-fold whereas the 
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expression in 22Rv1 was inhibited by 42%. Low concentrations of saffron crude extract (0.75 
mg/ml) significantly increased the expression of MMP9 by 26.7-fold in PNT1A cells but caused 
a 37% inhibition in 22Rv1 cells. In addition, high concentrations of extract (1.5 mg/ml) 
significantly reduced the MMP9 mRNA expression in both 22Rv1 by 60% and PC3 by 74%. 
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Figure 80: The effect of saffron and its active constituents on MMP9 mRNA expression 
level in PNT1A cell after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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Figure 81: The effect of saffron and its active constituents on MMP9 mRNA expression 
level in 22Rv1 cell after 72 hours of exposure. Bars with * symbol are statistically 
significant from control group (ANOVA; n = 3 replicates/treatment group, excluded 1500 
µg/ml saffron group from statistics, p<0.05). 
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Figure 82: The effect of saffron and its active constituents on MMP9 mRNA expression 
level in PC3 cell after 72 hours of exposure. Bars with * symbol are statistically significant 
from control group (ANOVA; n = 3 replicates/treatment group, p<0.05). 
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5.2. Discussion 
Multiple natural products have been suggested to provide protection and can also be used  
in the treatment of several different tumor types, including prostate cancer (Anand et al., 2008). 
Specifically, saffron and its components have proven results as being capable of acting against 
cervical, lung, breast, and neuroblastoma tumors (Samarghandian et al., 2011, Samarghandian et 
al., 2014, Escribano et al., 1996, Chryssanthi et al., 2007). Here, we compared the potential 
anticancer activity of saffron extract and its constituents (crocin, crocetin, picrocrocin, and 
safranal) in both prostate cancer and normal cell lines. Three prostate cell lines were selected 
which represent prostate cells in three different scenarios. PNT1A represents normal prostate 
cells, 22Rv1 cells represents early-stage prostate cancer, and PC3 represents aggressive and 
advanced prostate cancer. 
In this dissertation, our results indicated that saffron and its active constituents possess 
two important anticancer properties which are effective in cases of prostate cancer by preventing 
tumor promotion and treating of existing prostate cancer cells. Specifically, lowering free 
radicals can minimize the contributing factors involved in cancer initiation, promotion, and 
aggression and which in turn could prevent prostate cancer development (Hecht et al., 2016, 
Rebillard et al., 2013, Fuchs-Tarlovsky, 2013). Finding a phytochemical agent that possesses 
antioxidant activity with minimal toxic effects could make an excellent candidate as a cancer 
chemopreventive agent (Steward and Brown, 2013, Bahmani et al., 2016). Our results found that 
saffron and its active components have cancer-preventative properties through their scavenger 
abilities in addition to the activation of cellular antioxidant defense mechanisms which inhibit 
free radical formation. Pre-incubation of the normal prostate cells with saffron and its active 
constituents before inducing oxidative stress with H2O2 resulted in a decrease in reactive oxygen 
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species (ROS) formation. By preventing cell damage, cancer progression is inhibited. In general, 
the crocetin possesses greater activity as a chemical scavenger property when compared to 
safranal, but in our cell culture system, safranal displayed stronger antioxidant properties 
compared to both crocetin and the saffron extract. As a consequence, it is proposed that the 
ability of safranal to activate the cellular antioxidant mechanisms is greater than that for saffron 
extract and crocetin. Therefore, safranal removes free radicals more efficiently, even at a low 
dose (6 µg/ml), where saffron extract and crocetin require at least 200 µg/ml and 30 µg/ml, 
respectively (Table 21). The possible antioxidant mechanisms of saffron and its constituents 
involved the activation of catalase (CAT), glutathione peroxidase (GPx), glutathione S-
transferase (GST), and superoxide dismutase (SOD) enzymes (Samarghandian et al., 2013a, 
Niska et al., 2015, Altinoz et al., 2014). Therefore, using saffron and its active constituents at 
sub-toxic concentrations is promising as chemopreventive agents. 
Our observation has clearly supported other findings regarding the increase of the 
anticancer activity through the long-term incubation of cancer cells with saffron and its active 
components (Parizadeh et al., 2011, He et al., 2014, Chen et al., 2015, Feizzadeh et al., 2008). 
These suggested saffron extract taken in a low dose as a natural supplement and long-term is the 
optimum way to maximize saffron’s anticancer properties. The ethanolic saffron extract 
exhibited anticancer activity on prostate cancer cells, especially in androgen-dependent prostate 
cancer (22Rv1). Unfortunately, this activity lacked selectivity and caused severe cytotoxic 
effects in normal prostate cells compared to other saffron constituents. Additionally, the 
measured cytotoxicity from saffron extract in prostate cancer (IC50 for 22Rv1 and PC3 was 1.32 
and 1.77 mg/ml, respectively) was less than the reported effects achieved in various other cancer 
types such as breast cancer (MCF-7), lung carcinoma (A549), cervical cancer (HeLa), and 
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hepatocellular carcinoma (HepG-2) where IC50s equaled 400, 650, 800, 950 µg/ml, respectively 
(Tavakkol-Afshari et al., 2008, Samarghandian et al., 2011, Mousavi et al., 2009). Therefore, 
saffron extract is not strongly effective in the treatment of prostate cancer compared to its 
constituents (crocetin and safranal). 
Weak cytotoxic potential was also achieved using picrocrocin and crocin against prostate 
cancer, even with longer incubation periods, of up to 72 hours. Due to limited available studies 
concerning picrocrocin anticancer activity using in vitro models, we investigated its inhibitory 
effects against prostate cancer (22Rv1 and PC3) and normal cells (PNT1A). Picrocrocin 
concentrations of up to 2 mg/ml for 72 hours resulted in approximately a 30% reduction in 
prostate cancer growth. This reduction is considered to be a minor effect compared to results 
achieved with other types of cancer, such as cervical cancer (HeLa cell line) in which 991 µg/ml 
resulted in a 50% reduction in cell growth (Escribano et al., 1996). The cervical cancer study 
suggested the picrocrocin can be used to treat a variety of cancer types, but we found it was 
relatively inactive for treatment of prostate cancer. 
In the case of crocin, numerous studies have been conducted to determine the 
effectiveness of crocin in the treatment of various cancer types. Because crocin had demonstrated 
strong properties as an anticancer agent, we examined its potential as a treatment for prostate 
cancer. Cytotoxicity IC50s were detected in prostate cancer cell lines, but the activities were 
lower than that reported in other cancer types, including pancreatic adenocarcinoma (BxPC-3) 
and colorectal adenocarcinoma (Caco-2 and HT-29), where the IC50s were of 10 µg/ml, 150 
µg/ml, and 390 µg/ml, respectively (Garcia-Olmo et al., 1999, Bakshi et al., 2010, Eid et al., 
2012). Similar cytotoxicity was observed in gastric adenocarcinoma (AGS) and hepatocellular 
carcinoma (HepG2) with a IC50s of 2.7 mg/ml and 2.8 mg/ml, respectively (Kim et al., 2014, 
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Hoshyar et al., 2013). Therefore, crocin’s anticancer properties vary depending on the cancer 
type, with less efficacy in prostate cancer. 
Indeed, crocetin and safranal produced the strongest anticancer results among the tested 
saffron constituents. Crocetin arrested the growth of prostate cancer cells regardless of the 
androgen-dependency status of the prostate cancer cells. The IC50 after 48 hours was 86-90 
µg/ml, which was weaker than that required to have a positive effect on gastric adenocarcinoma 
(AGS) (IC50 of 32.8 µg/ml), but was stronger than its activity against lung adenocarcinoma 
(A549) and hepatocellular carcinoma (HepG2) with IC50s of 134 and 200 µg/ml, respectively 
(Bathaie et al., 2013, Kim et al., 2014). The most potent effect of crocetin was achieved after 72 
hours of incubation with an IC50 corresponding to 59-63 µg/ml. This anticancer property of 
crocetin comes at a price, which is the lack of selectivity toward prostate cancer cells. In fact, 
crocetin was most cytotoxic when it was incubated with normal prostate cells (PNT1A). The IC50 
was equal to 70 µg/ml and 47 µg/ml after 48 and 72 hours, respectively which is less than the 
required concentration to inhibit the growth of prostate cancer cells. Most of the available 
chemotherapeutic agents used today show lack of selectivity toward cancer cells. Despite the fact 
that saffron and crocetin showed higher toxicity in normal cells than in cancer cells, further 
safety studies need to be conducted to evaluate the efficacy and safety of using these natural 
compounds as a chemotherapeutic agent for cancer and as an alternative to traditional therapies 
for curing different diseases.  
Safranal was more potent in androgen-dependent prostate cancer (22Rv1) with an IC50 of 
10.9 µg/ml than with the androgen-independent prostate cancer cell line (PC3) with an IC50 of 
19.4 µg/ml. The statistical differences in the response of the two prostate cancer cell types may 
have indicated that the safranal activity is dependent to some degree on androgen receptor 
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cascades. In addition, the activity of safranal on prostate cancer was stronger than on cervical 
cancer (HeLa) cells with an IC50 of 120 µg/ml and breast cancer (MCF-7 and MDA-MB-231) 
with an IC50 of 75 µg/ml (Escribano et al., 1996, Chryssanthi et al., 2007). Hence, safranal could 
potentially be used specifically to treat prostate cancer. Moreover, our research demonstrated the 
selectivity of safranal against prostate cancer with minimal toxicity toward normal prostate cells 
(PNT1A) with an IC50 of 13.9 µg/ml. The IC50 of cytotoxicity of safranal in normal cells was 
higher than 22Rv1 but less than PC3. This result suggests the potential to use safranal with a 
higher safety margin compared to saffron, crocin, picrocrocin and crocetin as a chemotherapeutic 
agent for treating the early stages of prostate cancer which is usually an androgen-dependent 
cancer type. 
Cancer development is usually associated with abnormal apoptosis signaling pathways 
which is one of the primary factors that is responsible for treatment failure owing to mutations 
that suppress apoptosis and decrease treatment sensitivity. Drugs are needed that activate the 
apoptosis mechanism which can counteract the mutated oncogenes that disrupt the apoptosis 
cascades in cancer cells (Lowe and Lin, 2000). Therefore, it is an essential step to determine 
whether saffron and its active constituents exert their cytotoxicity through apoptosis or necrosis.  
Our study found that the cytotoxicity exerted by saffron and its active constituents was 
produced through apoptosis mechanisms. Faster responses in cancer cells were obtained when 
the effector caspases enzymes 3/7 were induced after 6 hours of incubation during the 
treatments. This activity was generally stronger in cancer cells compared to normal cells, 
although the saffron extract triggered the caspase 3/7 enzymes earlier than cancer cells. This 
result supported other findings about the activation of caspase 3/7 secretions upon the incubation 
of saffron extract with lung carcinoma cells (Samarghandian et al., 2013b). In prostate cancer 
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cells, the safranal and crocetin stimulated the caspase 3/7 production in a concentration-
dependent manner. Safranal cytotoxicity via apoptosis was also reported in neuroblastomas 
(Samarghandian et al., 2014).  In addition, similar results were observed on cervical cancer 
(HeLa), lung cancer (A549), and ovarian cancer (SKOV3) cell lines (Zhong et al., 2011). It is 
clear the cytotoxicity of saffron extract, crocetin, and safranal is primarily dependent on the 
activation of apoptosis pathways. Moreover, the androgen-sensitive prostate cancer cell line 
(22Rv1) responded to safranal more than the androgen-independent prostate cancer cell line 
(PC3), while on the contrary, the PC3 was more sensitive to crocetin than the 22Rv1.    
Our study focused on which apoptotic pathway was involved in the actions of saffron and 
its active constituents (intrinsic, extrinsic, or both). The extrinsic pathway heavily relies on 
caspase 8 and/or 10 pathways dependent on the activated death receptors such as the Fas receptor 
on the cell surface, whereas the intrinsic pathway is associated with the activation of caspase 9 
(Figure 83). We used real-time PCR to measure caspase 3, 7, and 9 in normal prostate cell lines 
to determine the major apoptotic pathway. Safranal and crocetin activity was dependent on the 
activation of the caspase 9 pathway, which means the active saffron components work through 
the intrinsic apoptosis pathway (Figure 84). The induction of caspase 9 expression may relate to 
the ability of saffron and its active constituents to upregulate Bax and p53 and suppress Bcl-2 
and NF-κB expression (Bathaie et al., 2013, Amin et al., 2011, Mousavi et al., 2009). In contrast, 
the levels of caspase 3, 7, and 9 were unchanged when incubated with saffron at both 
concentrations (0.75 mg/ml and 1.5 mg/ml) and for crocetin at a high concentration (200µg/ml). 
The unchanged gene expression could be explained in two ways.  
First, when the cells were incubated with saffron extract (0.75 mg/ml and 1.5 mg/ml) or 
with the high concentration of crocetin (200µg/ml), the caspase 3/7 enzymes were even higher 
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after 6 hours than those protein levels induced by safranal and a low crocetin concentration. 
Because we measured the caspase gene expression after 72 hours, it was possible that the caspase 
mRNA was higher at earlier points, but became degraded before we conducted the RT-PCR. 
This explanation is in agreement with the findings of a previous study which investigated and 
compared the stability of mRNA expression and its related proteins using a quantitative model. 
A research group studied over 5000 genes of mammalian cells with their corresponding 
expressed protein and calculated their half-lives. The half-life of mRNA was 9 hours, whereas it 
was 46 hours for proteins, which makes proteins, on average five times more stable than mRNA. 
According to that study, there was no correlation between the half-lives of mRNA and protein 
(Schwanhausser et al., 2011). Accordingly, earlier multi-time points of measuring mRNA will 
provide a more accurate result that reflects the corresponding mRNA expression level of caspase 
3, 7, and 9 genes. 
The second reason for the variation found in our study between the caspase’s mRNA and 
its proteins was the possibility of no direct relationship between the levels of mRNA and protein 
expression, which was proven in earlier studies. A proteomic study was conducted to investigate 
the correlation between 425 proteins and their corresponding mRNA. This study found that only 
19% had a good correlation between mRNA and protein expression and even 1% had an inverse 
correlation. Generally, there was no good correlation between all examined genes mRNA and 
proteins with R= 0.59 (Tian et al., 2004). Similar findings of another study were obtained with 
R= 0.46 and which additionally highlighted the importance of post-transcriptional regulation and 
processes which have an effect on the relationship between mRNA and proteins levels (Vogel et 
al., 2010). Therefore, the obtained mRNA of caspase is not necessary reflected in the caspase 
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enzymes levels when the cells are treated with saffron extract (0.75 mg/ml and 1.5 mg/ml) or 
crocetin (200µg/ml). 
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Figure 83: Cell death mechanisms 
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Figure 84: Proposed apoptosis mechanism of safranal and crocetin 
 
The migration of any cell depends on two factors, cell-cell interaction and chemotaxis 
(Liang et al., 2007). Our research demonstrated that saffron and its active constituents have the 
ability to inhibit prostate cancer cell migration. The present study measured the cell migration 
that was dependent on the cell-cell interaction behavior of cells, using a wound healing assay. 
Safranal at 12 µg/ml inhibited the cell migration of both types of prostate cancer while at the 
same time activating the migration of normal cells. In a different study, when crocetin at 32 
µg/ml was incubated with esophageal squamous carcinoma (KYSE-150), crocetin decreased cell 
migration by 20% (Li et al., 2015). Conversely, our investigation found that 30 µg/ml of crocetin 
activated the migration of both prostate cancer cell types while having no effect on normal cells. 
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Saffron extract at 100 µg/ml activated normal cell migration whereas a higher concentration (200 
µg/ml) inhibited the migration of both prostate cancer types.  
Furthermore, migration which is dependent on chemotaxis was assessed using a Boyden 
chamber. The saffron extract (100 µg/ml) activated the migration of normal cell lines and 
inhibited 22Rv1 cells, while a higher concentration (200 µg/ml) resulted only in an inhibition of 
22Rv1 migration. Using 12 µg/ml of safranal inhibited migration of both cancer cell types, 
whereas 30 µg/ml of crocetin activated migration of PC3 only. Combining data obtained from 
both these migration experiments that were based on different aspects of migration (cell-cell 
contact and chemo-attractive stimulation) identified that 12 µg/ml of safranal was the most 
suitable compound to inhibit cancer cell migration, but it increased the migration of normal cells. 
The higher concentration of crocetin (30 µg/ml) produced results that demonstrated its ability to 
induce cancer cell migration. Low concentrations of saffron induced the migration of normal 
cells, while higher concentrations inhibited cancer cell migration. As mentioned in previous 
studies, mature organisms depend heavily on physiological cell migration to play an important 
role in tissue homeostasis, immune response, and wound repair (Trepat et al., 2012). Because the 
saffron extract and safranal exclusively stimulated the migration behavior of normal cells, that 
makes them good candidates to use in conditions when a stimulation of the immune system as 
well as an acceleration of the wound healing process are required, such as in cases of burns to the 
skin (Khorasani et al., 2008). 
Generally, the invasive behavior of cells is dependent on two major factors, cell 
migration (cell motility) and extracellular matrix (ECM) digestion through secreting proteolytic 
enzymes (MMPs). Therefore, if cells cannot migrate, it means that the cells will not invade, 
whereas all invaded cells should be migrated cells. Therefore, we studied the ability of saffron 
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extract, crocetin, and safranal to inhibit the invasion behavior of prostate cancer cells using 
Boyden chambers. Safranal at a higher concentration (12 µg/ml) decreased the invasiveness of 
both prostate cancer cell lines and promoted the activity of normal prostate cells. Crocetin (15 
µg/ml) inhibited the invasive behavior of androgen-sensitive prostate cancer cells (22Rv1), 
whereas this behavior was triggered in the normal cell line. At different concentrations of 
saffron, the invasion of 22Rv1 was inhibited, while at higher concentrations the PC3 invasion 
was decreased, whereas at low concentrations invasiveness was stimulated. This data supported 
conclusions from a different study which confirmed the ability of saffron extract and crocetin to 
prevent the invasion of various cancer cells through down-regulation of MMP2 and 9 
(Chryssanthi et al., 2011, Mousavi et al., 2014). In our study, RT-PCR analysis of MMP1 and 
MMP9 demonstrated that MMP9 expression was related more closely to the anti-invasion 
activity of saffron and its active constituents, whereas the MMP1 was closely associated with 
migration behaviors (Tables 21-22). The correlation between MMP9 and invasion activity can be 
explained by the fact that the barrier used in the Boyden chamber consisted of matrigel, which is 
digested effectively with gelatinase enzymes such as MMP9 and less effectively with 
collagenase enzymes such as MMP1. It was proven in a previous study, when the MMP1 was 
knocked down, lung, breast, and prostate cancer cells lost their migration ability (Ho et al., 2009, 
Liu et al., 2012, Li and Tai, 2012, Casimiro et al., 2013).  
The MMP’s activity stimulates vascular endothelial growth factor (VEGF) expression 
which plays important roles in the angiogenesis process of a tumor. Because saffron and its 
active constituents decreased MMP1 and MMP9, it is possible that these natural products are 
capable of decreasing VEGF expression as they may be angiogenesis inhibitors (Kim et al., 
2010). Our results concluded that saffron and its active components inhibit migration as well as 
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the invasion of prostate cancer, and by doing this they could prevent cancer from metastasizing 
to distant sites. These inhibitory effects are not observed in normal prostate cells, however, but in 
certain situations saffron and its active constituents enhanced the migration activity, which may 
be considered to be an advantage when migration is required to treat other diseases and 
conditions.  
 
 
Table 21: Summary of antioxidant, migration, and invasion activity of prostate cells after 
treatments 
Measured effects Cell line 
Saffron extract 
(µg/ml) 
Crocetin (µg/ml) Safranal (µg/ml) 
100 200 15 30 6 12 
Oxidative stress PNT1A - ↓ - ↓ ↓ ↓ 
Migration 
activity 
Wound 
healing 
PNT1A ↑ - - - - ↑ 
22Rv1 - ↓ - ↑ - ↓ 
PC3 - ↓ - ↑ - ↓ 
Boyden 
chamber 
PNT1A ↑ - - - - - 
22Rv1 ↓ ↓ - - - ↓ 
PC3 - - - ↑ - ↓ 
Invasion activity 
PNT1A ↑ - ↑ - - ↑ 
22Rv1 ↓ ↓ ↓ - - ↓ 
PC3 - ↓ - - - ↓ 
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Table 22: Summary of MMP1 and MMP9 gene expression of prostate cells after treatments 
Measured effects Cell line 
Saffron extract 
(µg/ml) 
Crocetin (µg/ml) Safranal (µg/ml) 
750 1500 90 180 25 50 
MMP1 
PNT1A ↑ - ↑ - ↑ ↑ 
22Rv1 - - ↑ ↑ - - 
PC3 ↑ - - ↑ - - 
MMP9 
PNT1A ↑ - ↑ - - ↑ 
22Rv1 ↓ - ↓ ↓ - ↓ 
PC3 - - ↑ ↑ - - 
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5.3. Conclusion 
Saffron and its active constituents were used to assess their capability as chemo-
preventive and chemotherapeutic agents for the treatment of prostate cancer. Saffron extract, 
picrocrocin, crocin, crocetin, and safranal were used to treat two different human prostate cancer 
cell lines that differed in their androgen-dependency status (22Rv1 and PC3) and normal prostate 
cell line (PNT1A). Picrocrocin and crocin had weaker cytotoxicity compared to saffron extract, 
crocetin, and safranal. Viability of the prostate cancer cells was dependent on their androgen 
sensitivity status. The cytotoxic effects were exerted through an intrinsic apoptosis pathway. In 
addition, saffron extract, crocetin, and safranal demonstrated the ability to prevent metastasis 
through inhibiting prostate cancer cell migration, as well as their invasion, by decreasing matrix 
metalloproteases enzymes. In regards to the chemo-preventive ability of saffron extract, crocetin, 
and safranal, all of them decreased oxidative stress which plays a major role in the initiation and 
progression of cancer. Among these treatments, safranal had the lowest toxic effect on normal 
cell lines. Ultimately, the conclusion to this study is that the saffron extract, crocetin, and 
safranal have all clearly demonstrated properties that allow us to conclude they have potential as 
chemo-preventive and chemotherapeutic agents for prostate cancer.  
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CHAPTER 6: ZEBRAFISH XENOGRAFT MODEL OF HUMAN PROSTATE CANCER 
 
6.1. Results 
6.1.1. Creation of transfected prostate cancer cell lines with DsRed Express 2 protein 
First, the transfection process included determining the proper selective and maintenance 
concentrations of G418 antibiotic to exert a selective pressure to obtain stable transfected cell 
lines, followed by lowering the G418 antibiotic to the maintenance concentration so as to keep 
the transfection status unchanged. Second, evaluating the transfection procedure effects was 
carried out by measuring the cells’ doubling time to ensure the transfection did not cause any 
major changes in cell replication. Finally, the cytotoxicity of a known drug in both transfected 
and non-transfected cell lines was performed to ensure there was no significant impact of the 
treatment and the transfection process. 
 
6.1.1.1.  Determination of selective and maintenance concentration of G418 for cell 
transfection 
The plasmid used for DsRed Express 2 protein (Figure 11, Chapter 3) contains the G418 
resistance gene which is activated in mammalian cells once the transfection process has been 
successful whereas human cells (non-transfected) are sensitive to G418. This study evaluated the 
ability of prostate cancer cells to grow and form colonies by performing a clonogenic assay in 
the presence of geneticin (G418) antibiotic. After determining the required G418 concentration 
that caused the cell growth inhibition, this concentration was used to select the successfully 
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transfected cells and exclude the non-transfected cells. As shown in Figure 85, treatment of 
22Rv1 and PC3 prostate cancer cell lines with G418 at a concentration of 500 and 1000 µg/ml 
for 9 days caused a significant decrease in cell growth and the ability of a single cancer cell to 
form a colony. Figure 86 illustrates that a concentration of 500 µg/ml of G418 achieved stronger 
inhibitory effects in colony formation of 22Rv1 cells with a reduction of 94.29 ± 8.08% in 
formed colonies, whereas 500 µg/ml in PC3 cells caused an 89.19 ± 10.11% reduction in their 
ability to form colonies. The higher 1000 µg/ml concentration of G418 significantly suppressed 
the growth and colony formation ability in 22Rv1 and PC3 cells where a reduction in formed 
colonies was achieved by 100% and 97.3 ± 3.82%, respectively. 
 
 
Cell line Control 
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Figure 85: Representative pictures demonstrating the ability of non-transfected prostate 
cancer cell lines to form colonies after 9 days of G418 antibiotic exposure. 
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Figure 86: The effects of G418 on the colony formation in prostate cancer cell lines after 9 
days of incubation. Bars with a * symbol are statistically significant from the untreated 
control group (ANOVA, n = 3 replicates/group, p<0.05). 
 
 
 
6.1.1.2. Transfection of prostate cancer cell lines with DsRed Express 2 plasmid 
 Our goal in using DsRed Express 2 plasmid was to provide the cells with a tracking 
protein that would facilitate visualizing the cells with a fluorescent microscope after they were 
transplanted into a zebrafish embryo. After one month of using the selection concentration (1000 
µg/ml) of the G418 antibiotic, stable transfected cells were obtained for both cancer cell lines. 
Selected cells were maintained with the maintenance concentration (250 µg/ml) of the G418 
antibiotic. As depicted in Figure 87, both transfected cell lines (22Rv1 and PC3) expressed the 
DsRed Express 2 protein, which was visualized under the fluorescent microscope, using the 
proper filter combinations. The merging of a bright field with red filter pictures for each cell line 
indicated that all cells were capable of expressing the transfected protein. 
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Figure 87: The expression of DsRed Express 2 protein in 22Rv1 (A for bright field and B 
for red fluorescent filter) and PC3 (C for bright field and D for red fluorescent filter) of 
prostate cancer cell lines after 48 hours of incubation. The pictures were taken with 20X 
microscopic objective magnification. 
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6.1.1.3. The effects of DsRed Express 2 plasmid transfection on the proliferation rate of 
prostate cancer cell lines 
 This study investigated the possibility of the influence of the transfection process on the 
growth rate of prostate cancer cell lines by measuring the doubling time. After 48 hours of 
incubation, the doubling time was calculated and, as demonstrated in Figure 88, it was 
determined that no significant changes were found in either prostate cancer cell line. Doubling 
time was 42.48 ± 3.44 and 35.02 ± 2.6 hours for non-transfected 22Rv1 and PC3 cell lines, 
respectively, whereas it was 44.27 ± 3.24 and 36.49 ± 2.98 hours for transfected 22Rv1 and PC3 
cells. The results showed that the transfection of DsRed Express 2 plasmid did not cause any 
significant effects on the growth rate of prostate cancer cell lines. 
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Figure 88: The effects of DsRed Express 2 plasmid transfection on the proliferation rate of 
prostate cancer cell lines after 48 hours of incubation. Non and transfected cells within cell 
type were not significant different (t-test, n = 6 replicates/group, p<0.05). 
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6.1.1.4. The in vitro cytotoxicity of docetaxel in both non-transfected prostate cancer cell 
lines 
As previously mentioned, the aim of the transfection of the cells with the DsRed Express 
2 protein plasmid was tracking of the prostate cells after they were transplanted into zebrafish. 
Docetaxel is a known effective chemotherapy for prostate cancer. Hence, it was used to validate 
the xenograft model. We measured the cytotoxicity response of docetaxel in transfected cells to 
compare it with the cytotoxicity obtained in non-transfected cell lines so as to ensure there were 
no changes in the drug response caused by the plasmid transfection process. 
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6.1.1.4.1. The in vitro cytotoxicity of docetaxel in both non-transfected prostate cancer cell 
lines 
Because the incubation window available for evaluating the efficacy of any treatment 
using the in vivo zebrafish xenograft model is 48 hours, the cytotoxicity was determined for both 
non-transfected 22Rv1 and PC3 cell lines after 48 hours of treatment incubation. As shown in 
Figure 89, the docetaxel concentrations, ranging from 2.5-20 ng/ml, were used. After 48 hours of 
treatment exposure, it was found that the IC50 were 3.94 ± 0.87 and 11.47 ± 2.7 ng/ml for 22Rv1 
and PC3, respectively.   
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Figure 89: The cytotoxicity of non-transfected prostate cell lines after 48 hours using 
docetaxel. (ANOVA; N = 3) 
 
 
  
185 
 
6.1.1.4.2. The in vitro cytotoxicity of docetaxel in both transfected prostate cancer cell lines 
After 48 hours of incubating the transfected cell lines with docetaxel, as demonstrated in 
Figure 90, the IC50 for 22Rv1 was 4.11 ± 1.03 and 11.83 ± 3.43 ng/ml for PC3.  There were no 
significant changes found in the toxicity of the cells between transfected and non-transfected 
prostate cancer cell lines caused by docetaxel.  
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Figure 90: The cytotoxicity of non-transfected prostate cell lines after 48 hours using 
docetaxel. (ANOVA; N = 3) 
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6.1.2. Determination of a common temperature point  
 An experimental temperature point compatible with both human prostate cell growth and 
zebrafish larvae survival was optimized. Both maximal thermal tolerance of zebrafish and effects 
of that temperature on human prostate cell doubling time were assessed.  
 
 
6.1.2.1. The effects of various temperatures on zebrafish larvae survival 
 Normally, zebrafish are kept at 28oC. Hence, our study focused on finding the maximum 
temperature that zebrafish larvae could tolerate without affecting their survival. Whether the 
zebrafish larvae could grow within or close to the human normal temperature range (37oC) was 
investigated. Therefore, 28, 32, 35, and 37oC were chosen for assessment. After 6 days of 
incubation at each specified temperature, the total surviving zebrafish larvae were determined 
and compared to the control group (the zebrafish larvae incubated at 28oC). As shown in Figure 
91, there was a significant decrease in zebrafish larvae survival for those that were incubated at 
37oC, whereas no significant change was found between 32oC or 35oC and the control group 
(28oC). The 6th day survival of zebrafish larvae compared to the control group was 101.95 ± 
4.23%, 94.85 ± 5.36% and 65.94 ± 5.98% for 32, 35 and 37oC, respectively. 
 
  
187 
 
Temperature (
o
C)
%
 Z
e
b
ra
fi
s
h
 s
u
rv
iv
a
l
R
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l 
(2
8
o
C
)
28 32 35 37
0
20
40
60
80
100
120
*
 
Figure 91: The effects of multiple temperatures on zebrafish larvae survival after 6 days of 
incubation. Bars with a * symbol are statistically significant from the control group. 
(ANOVA, n = 3 replicates/group, each replicate consisted of 96-128 zebrafish, p<0.05). 
 
6.1.2.2. The effects of various temperatures on the proliferation rate of prostate cancer cell 
lines 
 Human cell lines are usually incubated at 37oC for optimal cell growth. Because the 
maximum tolerated temperature to zebrafish larvae was determined to be 35oC, the effects of 
incubating the human prostate cancer cell lines at 35oC on their growth rate were studied to 
determine whether the temperature changes have any significant effect. As described in Chapter 
3, the proliferation rate was determined by measuring the cell doubling time after 48 hours of 
incubation. Although the doubling time slightly increased in both cell lines, no significant 
changes were found (Figure 92). The doubling time at 37oC was 42.48 ± 3.44 hours for 22Rv1 
and 35.02 ± 2.6 hours, whereas the doubling time at 35oC was 46.67 ± 4.61 hours for 22Rv1 and 
38.77 ± 3.7 hours. These results revealed the possibility of incubating both prostate cancer cell 
lines at 35oC without any significant changes in their growth behavior. 
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Figure 92: The effects of multiple temperatures on the proliferation rate of prostate cancer 
cell lines after 48 hours of incubation. In neither cell line did temperature have a significant 
effect on cell doubling time. (t-test, n = 6 replicates/group, p<0.05). 
 
 
6.1.3. Xenograft of prostate cancer cells in Tg(fli1a:EGFP) and crossbred zebrafish 
comparison 
We studied the transplantation of transfected prostate cancer cells in different transgenic 
zebrafish lines. As shown in Figure 93, Tg(fli1a:EGFP) interfered with the transfected prostate 
cancer cells’ fluorescent emission due to the presence of larvae pigmentation. Using the 
transgenic line (Tg(fli1a:EGFP) x Casper) which we created in our laboratory, there was no 
interference found between the fluorescent emission of transplanted prostate cancer cells and the 
zebrafish larvae body. Actually, the embedded zebrafish endothelial cells in the tumor mass were 
easily observed 24 hours into the transplantation process (Figure 94). This benefit was only 
marginally evident using Tg(fli1a:EGFP). Therefore, our developed model using crossbred 
zebrafish larvae provide a great tool not only to study transplanted cancer proliferation and 
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migration, but also for use in studying the angiogenesis process involved in cancer generally, and 
prostate cancer specifically. This model could also be leveraged for angiogenesis inhibitor drugs 
discovery.  
 
 
A B
 
C D
 
Figure 93: The differences between Tg(fli1a:EGFP) and crossbred zebrafish after 
transplanting prostate cancer cells. A & B: PC3 xenografted into Tg(fli1a:EGFP) zebrafish 
and C & D: 22Rv1 xenografted into crossbred Tg(fli1a:EGFP) x Casper zebrafish. 
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Figure 94: The vascular endothelial cells of zebrafish recruited into prostate cell mass 
(angiogenesis). A: 24 hours after transplanting PC3 into zebrafish (2 dpf), B: 72 hours after 
transplanting 22Rv1 into zebrafish (4 dpf), and C: 72 hours after transplanting PC3 into 
zebrafish 
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6.1.4. Determination the time frame for the treatment study using the xenografted 
zebrafish model 
We investigated the duration that cells could be xenografted before cell viability was 
artificially compromised. The transplanted prostate cancer cells in zebrafish continued to grow 
and migrate until fourth day post injection (dpi). At 4 dpi, the transplanted prostate cancer cell 
number started to decline, which indicated the possibility of interference between the zebrafish 
immune system and the transplanted cancer cells. Figure 95, shows that the transplanted cells 
stopped growing and declined at 4 dpi. Therefore, our results suggest that the maximum time 
frame for this model is 3 dpi (4 dpf) to avoid overestimation of the screened drug activity. 
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Figure 95: The growth of PC3 xenografted in zebrafish up to 5 dpf (4 dpi). A: 2 dpf, B: 3 
dpf, C: 4 dpf, and D: 5 dpf 
 
 
 
 
6.1.5. Drug toxicity screening using zebrafish 
Docetaxel and safranal toxicity was assessed in zebrafish to determine the maximum 
tolerated concentrations of these agents without causing any significant changes in zebrafish 
survival compared to controls. 
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6.1.5.1.  Docetaxel toxicity in zebrafish 
Zebrafish at 48 hpf were exposed to multiple docetaxel concentrations (200, 400, 2000 
ng/ml) daily. After 48 hours of exposure (96 hpf), the 200 and 400 ng/ml concentrations of 
docetaxel did not show any significant changes in zebrafish survival compared to the control 
group and their survival was 97.06 ± 4.41% and 93.38 ± 6.74%, respectively (Figure 96). 
However, the concentration of 2000 ng/ml significantly reduced zebrafish survival to 79.41 ± 
10.11%. The results indicated there was no observed toxicity when 48 hpf zebrafish are exposed 
to a docetaxel concentration of up to 400 ng/ml. 
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Figure 96: The toxicity of multiple concentrations of docetaxel in zebrafish after 48 hours 
of exposure. Bars with a * symbol are statistically significant from the control group. 
(ANOVA, n = 3 replicates/group, each replicate consisted of 48 zebrafish, 1 larva per well 
of 48 well plate in 200 µl of solution, p<0.05).  
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6.1.5.2.  Safranal toxicity in zebrafish 
Zebrafish larvae (48 hpf) were exposed daily to 7.5, 15, or 30 µg/ml of safranal. The 7.5 
and 15 µg/ml concentrations of safranal did not significantly decrease zebrafish survival (98.53 ± 
5.55% and 94.12 ± 7.75%, respectively) (Figure 97). On the other hand, 30 µg/ml caused a 
significant reduction in zebrafish survival, which dropped to 57.35 ± 14.47%. Thus, safranal up 
to 15 µg/ml was safe to use in zebrafish without decreasing their survival. 
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Figure 97: The toxicity of multiple concentrations of safranal in zebrafish after 48 hours of 
exposure. Bars with a * symbol are statistically significant from the control group. 
(ANOVA, n = 3 replicates/group, each replicate consisted of 48 zebrafish, p<0.05). 
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6.1.6. The activity of docetaxel on the transplanted prostate cancer cells 
Crossed transgenic zebrafish larvae (Tg(fli1a:EGFP) x Casper) were injected with 300-
400 cells at 48 hpf. To validate the developed model, the xenografted prostate cancer cell models 
were treated with two different concentrations of docetaxel (200 ng/ml and 400 ng/ml) which is a 
established chemotherapy drug used in treating prostate cancer. Each treatment group consisted 
of 3-7 zebrafish larvae. As the concentration of docetaxel increased, the transplanted prostate 
cancer growth declined (Figures 98-99).  At three dpi, the growth of the 22Rv1 untreated control 
group was 136.74 ± 18.06% compared to the 1st dpi, whereas PC3 control group reached 138.28 
± 16.05%. The docetaxel at 200 ng/ml decreased the growth of 22Rv1 and PC3 cells by 36.77 ± 
4.01% and 30.32 ± 4.7%, respectively from the untreated controls at 3 dpi. The growth of 22Rv1 
and PC3 decreased by 47.63 ± 12.13% and 34.58% ± 5.48%, respectively, when a higher 
concentration of docetaxel (400 ng/ml) was used. The projected IC50s were 393.8 ± 153.54 and 
620.8 ± 254.35 ng/ml for 22Rv1 and PC3 cells, respectively. The docetaxel growth inhibition 
was stronger in 22Rv1 than in PC3 cells, which was in accord with the in vitro results 
determined in this study where IC50 were ≈ 4 and 12 ng/ml, respectively. Therefore, these results 
support that the developed xenograft model is a reliable way to investigate, in vivo, candidate 
drugs quickly.  
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Figure 98: Docetaxel activity in xenograft zebrafish model transplanted with 22Rv1 cells. 
Bars with a * symbol are statistically significant from the untreated control group at 3 dpi 
(ANOVA, n= 3) 
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Figure 99: Docetaxel activity in xenograft zebrafish model transplanted with PC3 cells. 
Bars with a * symbol are statistically significant from the untreated control group at 3 dpi 
(ANOVA, n= 3-7) 
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6.1.7. The activity of safranal on transplanted prostate cancer cells 
The in vitro results showed that safranal was cytotoxic for both prostate cancer cell lines 
with lower cytotoxicity in the normal cell line. Based on our findings, we investigated the 
activity of safranal using our developed xenograft model. Each treatment group consisted of 3 
zebrafish larvae. Two concentrations of safranal (7.5 µg/ml and 15 µg/ml) were used and 15 
µg/ml of safranal inhibited the growth of transplanted 22Rv1 cells significantly (Figure 100). 
The growth of 22Rv1 cells was decreased from 136.74 ± 18.06% to 105.51 ± 3.77% and 86.57 ± 
2.15% when the larvae were incubated with 7.5 µg/ml and 15 µg/ml of safranal, respectively. 
The expected IC50 for safranal was 25.68 ± 8.14 µg/ml. Therefore, our results showed that 
safranal was effective in vitro as well as in vivo, which make it an excellent candidate for further 
studies. 
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Figure 100: Safranal activity in xenograft zebrafish model transplanted with 22Rv1 cells. 
Bars with a * symbol are statistically significant from the untreated control group at 3 dpi 
(ANOVA, n= 3) 
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6.2. Discussion 
Zebrafish is a popular vertebrate animal model for various human diseases (Lieschke and 
Currie, 2007). For example, zebrafish and human hepatocellular carcinoma share the same 
molecular pathway characteristics which highlights the utility and relevance of zebrafish as an 
alternative to mammalian models (Lam and Gong, 2006). Here, we developed a zebrafish-based 
xenograft model for human prostate cancer. Using two different cell lines, we optimized the 
conditions and procedures for a reproducible xenograft zebrafish model for human prostate 
cancer cells (22Rv1 and PC3).  The studied parameters included zebrafish and human prostate 
cells’ incubation temperature, zebrafish age, time frame for experiment, injection site, and 
injection method.  
The importance of using crossbred transparent zebrafish (Casper) with the 
Tg(fli1a:EGFP) zebrafish can be viewed from two perspectives. First, in wild type as well as 
Tg(fli1a:EGFP) zebrafish, pigment develops gradually and is easily visualized at 1 dpf and is 
more obvious at 2 dpf. The pigmentation would decrease the quantification sensitivity of the 
transplanted prostate cancer cells because it blocks the emission of the cancer cell fluorescent 
protein marker. Thus, cell visualization and quantification is adversely impacted. This 
disadvantage is not present in the Casper zebrafish because the genes responsible for 
pigmentation are mutated, so when the prostate cancer cells are transplanted, they can be 
accurately quantified. At the same time, Tg(fli1a:EGFP) zebrafish provide a great advantage 
over Casper zebrafish. The unique advantage is the green fluorescence of the zebrafish 
vasculatory system allows for tracking the interaction between the zebrafish blood vessels and 
the prostate cancer cells after transplantation. Therefore, visualization of the route used by the 
cancer cells to migrate and invade distant sites, as well vascular tract recruitment are possible 
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with Tg(fli1a:EGFP) but not Casper fish. Therefore, using the crossbred zebrafish larvae 
provided a great opportunity to visualize the relationship between the endothelial cells of 
zebrafish embedded in human prostate cancer masses and enable an accurate quantification of 
transplanted cancer cells.  
The cancer cells were quantified by measuring the red fluorescent intensity of DsRed 
Express 2 protein. Because the crossed zebrafish larvae (Tg(fli1a:EGFP) x Casper) are 
transparent, the interaction of labeled human prostate cells and zebrafish endothelial cells was 
easily visualized using a fluorescent microscope. The tumorigenesis of human prostate cancer 
cells was fast and easily assessed using the xenograft zebrafish model. Furthermore, zebrafish 
endothelial cell recruitment to the human prostate cancer masses was apparent.  
Our study optimized the appropriate temperature to accommodate both human cell 
proliferation and zebrafish larvae survival. We found that 35oC represents the best incubation 
temperature without affecting human cells’ proliferation or zebrafish survival. 
The best time frame to conduct the experiment using the developed xenograft model was 
also optimized. Multiple studies have used different time frames of up to 10 dpf for their 
xenograft zebrafish larvae models without stating their reasons for the time frame choice 
(Huiting et al., 2015, Geiger et al., 2008, Teng et al., 2013). Based on that, our study screened 
the time frame window ranging from 1-9 dpf. We noticed that the cells started to decline in some 
zebrafish when their age reached 5 dpf, although in some zebrafish the transplanted cells 
continued to survive and grew up to 9 dpf. Decreased cell viability could be explained by the fact 
that T cell progenitors are fully colonized in thymus at 5 dpf and the immune system is totally 
mature when the zebrafish larvae reach 4-6 wpf (Trede et al., 2004). Accordingly, our study 
  
200 
 
suggested terminating the experiment at 4 dpf (3 dpi) to avoid misleading results produced by the 
developed zebrafish immune system that could be responsible for the transplanted cells’ decline.    
We tried multiple time points to inject zebrafish ranging from 1-4 dpf and found that 
prostate cancer cells transplanted into the zebrafish yolk sac at 1 dpf was best so that the prostate 
cancer cells grew, formed masses, and migrated to distant site locations in zebrafish faster 
compared to other time points of transplantation. These results could be explained based on the 
fact that zebrafish embryos form a complete and functional vascular system by 30 hpf 
(Ellertsdóttir et al., 2010). Moreover, similar to humans, the formation of zebrafish blood vessels 
is triggered by the high expression of VEGF (Goishi and Klagsbrun, 2004). In addition, prostate 
cancer is known to be express high VEGF (Botelho et al., 2010). By transplanting the cancer 
cells before 30 hpf, the prostate cells can embed and recruit zebrafish blood vessels into a tumor 
mass which in turn, carries blood and necessary nutrition to prostate cancer cells. Therefore, our 
results suggested that the best time for xenografting human cancer cells into zebrafish is 1 dpf to 
optmization optimum microenvironment for cancer cell proliferation. 
Both prostate cancer cell lines (control groups) proliferated, formed a tumor mass and 
migrated to a distant site when xenografted into zebrafish larvae. This was slightly more obvious 
in the aggressive type of prostate cancer cell line (PC3), especially regarding the migration 
behavior in comparison to the 22Rv1 cell line (data not shown). These results were similar with 
the normal in vitro behaviors of the different cell lines as well as in vivo studies when these cell 
lines were transplanted in a xenografted mice model (Drake et al., 2009). Our finding 
highlighted the suitability of using the xenografted zebrafish model because it does not interfere 
with functions and behaviors of the transplanted prostate cancer cells. 
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Docetaxel is a known as a chemotherapy drug used in the treatment of multiple cancer 
types such as prostate, breast, and gastric cancer. In 2004, the FDA approved the use of 
docetaxel for treating prostate cancer patients by administrating it intravenously (75 mg/m2) 
every three weeks with 5 mg oral prednisone twice daily for 10 cycles (Fda, 2014). In a previous 
human study, it was found that the plasma concentrations of docetaxel were 3.54-4.06 µg/ml, 
when the patients were treated with 75 mg/m2 for various cancer types, including prostate cancer 
(Ten Tije et al., 2005). 
As a positive control, we first tested docetaxel to validate the developed in vivo model. 
The higher concentrations of docetaxel (200 and 400 ng/ml) which were added daily to expose 
xenografted zebrafish larvae produced growth inhibition effects, and the projected IC50s ranged 
between 394-621 ng/ml. The in vivo IC50 were higher compared to in vitro studies which ranged 
from 4-12 ng/ml. Because, in vitro results showed suggested efficacy of safranal in treating 
prostate cancer, we also screened its efficacy using the xenografted zebrafish model. It was clear 
that safranal showed anticancer activity in vivo with a projected IC50 of 25.7 µg/ml, which makes 
it a good candidate for further investigation. 
One important consideration highlighted in Table 23 from our preliminary studies, is that 
the calculated in vivo IC50 both exceeded our dose range and may reach concentrations acutely 
toxic to the zebrafish larvae. It will be important to further establish the predicted therapeutic 
relevance of cancer cell growth inhibition. For example, we must determine what percent 
inhibition is therapeutically meaningful. Furthermore, to complement even easier in vitro testing 
paradigms, the zebrafish model fundamentally must provide enhanced in vivo relevance (e.g. 
associated absorption, distribution, and metabolism) across species. Future studies can 
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investigate prodrug positive controls to further validate metabolic drug activation by larval 
zebrafish. 
The variation between the data obtained from in vitro and in vivo was expected for 
various reasons. First, the cells in in vitro studies obtained the drug directly on exposure, whereas 
in the in vivo model, the drug will undergo multiple pharmacokinetic processes, including 
absorbance, metabolism, distribution, plasma binding, and excretion, which will affect the 
availability of the drug to the transplanted cells. Second, because the in vitro studies are 
conducted with a controlled system (specific growth media compositions), it may disable or 
activate survival or apoptotic pathways as a result of the absence of specific hormones or 
molecules. Therefore, it is possible for the cells to gain these activities again when they are 
transplanted into an in vivo model due to the presence of the proper microenvironment. Finally, 
the docetaxel has low stability in water at room temperature (25oC), which is 4 hours (Hart and 
Acott, 2010). Because we incubated the xenografted zebrafish at 35oC, there is a possibility that 
the docetaxel was degraded during our exposures. Other drug delivery mechanisms including 
microinjection of larvae could be used for water insoluble or unstable drug leads. 
 
 
Table 23: Comparison between the calculated IC50 concentrations between the different 
tested model systems 
Treatment 
In vitro study In vivo study Reported serum human 
concentrations 22Rv1 PC3 22Rv1 PC3 
Docetaxel  4 ng/ml 12 ng/ml 394 ng/ml 621 ng/ml 3.5 - 4.1 µg/ml 
Safranal 15 µg/ml 30 µg/ml 25.7 µg/ml - - 
(Ten Tije et al., 2005) 
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Zebrafish larvae provided a relatively high-throughput approach for conducting 
preclinical studies (Huiting et al., 2015). Because the whole procedure can be completed within 
one week, new drug leads can be screened quickly. Using this alternative to mammalian models 
will shorten the required time to move the candidate drug from an in vitro investigation into 
clinical human trails. 
Another advantage of the model is the need for only small numbers of cancer cells 
(hundreds). This advantage presents the opportunity to take a biopsy from a cancer patient, 
dissociate the cells then transplant it in numerous zebrafish that can be divided in multiple 
treatment groups. From this type of study, a best treatment option could be identified within a 
single week. Therefore, this model could help personalize cancer treatments to ensure the 
maximum chance for effective treatment and help avoid chemotherapy failure. This advantage is 
not possible using mammalian models because of the need for high number of tumor cells 
(millions) required per animal. Experience shows that it is impossible to obtain sufficient 
numbers of cells from a biopsy to transplant them into mammals in multiple groups. 
Furthermore, mammalian experiments take appreciably longer to complete, which is not in the 
best interest of the patient. Therefore, greater emphasis should be placed on increasing the 
zebrafish xenotransplantation research to advance the potential of the methods investigated to 
provide an effective anti-cancer treatment and to therefore increase cancer patients’ survival 
rates. 
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6.3. Conclusion 
The xenograft zebrafish model is an excellent in vivo model and especially for prostate 
cancer cells. We optimized multiple factors that may have an effect on the integrity and validity 
of this model, including the time frame for the experiment (transplantation and termination time 
points), the imaging procedure, drug toxicity screening time, temperature effects in zebrafish and 
human prostate cancer cells, and transfection procedure effects. The model was validated by 
using docetaxel which was found to be effective in treating the transplanted prostate cancer cells. 
Therefore, we are confident that the xenografted zebrafish model will be a highly useful and 
relevant addition in cancer drug discovery. 
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CHAPTER 7: FUTURE STUDIES 
 
Saffron extract, crocin, crocetin, and picrocrocin produced stronger cytotoxicity in 
normal human prostate cells as opposed to prostate cancer cells. It is possible this cytotoxicity is 
unique because the normal cell line (PNT1A) used in this study is more sensitive as result of 
genetic variation in population, or because prostate cells are generally more sensitive compared 
to other organs’ cells. Therefore, studying the cytotoxicity effects of previously mentioned 
agents in various of normal prostate cell lines as well as other organ cell lines will confirm 
whether the observed cytotoxicity is specific to this cell line, cancerous and noncancerous 
prostate cells, or all normal cells.   
Saffron extract showed excellent anti-cancer activity (1.32-1.77 mg/ml), but its activity 
on cancer cells and the cytotoxicity in normal cells was dependent on the method of saffron 
extraction used. Because there is a great deal of saffron extract available on the market as a 
natural health supplement, it is necessary to investigate activity of these supplements on cancer 
cells and their cytotoxicity in normal cells. The importance of such a study is because saffron 
extract supplements depend on saffron quality, and different saffron batches tested herein 
produced different cytotoxicity in normal cells. Furthermore, the in vivo stability and metabolic 
fate of saffron constituents in human is largely unknown. Concentrations that can realistically be 
achieved in the prostate must be investigated. 
Additional studies on saffron extract and its active constituents in the apoptosis assay at 
different time points (<72 hours), will be important to correlate the observed caspase protein 
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expression with its mRNA. In addition, studying the extrinsic apoptosis mechanisms will provide 
valuable information about the cytotoxicity effects produced by saffron and its active 
constituents. Further insight into cell death mechanisms will reveal if saffron and its active 
constituents work exclusively through activation of intrinsic pathways as our studies suggest.         
Saffron is an expensive spice which enhances the probability of its adulteration before 
being sold. Developing a rapid and comprehensive new method to help in identification of the 
original region of cultivation and will enable its acquisition in its pure and not adulterated form. 
In addition, it will authenticate and prevent the variations in chemical composition that can 
impact biological activity when using saffron from differing batches. 
Finally, our study successfully developed new a xenograft zebrafish model. Using this 
model with different cancer types, we have aimed to establish this model’s efficacy as an 
alternative to mammalian models. We believe that validating the use of xenograft models for 
different cancer types will greatly facilitate effective cancer research and facilitate discovering 
new and successful treatment options. 
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Appendix 1: TNM Staging System 
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The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the 
lymph nodes (N), and the presence of metastasis (M) (Edge et al., 2010). 
 
 
TNM categories 
The T category describes the original tumor 
TX Primary tumor cannot be evaluated 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 - T4 Size and/or extent of the primary tumor 
The N category describes whether or not the cancer has reached nearby lymph nodes 
NX Regional lymph nodes cannot be evaluated 
N0 No regional lymph node involvement 
N1 – N3 Involvement of regional lymph nodes 
The M category describes whether there are spread of cancer to other parts of the body 
M0 No distant metastasis 
M1 Distant metastasis 
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Appendix 2: HPLC chromatograms 
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HPLC chromatogram of standard picrocrocin at wavelength 257 nm. 
 
 
 
HPLC chromatogram of standard crocin at wavelength 440 nm. 
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HPLC chromatogram of standard safranal at wavelength 325 nm. 
 
 
 
HPLC chromatogram of standard crocetin at wavelength 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 95% ethanol at wavelengths (A) 257, 
(B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 80% ethanol at wavelengths (A) 257, 
(B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 70% ethanol at wavelengths (A) 257, 
(B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 60% ethanol at wavelengths (A) 257, 
(B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 50% ethanol at wavelengths (A) 257, 
(B) 325, and (C) 440 nm. 
  
252 
 
 
 
HPLC chromatogram of saffron #18258 extract used 95% methanol at wavelengths (A) 
257, (B) 325, and (C) 440 nm. 
  
253 
 
 
 
HPLC chromatogram of saffron #18258 extract used 80% methanol at wavelengths (A) 
257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 70% methanol at wavelengths (A) 
257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 60% methanol at wavelengths (A) 
257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of saffron #18258 extract used 50% methanol at wavelengths (A) 
257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18248 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18249 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18250 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18251 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18252 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18253 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
  
263 
 
 
 
HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18254 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18255 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18256 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
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HPLC chromatogram of 95% ethanolic extract of saffron commercial sample #18257 at 
wavelengths (A) 257, (B) 325, and (C) 440 nm. 
 
 
 
  
267 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3: UHPLC-MS 
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A
B
C
 
 
 
UHPLC-MS chromatogram of 95% ethanolic extract of saffron sample #18258 at 
wavelengths (A) 260, (B) 325, and (C) 440 nm 
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A
B
 
 
 
 
UHPLC-MS chromatogram of 95% ethanolic extract of saffron sample #18258 at different 
ionization methods. A: Positive ESI and B: Negative ESI 
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Appendix 3: Fluorescent microscope filters selection 
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A
B
C
 
 
Microscopic pictures of zebrafish using wide range fluorescence filters show A) bright field, 
B) broad fluorescence filter for EGFP, C) broad fluorescence filter for DeRed Express2. 
Proper filter selection is a crucial step to get an accurate quantitative results and avoid 
interfering bandwidth between multiple fluorescence wavelengths. 
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